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Mtmr  Myotubularin related protein 
NAB50  Nuclear polyadenylated RNA-binding protein, 50-KD 
NAPOR  Nuclear polyadenylated RNA-Binding protein 
NEDD9  Neural precursor cell expressed, developmentally down-regulated 9 
NF1  Neurofibromin 1 
NFY  Nuclear transcription factor Y 
NF-κB  Nuclear factor kappa beta 
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NM  Nodular melanoma 
NMDAR-1 N-methyl-D-aspartate receptor subunit NR1 
NMR  Nuclear magnetic resonance 
NRAS  Neuroblastoma RAS viral oncogene homolog 
NSCLC  Non-small cell lung carcinoma 
OIS  Oncogene induced senescence 
p  Probability values 
PARN  Poly(A)-specific ribonuclease 
PCAF  P300/CBP-associated factor 
PCR  Polymerase chain reaction 
PD-1  Programmed cell death protein 1 
PD-L1  Programmed death-ligand 1 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKC  Protein kinase C 
poly(A) tail Poly-adenosine tail 
PPFIBP1 PTPRF interacting protein, binding protein 1 
PPP6C  Protein phosphatase 6, catalytic subunit 
PTB  Polypyrimidine-tract-binding protein 
PTEN  Phosphatase and tensin homolog 
qPCR  Quantitative polymerase chain reaction 
RAB27A RAS-related protein Rab-27A 
RAC1  RAS-related C3 botulinum toxin substrate 1 
RAS  Rat sarcoma 
Rb  Retinablastoma 
RBM47  RNA binding motif protein 47 
RBP  RNA binding protein 
RCF3 K homology (KH) domain-containing nuclear-localized putative RNA-binding 
protein 3 
RGP  Radial growth phase 
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Rho  Rhodopsin 
RIP-SEQ RNA immunoprecipitation - sequencing 
RNA  Ribonucleic acid 
RRM  RNA recognition motif 
RT  Room temperature 
RyR1  Ryanodine receptor 1 
S phase  Synthesis phase 
SA‐β‐Gal Senescence-associated beta-galactosidase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEER  Surveillance, epidemiology, and end results 
Serca1  Sarcoplasmic/endoplasmic reticulum calcium atpase 1 
SHMT1   Serine hydroxymethyltransferase 1 
shRNA  Short-hairpin RNA 
siRNA  Short interfering RNA 
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily A, member 4 
snRNA  Small nuclear RNA 
Sorbs1  Sorbin and SH3 domain containing 1 
SSM  Superficial spreading melanoma 
SWI/SNF Switch/Sucrose Non-Fermentable 
TBX2  T-Box protein 2 
TCF3  Transcription factor 3 
TCGA  The Cancer Genome Atlas 
TERT  Telomerase reverse transcriptase 
TIA-1  T-cell internal antigen 1 
TITF1  Thyroid transcription factor 1 
TMA  Tissue Microarrays 
TNF-α  Tumor necrosis factor alpha 
TNM  Tumor‐Node‐Metastasis 
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TRP2  Tyrosinase-related protein 2 
TYR  Tyrosinase 
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SUMMARY 
Melanoma is a prime example of an aggressive tumor that accumulates a plethora of changes in 
the transcriptome and the proteome. Consequently, distinguishing drivers from inconsequential 
passenger events has been a main challenge in this disease. Consequently, and despite great 
progress in identifying (epi)genetic defects accumulated during melanoma progression, the 
molecular bases underlying the aggressive behavior of this tumor type are not completely 
understood.  
RNA binding proteins remain largely unexplored in melanoma. We considered this lack of 
information of prime relevance as transcripts of nearly all known oncogenes and tumor 
suppressors may be regulated by alternative splicing and/or controlled by various mechanisms that 
define mRNA stability and ultimately, competency for translation. Here we show that a screen for 
all reported mRNA binding proteins (mRBPs) suggested that these genes are not prime targets of 
mutation or copy number variation. Instead, a customized microarray revealed a series of RBPs 
overexpressed in melanoma cells when compared to normal melanocytes. Of those factors, we 
found particularly attractive the CUGBP1/CELF1 protein. First, CUGBP1 is a multifunctional mRBP 
with a broad spectrum of functions, ranging from the modulation of alternative splicing to  
modulation of mRNA decay. Secondly, there is little information on comprehensive genome-wide 
analyses for CUGBP1 in cancer cells, with no previous report in skin cancer. Therefore this PhD 
thesis was set to address the following unknown aspects of CUGBP1 in melanoma: (i) expression, 
(ii) functional requirement, and (iii) mechanism of action.  
In brief, CUGBP1 was found overexpressed in human melanoma cells and tissue specimens.  
Targeted gene depletion demonstrated that CUGBP1 is required to sustain melanoma cell 
proliferation. Mechanistically, genome wide human junction arrays, RNA immunoprecipitation 
followed by sequencing and iTRAQ-MS/MS proteomics assays were utilized and identified novel 
and direct targets of CUGBP1. Together, these high throughput approaches (to our knowledge the 
first in class for this gene) uncovered a coordinated network of tumor-associated cell cycle 
regulators and chromatin remodelers as CUGBP1 targets. Central in this CUGBP1 regulated 
networks was the oncogene DEK, a feature we validated by targeted gene depletion, cDNA arrays 
and histological validation in clinical datasets. Mechanistically, CUGBP1 was found to bind to the 
3’UTR of DEK stabilizing its mRNA levels and ultimately allowing for an efficient cell proliferation. 
These results illustrate the power of comprehensive analyses of RNA regulators in the 
identification of novel malignant features of cancer cells.  
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PRESENTACIÓN 
El melanoma es un tipo de tumor muy agresivo que acumula una gran cantidad de aberraciones 
en su transcriptoma y proteoma, por todo esto, la identificación de genes esenciales para el 
desarrollo de esta neoplasia  es uno de los grandes retos pendientes.  Pese a los grandes avances 
en la identificación de alteraciones genéticas y epigenéticas que ocurren durante la progresión del 
melanoma, las bases moleculares que explican el comportamiento tan agresivo de este tumor no 
se han descrito en profundidad. 
Las proteínas de unión a  ARN no han sido caracterizadas en detalle en este tipo de tumor. 
Consideramos que esta falta de información es de gran relevancia ya que los transcritos  de casi 
todos los oncogenes y supresores tumorales conocidos pueden estar regulados por procesos de 
splicing alternativo y/o diversos mecanismos que definen la estabilidad del ARNm, y por último, la 
competencia para su traducción. En una búsqueda de todas las proteínas de unión a ARNm 
(mRBPs) previamente descritas, hemos observado  que estos genes no son los principales objetivos 
de mutaciones o alteraciones en el número de copias. En cambio, un microarray personalizado 
para este tipo de proteínas ha revelado numerosas mRBPs  sobreexpresadas en células de 
melanoma en comparación con melanocitos primarios. De esos factores, hemos encontramos 
particularmente atractiva la proteína CUGBP1/CELF1. En primer lugar, CUGBP1 es una mRBP 
multifuncional con un amplio espectro de funciones que van desde la modulación del splicing 
alternativo hasta la regulación del deterioro del ARNm. En segundo lugar, existe poca información  
del papel de CUGBP1 en análisis exhaustivos de todo el genoma realizados en líneas celulares 
tumorales, sin reportes previos en cáncer de piel. Por todo lo anterior, esta tesis doctoral se 
estableció para abordar los siguientes aspectos desconocidos de CUGBP1 en melanoma : (i) su 
expresión , (ii) requisitos funcionales, y (iii) mecanismo de acción . 
En breve, CUGBP1 está sobre expresado en líneas celulares de melanoma y biopsias clínicas 
humanas. La depleción de CUGBP1 demostró que este gen es requerido para el mantenimiento y la 
proliferación del melanoma. Mecanísticamente, estudios de asociación de uniones en el genoma 
humano, inmunoprecipitación de ARN  seguida de secuenciación y espectrometría de masas  
fueron empleados para identificar nuevas dianas de CUGBP1. Juntos, estos enfoques alto 
rendimientos (a nuestro conocimiento la primera vez que sea realiza para este gen) han 
descubierto una red de reguladores del ciclo celular asociados a tumores y remodeladores de la 
cromatina como dianas de CUGBP1. En estas redes, el oncogén DEK tiene un papel central. Estos 
resultados fueron validados mediante la depleción del gen, arrays de ADNc y validación histológica 
en biopsias clínicas. Mecanísticamente, CUGBP1 se une a la región 3'UTR de DEK para estabilizar 
sus niveles de ARNm logrando así una proliferación celular eficiente. 
Estos resultados demuestran el potencial de los análisis a gran escala de reguladores de ARN en 
la identificación de nuevas características de células tumorales.  
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1. MELANOMA 
Melanoma is a cancer type that arises from melanocytes, neural crest-derived melanin-producing 
cells1, which reside mainly in basal layer of the skin2, and also in the hair follicles3, the inner ear4, 
meninges5, uvea6, connective tissues7 and heart8. This tumor is clinically relevant for its increasing 
incidence and mortality (responsible for 80% of skin cancer related deaths) due to high aggressive 
capacity to metastasize9-12. 
1.1. INCIDENCE, MORTALITY, DIAGNOSIS AND RISK FACTORS 
During the last four decades, melanoma incidence has been increasing worldwide, mainly in the 
developed countries. According to the latest surveillance, epidemiology, and end results (SEER) 
program reports, in the United States, the incidence rate has increased 4-folds since 197513. It is 
the fifth and seventh most frequent cancer type in United States among males and females, 
respectively14. Approximately 79000 new melanoma cases and more than 10000 melanoma-
related deaths are expected as year of 201615. In Spain, incidence rate is 13.11/100000 in 
population and this number is estimated to increase to 13.64 by 202216. 
The most important environmental risk factor for melanoma development is natural and artificial 
ultraviolet-exposure17,18.  Other contributing risk factors can be listed as: family history (genetic 
disposition)19-21, number of nevi22, bearing dysplastic nevi, eye/hair color23, suppressed immune 
system due to organ transplantation24,25 or HIV infection26,27. 
In addition to its complex genetic and histopathological background28,29, its ability to develop 
chemoresistance hardens the struggle against finding cure to melanoma30,31. Since the major risk is 
a preventable factor (UV-exposure), and its observability in the skin is relatively easy compared to 
other cancer types, early detection and prevention campaigns to raise awareness of this disease in 
the society is important. Over the last years, these campaigns have helped to improve the survival 
rates of melanoma patients in high incidence countries. Early detection is particularly important32-
34. 5-year survival rates fall to 17% if the disease is at its later stages, such as distant metastasis15. 
This rate is reversely correlated by the depth of the malignant lesion, the Breslow depth (named 
after pathologist Alexander Breslow in 1970)35. In addition to Breslow depth, staging criteria 
include metastasis, mitotic rate, and ulceration36. The correct staging is important for patient 
management for the correct treatment regimen of patient. 
However, Breslow depth method is limited to physical examination of the lesion(s) and evidently 
prone to human errors37,38. Therefore, search for better diagnostic markers is a hot topic in 
melanoma field (reviewed in refs39,40). 
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1.2. MELANOCYTIC LESIONS 
Melanocytes, precursors of melanocytic lesions including melanoma, as described above, are of 
neural crest origin and melanoblasts migrate during embryonic development mostly to the normal 
skin, where melanocyte:keratinocyte number ratio is typically of 1:101,2. Melanocytes are 
specialized in melanin production, transferring the melanin to keratinocytes in the epidermis, 
hence the pigmentation of skin and hair (also feather and fur, in other animals) in order to provide 
protection against the damaging effects of UV radiation by forming a photo barrier41. In more 
detail, UV-radiation causes elevated expression of tumor protein 53 (TP53) in keratinocytes which 
increases the transcription of melanocyte-stimulating hormone (MSH)42. Secreted MSH binds and 
activates melanocortin 1 receptors (MC1R) on melanocyte surface, which activates adenylate 
cyclase cascade and the CREB pathway, ending in the activation of microphthalmia-associated 
transcription factor (MITF)43. MITF promotes melanin synthesis and the skin gets darker as a result 
of accumulated melanin in keratinocytes. Any defect in melanocytes may lead to pigmentation 
disorders, benign melanocytic neoplasms (nevi or moles) or can go further and lead to formation of 
malignant tumors (melanomas)28,44. These melanocytic lesions have characteristic clinical, 
histopathological and molecular features28,45,46. 
1.2.1. Benign Melanocytic Lesions: Nevi 
Nevus, also generally known as mole, is the medical term used for clearly bounded chronic 
lesions of the melanocytes45. Despite the lack a universal classification consensus, nevi are typically 
classified based on their time of onset (congenital or acquired) and histological structure 
(junctional, compound, dermal or dysplastic)47,48. 
Congenital nevi appear at birth or within the six months after birth49, whereas acquired nevi are 
described to appear after more than six months of age44. Although the chances of malignant 
transformation of congenital and acquired nevi are low, high number of nevi is one of the risk 
factors for developing melanoma22,50. Congenital and acquired nevi can be further sub-classified 
into junctional, dermal, compound or dysplastic nevi according to their histological location within 
the skin45,51,52. Recently, dysplastic nevi has been shown to be an intermediate lesion for 
developing melanoma53 and patients with dysplastic nevi syndrome have high risk of developing 
melanoma54. Nevertheless, the question to which extent nevi can transform into melanoma cells 
still stands55.  
Time of onset, histological location and mutation status of the lesions form the basis for the 
current benign nevi classification (classes such as common acquired, congenital, Spitz and blue nevi 
etc.) by World Health Organization (WHO)45,56-59.  
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Some mutations observed in nevi (i.e. BRAF, NRAS etc.) are also frequently observed in 
melanoma lesions; and in addition, histological similarities between benign and malignant lesions 
lead to misdiagnosis37,38. Indeed, errors in diagnosis of melanoma is one of the major issues for 
cancer malpractice60. 
1.2.2. Malignant Melanocytic Lesions: Cutaneous Melanoma 
Classically, malignant melanomas were classified according to their physical properties such as 
anatomical location, histopathological features and sun damage level28,44,45. The cutaneous 
melanoma was subdivided into 4 categories: superficial spreading melanoma (SSM), nodular 
melanoma (NM), lentigo malignant melanoma (LMM) and acral lentigious melanoma (ALM). Now, 
we know that each melanoma type has its characteristic mutational status as summarized in Figure 
161. SSMs grow horizontally on the skin62 and mostly observed at intermittent sun exposed body 
parts of the body. NMs, considered the most aggressive and invasive type, grow quickly and 
deeper in the intermittent and accumulated sun exposed body parts44,62. LMMs are rarer, grow 
slowly and observed more in elder people and more on skin frequently exposed to the sun63,64. 
ALMs are typically observed on the palms on the hands, on the soles of the feet, and is the most 
common form of melanoma seen among black and Asian ethnic groups63.  Also other rare forms of 
melanoma, uveal melanoma (UM) and mucosal melanoma (MM) exist and together make up the 
non-cutaneous melanomas64. UMs, which make up about 3% of all melanoma cases, occur in the 
iris, ciliary body and choroid of the eye28,65,66. MMs, on the other hand, may arise from 
melanocytes located in mucosal membranes lining several organs such as nasal cavity, oral cavity 
etc.67. 
 
  
Figure 1: Representative characteristic melanoma subtypes along with their most 
frequently associated mutated oncogenes (the most frequent in bold). Source: Ref
61
. 
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According to the WHO classification45 there are also other very rare types of melanoma which 
differ in their specific clinical and/or histological presentation such as desmoplastic melanoma68, 
blue naevus originated melanoma69, naevoid melanoma70, persistent melanoma71, congenital nevi 
originated melanoma72, and melanoma of the childhood73. While ALM and other rare melanomas 
make up about 10% of all melanoma cases, SSM, LMM and NM constitute the majority of the cases 
with 90%. 
1.3. MELANOMA PROGRESSION MODEL 
In 1984, based on histological classification, Clark and colleagues have proposed a linear 
evolution model for melanoma progression in five consecutive stages74-76: acquired and congenital 
nevi formation; transformation into dysplastic nevi with structural and architectural atypia; radial-
growth phase (RGP) melanoma; vertical-growth phase (VGP) melanoma; and metastatic 
melanoma. 
In contrast to this initial five consecutive step model, most of the melanoma patients don’t have 
intermediate stages between normal melanocytes and melanoma lesions77-82 suggesting de novo 
formation of melanoma lesions from melanocytes directly83 (Figure 2).  
 
In these models, generally first phenotypic change in melanocytes is the development of benign 
nevi or dysplastic nevi.  
In benign nevi, frequently observed mutations in mitogen-activated protein kinase (MAPK) 
pathway activating oncogenes (BRAF, NRAS or HRAS) are not enough for malignant transformation 
of the melanocytes85. This phenomenon is known as oncogene-induces senescence (OIS), a tumor 
Figure 2: Model for melanoma progression. Adapted from ref
84
. 
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suppression mechanism that detain the progression of benign tumors into malignant tumors by 
acting as a potent barrier to oncogenic transformation55,86-88. By these mechanisms a nevus can be 
growth-arrested for decades. Tumor suppressor pathways, p19ARF-p53 or p16INK4A-Rb, play critical 
roles in execution of OIS (reviewed in refs89,90). OIS-related phenotype, such as multinucleated 
giant cells and positive SA‐β‐Gal; and expression of OIS markers, such as high levels of p16INK4A and 
decreased levels of Ki67, are observed in benign melanocytic lesions87,91-98. However, these 
features cannot be used as specific markers of benign melanocytic tumors since malignant 
melanoma cells may also exert similar phenotypic and molecular signatures99-103.  
Less understood is the formation of dysplastic nevi, abnormal growth of melanocytes in a pre-
existing nevus or new location resulting in a pre-malignant lesion with random cytologic atypia74. 
Major genetic changes in the transition from benign lesions into dysplastic nevi are the deletion of 
cyclin-dependent kinase inhibitor 2A (CDKNA2), phosphatase and tensin homolog (PTEN) loci and 
mutations in the telomerase reverse transcriptase (TERT) promoter10,51,53.  
Radial growth phase is defined as the horizontal proliferation of melanoma cells intra-
epidermally, as a result of bypassing OIS barrier and accumulating genetic alterations such as loss 
of tumor suppressor genes, mainly CDKN2A104, PTEN105,106, TP53107,108, retinoblastoma 1 (RB1)108 or 
neurofibromin 1 (NF1)109; and the activation of additional oncogenes, such as v-akt murine 
thymoma viral oncogene homolog 3 (AKT3)110 and MITF111. At this stage, melanoma cells are not 
capable of invasion and their survival still depends upon the continuous signaling from 
keratinocytes10,112,113.  
At vertical growth phase, melanoma cells acquire the ability to survive without signaling through 
keratinocytes, resulting in the competency to invade into the dermal layer, thus the capacity to 
metastasize through circulation or lymphatic system. They promote angio‐ and lymphangiogenesis 
by secreting factors such as vascular endothelial growth factors (VEGFs) and fibroblast growth 
factor‐2 (FGF‐2)114. Downregulation of differentiation115 and proapoptotic genes116, or abnormal 
expression of miRNAs117,118 have been credited to this phenotype switch. In addition, deregulation 
of cell adhesion and matrix remodeling factors, such as E‐cadherin, N‐cadherin, matrix 
metalloproteinase‐2 (MMP‐2) and cathepsins have shown to be partially involved in this process119-
121. Secretion of soluble factors and extracellular matrix proteins enable melanoma cells to interact 
and communicate with their microenvironment cells such as fibroblasts, macrophages, mast cells, 
and endothelial cells122,123. Melanoma cells also promote progression by blocking the anti‐tumor 
response of immune cells residing in or recruited to the tumor microenvironment124,125. Over the 
last two decades, with the advances in sequencing technology, several transcriptomic data have 
been produced comparing different stages of melanoma progression. One of the main outcomes of 
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these studies is that the transition from RGP to VGP entails the highest level of molecular changes 
compared to other steps required126-129. These studies helped scientists to identify the players and 
underlined the importance of epithelial-to-mesenchymal (EMT) transition in melanoma 
progression129,130. 
At the metastatic phase, melanoma cells are capable of surviving in the circulation and colonizing 
distant organs upon arrival131. Skin, lymph nodes, brain, liver, bone and intestine are the sites that 
are most frequently colonized by metastatic melanoma cells83. Also in the last decade, studies from 
several groups showed that melanoma cells start sending out signals from the very early stages of 
progression; and these signals prepare (or so to say educate) the organs132 to be metastasized for 
the colonization of melanoma cells to come (for this theory, the term “seed-and-soil” had been 
first coined by Stephen Paget in 1889133). These factors can be sent soluble such as VEGFC134,135, or 
in vesicle enclosed form (exosomes) for distant metastasis136,137. Nevertheless, still there are no 
molecular markers in order to distinguish these steps with high accuracy. 
1.4. GENETIC ASPECTS OF MELANOMA 
To date, numerous genes have been implicated in melanoma development and progression. The 
majority of these genes are involved and have impact on MAPK and phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) pathways as well as cell cycle check-points.  
The v-raf murine sarcoma viral oncogene homolog B (BRAF) is the most frequently mutated 
oncogene among melanoma patients with 50%138,139 (as well as in other cancers66). BRAF, upon 
stimuli from extracellular matrix, such as growth factors, activates downstream MAPK kinases 
(MEK1/2) via phosphorylation which activates downstream extracellular signal-regulated kinases 
(ERK1/2) also via phosphorylation (MAPK pathway), which in turn regulates cell cycle genes (such 
as upregulation cyclin D1 and downregulation of cyclin-dependent kinase inhibitor 1B, p27Kip1), 
altogether leads to hyperphosphorylation of Rb protein and derepression of E2 factor (E2F) 
transcription factor and finally progression through the G1/S phase of cell cycle140,141. A point 
mutation in BRAF gene (predominantly V600E, but also V600K and K601E) causes constitutive 
activation of this gene, resulting in the activation of downstream MAPK pathway without 
extracellular signals, and the promotion of the cell cycle progression continuously140.  
Rat sarcoma (RAS) family proteins act upstream of RAF genes including BRAF, and activate them 
via phosphorylation. In addition, they also activate PI3K/Akt pathway, thus inducing cell 
proliferation and survival. In melanoma, neuroblastoma RAS viral oncogene homolog (NRAS) gene 
is the most frequently mutated member of the RAS family138. BRAF and NRAS mutations appear to 
be mutually exclusive and both lead to activation of the MAPK pathway with the resulting 
induction of proliferation and survival142. Capable of activating both MAPK and PI3K/Akt pathways, 
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NRAS has broader effects on melanoma progression, however the mutation rate of NRAS is lower 
than that of BRAF, around 20%. And as mentioned earlier, mutations in these two oncogenes are 
also found in benign melanocytic lesions: BRAFV600E in 82% of common nevi58 and NRAS in 56% of 
congenital nevi30. As a result of OIS, the overexpression of such oncogenes in cultured melanocytes 
triggers a nonproliferative state91,97, thus other mutations or genetic abnormalities are required to 
develop melanoma. 
Another frequent event (50-60%) observed in melanoma patients is the loss of PTEN. PTEN 
inhibits the activation of PI3K/Akt by inhibiting Akt phosphorylation, thus acts a negative regulator 
of cell cycle143. Loss of PTEN contributes to the promotion of cell cycle in melanoma cells144.  
Another gene that is frequently inactivated in melanoma is CDKN2A: 20-40% of familial 
melanomas harbor germline mutations in this gene. CDKN2A codes for two proteins, p14ARF and 
p16INK4A, both of which have cell cycle inhibitory actions. p14ARF, stabilizes p53 by binding to mouse 
double minute 2 homolog (MDM2) and inhibiting its function, which is to target p53 for 
proteasomal degradation145. p16INK4A, on the other hand, binds to cyclin-dependent kinase 4/6 
(CDK4/6), inhibits its binding to cyclin D1, thus preventing the phosphorylation of Rb protein. So, 
mutations in the CDKN2A gene results in degradation of p53 and hyperphosphorylation of 
retinoblastoma at the same time and promote cell proliferation.  
During the last decade, many genome-wide sequencing studies on melanoma samples have been 
performed and these studies contributed to the identification of other genes mutated or 
deregulated in this disease; such as cell cycle regulators, CCND1, CDK4, TP53, RB, MDM2/4; 
chromatin remodeling genes, ARID1A-B, ARID2, SMARCA4, IDH1, and EZH2 or BAP1 in uveal 
melanoma; MAPK, PI3K pathways regulators, cKIT, GNAQ, ERBB4, AKT3; and also cell-cell 
interaction and cell adhesion proteins, NEDD9 and RAC1 (see Table 1 for a summary of driver and 
additional genetic alterations observed in cutaneous melanoma). However, underlying 
mechanisms driving these molecular changes are not completely understood yet44,59,146-148. 
Besides these aberrant activated/deactivated genes which are shared among different types of 
cancer, there are also some genes which are specific to particular cancer types. These oncogenes 
are known as lineage-specific oncogenes, such as thyroid transcription factor 1 (TITF1) in lung 
cancer149, caudal type homeobox 1 (CDX1) in colorectal cancer150, androgen receptor (AR) in 
prostate cancer151, and estrogen receptor 1 (ESR1) breast152 (reviewed in refs153,154). In melanoma, 
MITF is the best characterized lineage specific gene111. It has been identified to be amplified in 
more than 20% of the cases111. MITF is the master regulator of melanocytic development and 
function by regulating proliferation (positively CDK2 and TBX2; and negatively p16INK4A and 
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p21155,156), survival (BCL2A1, BCL2 and BIRC7157,158) and pigmentation genes (TYR, TYRP1, TRP2 or 
RAB27A159,160).  
Table 1: Driver and additional genetic alterations in melanoma development and progression. 
Sources: Refs
44,146,147,154,161
 
a: 10% acral and 10% mucosal; b: 70-80% uveal; c: metastatic. 
1.5. DEK AS A MELANOMA DRIVER ONCOGENE 
In addition to the above-indicated genes, alterations in chromosome 6 are observed frequently 
in melanoma patients162. Especially, short arm (p) of chromosome 6 amplification is a common 
cytogenetic alteration in cutaneous, mucosal, acral and uveal melanomas163, which is predicted to 
correlate with the poor survival outcome164. Within this amplified area maps the chromatin 
remodeling oncogene DEK. DEK is a DNA binding protein with functions in transcriptional 
modulation, apoptosis, cell proliferation, senescence, differentiation and mRNA splicing (see 
below). Efforts of the Center for Cancer Genomics' (National Cancer Institute) The Cancer Genome 
Atlas (TCGA)161 project recently unrevealed that DEK locus is amplified in 6% and DEK mRNA is 
upregulated in 22.3% of melanoma cases. It is also known to be upregulated in several cancer 
types, such as colon165, breast166, cervical167, hepatocellular168,169 and ovarian170 cancers.  
GENE  ALTERATION  FREQUENCY  
AFFECTED 
PATHWAY  
FUNCTION  
Driver genetic abnormalities  
BRAF  Point Mutation  50%  MAPK  Signaling kinase 
NRAS  Point Mutation  20%  MAPK, PI3K  Signaling kinase 
KIT  Point Mutation  1% overall
a
 MAPK, PI3K  Tyrosine kinase 
GNAQ  Point Mutation  <1% overall
b
 MAPK, PI3K  G protein-coupled receptor  
ERBB4  Point Mutation  15-20%  PI3K  Tyrosine kinase  
CCND1  Amplification  10-18%  Cell cycle  G1 entry  
CDK4  Mutation/Amplification  5-37%  Cell cycle  G1 entry  
Additional genetic abnormalities  
MITF  Amplification  20%  
Melanocyte 
lineage  
Transcription factor  
ETV1  Amplification  15%  MITF, MAPK  Transcription factor  
AKT1/3  Mutation/Amplification  25%  PI3K  Signaling kinase  
PTEN  Mutation/Deletion  50-60%  PI3K  Tumor suppressor  
CDKN2A
 
 Mutation/Deletion  30%  Cell cycle  Tumor suppressor  
TP53  Point Mutation  5-19%  Cell cycle  Tumor suppressor  
RB  Point Mutation  6-14%  Cell cycle  G1/S transition  
MDM2/4  Amplification 3-5%  Cell cycle  S phase  
PPP6C  Point Mutation  9%  Cell cycle  Tumor suppressor  
NEDD9  Amplification 36%
c
 Focal adhesion  Cell-cell interaction, invasion  
RAC1  Point Mutation  5%  Rho  Adhesion/Migration/Invasion  
ARID1/2  Point Mutation  13%  SWI/SNF complex  Chromatin remodeling  
EZH2  Point Mutation  3%  
Histone 
modification  
Chromatin remodeling  
DEK  Amplification  6%  
Histone 
modification  
Chromatin remodeling  
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1.5.1. Cellular Functions of DEK Oncogene 
DEK has contradictory functions on gene regulation as it can activate or repress transcription of 
the target gene. DEK promotes the transcription of complement receptor 2 (CR2) and 
topoisomerase 1 by binding to their promoters in euchromatin171,172. DEK also increases the activity 
of transcription activators activator protein 2 alpha (AP-2α), CCAAT-enhancer-binding protein 
alpha (C/EBPα) and myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 (MLLT3)173-175. 
On the other hand, in other settings, DEK is involved in preserving heterochromatin176. It has been 
shown to interact with death-domain associated protein (Daxx) in a transcription repression 
complex and act antagonistically with nuclear factor kappaB (NF-κB) and tumor necrosis factor 
alpha (TNF-α)177,178. DEK represses the transcription of peroxiredoxin 6 by inhibiting the acetylation 
of its promoter, most likely through inhibition of p300 and p300/CBP-associated factor (PCAF) 
histone acetyltransferases179,180. Thus, DEK is implicated in gene regulation but its precise role is yet 
to be elusive. 
Interestingly, DEK also has been found to be secreted by macrophages in secretome or in 
exosomes. Its secretion attracts immune cells such as neutrophils, natural killer cells and T-cells181; 
and its secretion in exosomes, sequential uptake by DEK depleted target cells and translocation to 
the nucleus has been observed to correct heterochromatin depletion and DNA repair deficits182. 
DEK is overexpressed in highly proliferative cells and its expression decreases with differentiation 
183,184. In melanoma cells, our group has shown that: (i) DEK is upregulated in melanoma cells, (ii) 
DEK downregulation results in impaired proliferation and increased senescence, and (iii) DEK 
contributes to chemoresistance of melanoma cells due to upregulation of myeloid cell leukemia-1 
(MCL-1) gene185. Similarly reduced proliferation was observed in keratinocytes and breast cancer 
cell lines upon shRNA mediated depletion of DEK (results validated by overexpression as well)183,184. 
Depletion of DEK causes apoptosis in p53-dependent186 or independent manners (the latter 
through MCL-1)186. DEK also contributes to the chemoresistance against genotoxic agents186,187, 
whereas its depletion prevents the activation of DNA damage response188. And also, its 
overexpression in HRAS and HPV-E6 and E7 oncogenes induced keratinocytes led to the increased 
colony formation in anchor independent medium189.  
Another function of DEK, although the mechanism is not fully clear, is reported to be to interact 
with splicing factor U2AF and to be essential for intron removal190,191. 
1.5.2. Regulation of DEK Oncogene 
At the transcriptional level, DEK has been shown to be regulated by transcription factors E2F1192, 
NFY, YY1193 and ERα194. On the posttranslational level, phosphorylation, acetylation and poly(ADP-
ribosyl)ation regulates DEK. Casein kinase 2 (CK2) phosphorylates DEK and decreases its DNA 
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binding affinity and increases its interaction with histones and histone chaperone activity195,196. 
Acetylation of DEK also decreases its DNA binding affinity and allocates DEK to interchromatin 
granule clusters with RNA processing machinery197. Also, miR-489 was shown to suppress DEK 
expression in muscle stem cells198 (see Figure 3 for summary). Nonetheless, the intracellular 
mechanisms underlying DEK regulation, especially at post-transcriptional level are not completely 
understood, particularly in melanoma. 
 
1.6. CURRENT TREATMENT OPTIONS FOR MELANOMA 
Until few years ago the standard treatment for metastatic melanoma was limited with the 
alkylating agent dacarbazine, which presented very low response rates200,201. In 1998, Food and 
Drug Administration (FDA) approved use of high doses of interleukin-2 (IL-2), but the outcome was 
still far away from expectations with serious side effects202,203. In the last 5 years, therapies 
targeting MAPK pathway started to emerge. In 2011 and 2013, FDA approved BRAFV600E inhibitors, 
vemurafenib and dabrafenib; and a MEK inhibitor204-206. Nevertheless, these inhibitors were 
effective only in patients with mutant genes and tumor resistance and relapses appeared in most 
of patients after initial recession207. Other immunotherapeutic approaches approved by FDA are 
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor, ipilimumab; and programmed 
cell death protein 1 (PD-1) inhibitors pembrolizumab and nivolumab208. CTLA-4 inhibitors bind to 
CTLA-4 expressed on tumor cell surface and block the inhibitory action of these molecules on T-
cells209,210. PD-1 inhibitors, on the other hand, bind and block the inhibitory signal from PD-L1 
molecules on melanoma cell surface211-213. But still, the efficacy of these treatments depends on 
pre-existing T-cells in the microenvironment and/or PD-L1 expression by melanoma cells, which 
limits these therapies to a division of patients214,215. Currently, many studies are directed to unveil 
new drug targets to design new strategies in order to improve patient outcome. However, 
malignant melanoma which is characterized by its high propensity to metastasize and by being the 
Figure 3: Schematic summary of DEK regulation. SAF: scaffold attachment factor-box, NLS: nuclear 
localization signal, CK2: Casein kinase 2. Adapted from ref
199
. 
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most lethal form of skin cancer, accumulates a plethora of changes in the transcriptome and the 
proteome28,31,216 with approximately 79000 mutations/genome217; which makes the search for new 
targets very intricate.  
2. RNA BINDING PROTEINS (RBPs) 
RNA binding proteins are one of the most abundant groups of proteins. In a recent study, 1542 
manually curated RBPs were identified by bioinformatic analyses and manual curation218. Cellular 
functions controlled by RBPs (described below) range from alternative splicing to RNA decay; from 
RNA transportation to translational control219-221 (see Figure 4). Ultimately RNA binding proteins 
control levels of overall and isoform specific translation, localization and export of mRNAs222.  
2.1. RBPs IN ALTERNATIVE SPLICING 
The spliceosome is the largest multiprotein complex, which is composed of 5 uracil rich small 
nuclear RNAs (snRNA – U1, U2, U4, U5 and U6) and more than 200 highly dynamic proteins223,224; 
and RBPs are main components of this complex. Studies estimate that more than 95% of multiexon 
genes undergo alternative splicing, which expands the proteomic reservoir225-227.  
2.2. RBPs IN RNA EDITING 
RBPs can also function in RNA editing. Adenosine-to-inosine editing by adenosine deaminase 
acting on RNA (ADAR) proteins change the splicing and the protein outcome of the mRNAs since 
inosine is interpreted by the spliceosome or translation machinery as guanosine228,229. In melanoma 
cells, ADAR1 expression has been shown to be low, and restoring its expression suppresses 
melanoma growth and metastasis in vivo through editing miR-455-5p and changing the set of gene 
targets of it230.  
2.3. RBPs IN NUCLEAR AND CYTOPLASMIC POLYADENYLATION 
Almost all eukaryotic mRNAs undergo several modifications in the nucleus that include, among 
others, the addition of a poly-adenosine tail (poly(A)) at the 3’ end231. This poly(A)-tail contributes 
not only to mRNA stability and nuclear export, but also to translation initiation, thus expression of 
the transcript232,233. In addition to nuclear polyadenylation, around 20% of transcripts undergo 
cytoplasmic polyadenylation234 by cytoplasmic polyadenylation element binding proteins (CPEBs). 
CPEBs have functions in several biological processes including senescence and tumor formation by 
altering and regulating stability of their targets (reviewed in ref235). In melanoma, it has been 
shown that the inhibition of CPEB1 by miR-455-5p is required to sustain the metastatic potential of 
melanoma cells230. 
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2.4. RBPs IN mRNA STABILITY AND TRANSLATION 
One of the most direct effects of RBPs on gene expression is exerted by their function on mRNA 
stability and translational regulation. For example, HuR/ElavL1 protein binds to AU-rich elements 
(ARE) on its targets and stabilize them by protecting them from degradation machinery leading to 
more translation (by interacting with polysomes) and more protein levels236. In docosahexaenoic 
acid treated melanoma cells, HuR was shown to stabilize COX-2 mRNA and contribute to apoptosis 
resistance237. On the contrary, K homology splicing regulatory protein (KSRP) binds to AU-rich 
elements and recruit exonucleases as well in order to destabilize the target mRNA, leading to lower 
protein levels238.  
2.5. RBPs IN mRNA EXPORT AND LOCALIZATION  
mRNA export and localization is regulated and operated by RBPs, such as UAP56 and ALY, which 
would eventually enable the translation of the nascent transcripts239,240. Recently, Luzp4, an export 
adaptor RBP, has been found up-regulated in a wide range of tumors and preferentially in 
melanoma cells241. In this study, it has also been reported that Luzp4 interacts with other RBPs, 
UAP56 and Nxf1, and that Luzp4 downregulation results in decreased number of colonies formed, 
suggesting an essential role in melanoma cell growth.   
Moreover, many RBPs, such as polypyrimidine-tract-binding protein (PTB), RNA binding motif 
protein 47 (RBM47), heterogeneous nuclear ribonucleoprotein A1 and members of CUG repeat 
binding protein, Elav-like family (CELF1/CUGBP1 and CELF2/CUGBP2) bind to multiple targets and 
operate in diverse processes242-245. The functions of these multifunctional proteins are system and 
cell type dependent and they have been reported to be involved in various cancer types such as 
breast and oral squamous carcinomas243,246,247. Evidently, abnormalities in RBPs expression can lead 
to different diseases, including cancer219,248-250. 
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3. CUG REPEAT BINDING, ELAV-LIKE FAMILY PROTEINS (CELF/CUGBP) 
Several names have been used for the members of this protein family, the most common ones 
are CELF and CUGBP (see other names in Table 2). Here we will follow the CUGBP nomenclature. 
Table 2: Different names of CUGBP family members. 
Gene Name CELF1 CELF2 CELF3 CELF4 CELF5 CELF6 
Protein 
Name 
CUGBP1 
CUGBP 
BRUNOL2 
NAB50 
CUGBP2 
BRUNOL3 
ETR3 
NAPOR 
CUGBP3 
TNRC4 
BRUNOL1 
CAGH4 
CUGBP4 
BRUNOL4 
 
CUGBP5 
BRUNOL5 
 
CUGBP6 
BRUNOL6 
 
 
There are 6 members of CUGBP family which are very similar in their domain structure. CUGBPs 
contain 2 RNA recognition motifs (RRM) in their N-terminal region, and 1 RRM in their C-terminal 
region connected by a linker region251. Based on their sequence similarities, they can be divided 
into two subfamilies: CUGBP1-2 in one subfamily and CUGBP3-6 in another one (see Figure 5A and 
5B). The structure similarities between members of the subfamilies are also reflected in their 
expression patterns and functions252.  
mRNA and protein expression of CELF genes has been shown in various organisms including 
frogs253,254, fish255, birds256, mice257,258 and humans259-261, demonstrating that  CUGBP3-6 are largely 
Figure 4: Functions of RNA binding proteins. 
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restricted to the nervous system in adults, whereas CUGBP1 and CUGBP2 show ubiquitous 
expression in tissues such as eye, cardiac and skeleton muscle cells as well as nervous system 
during embryonic development and later on during adulthood245,256,261,262.  
In functional terms, although expression of CUGBP3 is predominantly in the brain,  Celf3 
knockout mice display spermatogenesis defects263. Moreover, expression level of CUGBP3 
deregulates  cell proliferation of endoderm-origin organ development in Xenopus models264. 
CUGBP4 scarcity has been shown to give rise to eye defects and seizure lesions in the brain both in 
human patients and mouse models265-267. Also, studies with Cugbp6 knockout mouse model have 
showed autism‐related behaviors268. 
CUGBP2 has been most intensively studied in the brain269-274, muscle cells275 and recently in few 
cancer models276-279; and its apoptosis related roles have been shown following irradiation of 
cancer cells272,280-282. Moreover, its genomic deletion has been implicated in cardiac and thymus 
defects260. 
The most studied member of this protein family has been CUGBP1 and its characteristics are 
discussed below in detail. 
 
  
Figure 5: A, Domain structures of CUGBP family members. Source: Ref
251
. B, Domain sequence similarities 
(as percentage) amongst CUGBP family members. Source: Ref
252
. 
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4. CUG-REPEAT BINDING PROTEIN 1 (CUGBP1) 
CUGBP1 is a multifunctional RBP that confers post-transcriptional functions on pre-mRNAs by 
regulating alternative splicing, and also on mature mRNAs by regulating translation and modulating 
stability283-285. CUGBP1 was identified in a search for RBPs that bind to a transcript generated from 
CTG repeat expansion in dystrophia myotonica protein kinase (DMPK) gene286.  DMPK is the 
genetic cause of myotonic dystrophy type I disease (DM1 or Steinert disease) with symptoms such 
as wasting of muscles, heart conduction defects and myotonia286. In DM1, available CUGBP1 levels 
are reduced (due to the sequestration onto the expanded CUG repeats in DMPK mRNA). This alters 
the balance of CUGBP1 functions, such as alternative splicing of several mRNAs (explained 
below)286. 
4.1. CONSERVED BINDING SEQUENCES OF CUGBP1 
Initially, CUGBP1 was found to bind to CUG repeats, a feature supported by electron 
microscopy287. Subsequently, yeast two hybrid studies revealed UG repeats as CUGBP1 targets288, 
and most recently, the binding sequence of CUGBP1 has been defined as GU-rich elements (GREs), 
the most accepted being the 11-mers UGUUUGUUUGU and UGUGUGUGUGU284,289. From a 
mechanistic perspective, spectroscopic nuclear magnetic resonance (NMR) and crystallography 
revealed recognition sites for the RRM1 and RRM2 domains290,291: CUG for RRM1, and UGUU for 
RRM2. Other studies point instead to RRM3 as the more relevant RNA recognition motif292,293. In 
addition, the divergent domain connecting RRM1 and RRM2 to RRM3 has also been reported as 
relevant, most likely via exerting conformational changes in CUGBP1288. Overall, these studies show 
the binding preferences of different RRMs of CUGBP1 for different sequences with the 
indispensable contribution of the linker domain. In all scenarios, most known CUGBP1 sequences 
are GREs, although whether this is the case in melanoma is unclear, and addressing this question is 
a main objective of this PhD Thesis. 
4.2. CUGBP1 REGULATION 
At the transcriptional level, studies in normal and differentiated myoblasts have identified 
several transcriptional modulators of CUGBP1: myogenin as a key one, acting through a E-box3 in 
the CUGBP1 promoter294. In addition, three micro-RNAs have been show to regulate CUGBP1 at 
posttranscriptional level295,296. Specifically, studies in inducible heart specific dicer knockout mice 
and in rat intestinal crypt cell lines (IEC-6) have demonstrated that miR-23a/b295, miR-222296 and 
miRNA-503297 regulate the CUGBP1 mRNA levels by recruiting it to the processing bodies.  
Regarding posttranslational regulation, CUGBP1 stability and cellular functions have been related 
to phosphorylation at residues S28 and S302298. In DM1, this phosphorylation (in part mediated by 
PKC) promotes CUGBP1 upregulation in muscle cells of affected patients298. PKC-mediated 
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phosphorylation of CUGBP1 was also found relevant in postnatal heart and skeletal muscle 
differentiation, as defined by PKC inhibitors (Nis-IX and Bis1)299. S28 can be modified by AKT, a 
process that increases CUGBP1 interaction with target mRNAs, modulating its roles on protein 
translation300.  In turn, S302 is phosphorylated by cyclin D3/Cdk4-6 in aging mouse liver, increasing 
the interaction affinity of CUGBP1 with eukaryotic initiation factor 2 (eIF2)301.  
4.3. CELLULAR FUNCTIONS OF CUGBP1 
Roles of CUGBP1 in cancer are not completely understood, but are likely to depend on the 
position of the GREs in the target mRNA, as described in other systems. Thus, (i) GREs at flanking 
areas of introns can modulate alternative splicing, (ii) at 5’UTR, regulate translation, and (iii) the 
3’UTR can affect deadenylation (see Figure 6). However, it is important to note that these three 
functions are cell type and target dependent. To follow is a more detailed summary of cellular 
functions of CUGBP1. 
 
4.3.1. CUGBP1 as an Alternative Splicing Regulator 
The role of CUGBP1 as an alternative splicing regulator has been mainly studied in muscle cells, 
in vitro and in vivo (see summary and references in Table 3). There, CUGBP1 may favor exon 
inclusion or exclusion depending on the localization of the GRE that it targets. For example in the 
C2CL12 mouse myoblast cell line, CUGBP1 can facilitate exon skipping when GREs are located in 
introns at the 5’ flanking site of the exon;  instead when the GREs are the 3’flanking intron, exons 
may be included283.  Among the alternative splicing events that have been linked to CUGBP1 
(summarized in Table 3) one of the best characterized is the insulin receptor (IR) gene302-304. In vitro 
and in vivo studies using normal and myotonic dystrophy myoblasts, and mouse models 
demonstrated that CUGBP1 overexpression favors the inclusion of IR exons 5 and 11 as a result of 
agonistic and antagonistic interactions with two other trans-acting RBPs (hnRNP-h and MBNL1)302-
304. Other relevant splicing events are exon 22 of SERCA1305, exon 17 of FXR1305, exon 5 of 
FAM188A305, exon 21 of ANK2305, exon 20 of ACTN1306,307, exon 7a of MEF2A306,307 and exon 9 of 
PPFIBP1306,307. Here we will show that main known CUGBP1 splicing targets are not altered by 
Figure 6: Cellular functions of CUGBP1. 
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depletion of this gene in melanoma cells, pointing to new mechanisms of action of this RNA 
binding factor. 
Table 3: Genes and exons regulated by alternative splicing function of CUGBP1 in different cell lines.           
* indicates studies that used cancer cells. 
TARGET SYSTEM [REF.] 
cTNT (e5) Cardiac and skeletal muscle cells 308 
C/EBPb ( LIP/LAP) Mouse liver 309 
a-actinin ( SM/NM exon) Muscle cells 307 
a-actinin (SM/NM exon) Mouse fibroblast L cells 310 
C/EBPb (LIP/LAP) Cardiac and skeletal muscle cells 311 
C/EBPb (LIP/LAP) MCF10A (mammary epithelial cell) 312 
Mtmr1 (e2.2), MEF2A (e16), ITGB1 (eD), BIN1 
(e10) 
Cardiac and skeletal muscle cells 306 
Tnnt2 (e5), Mtmr1 (e2.2), Clcn1 (e7a), IR (e5), 
cTNT (e11), Clcn1 (e2) 
Cardiac and skeletal muscle cells 303 
C/EBPb (LIP/LAP) Mouse liver 313 
C/EBPb (LIP/LAP) 3T3-L1 preadipocytes  314 
IR (e11) Normal and myotonic dystropy myoblasts 304 
Clcn1 (e7a), TnnT3 Inducible CTG repeat mouse model 315 
C/EBPb (LIP/LAP) Primary macaque macrophages & U937 316 
Clcn1 (e7a), Serca1 (e2.2), Cypher (e11), Ank2 
(e21), Capzb (e8), Fxr1 (e15, e16) 
Cardiac and skeletal muscle cells 305 
NMDAR-1 (e5), GABT4 (e7) 
SK-N-SH (Neural (bone marrow metastasis) from 
human) 
317 
Clcn1 (e7a), MBNL1 
Kennedy Disease mouse model 
(CAG repeats in AR gene) 
318 
Ank2 (e21), Cypher (e11), Mtmr1 (e2.2), H2afy 
(e6b), Capzb (e8), Serca1 (e2.2), Fxr1h (e15), 
RyR1 (e70), Gfat (e10) 
Skeletal muscle 319 
Ank2 (e21), Sorbs1 (e6), Mtmr3 (e16), Mfn2 
(e3), H2afy (e6) 
Heart muscle 295 
B-tropomyosin (e6b) Skeletal muscle 320 
Bcl-x Rat oligodendrocyte progenitors, HeLa & C6 Cells 321* 
C/EBPb ( LIP/LAP) HeLa 322* 
4.3.2. CUGBP1 as a Translational Regulator 
Translational regulation is the least studied and understood function of CUGBP1. In particular, 
CUGBP1 has been shown to increase p21 protein (but not mRNA levels) during muscle cell 
differentiation285. Other systems where p21 has been modulated by CUGBP1 are mouse embryonic 
fibroblasts (MEFs) undergoing premature senescence323. 
Another known target of CUGBP1 in translational control is the CCAAT/enhancer-binding protein 
beta (C/EBPβ) gene, reported in liver309,322. C/EBPβ is an intronless gene, coding for several 
isoforms due to alternative ATG start sites. The ratio between the longer isoform, liver-enriched 
activator protein (LAP), and the shorter isoform, liver-enriched inhibitory protein (LIP), is an 
important modulator of cell cycle progression during liver regeneration324. After partial 
hepatectomy in mice, CUGBP1 gets hyperphosphorylated and replaces calreticulin (CRT), which in 
turn increases LIP/LAP ratio expression313. In the same study CUGBP1 was shown to bind to 
translation initiation factors eIF2a and eIF2b targeting them to the downstream ATG of C/EBPβ 
ultimately increasing the LIP/LAP ratio. CUGBP1-dependent increase in LIP/LAP ratio has also been 
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observed in preadipocyte cell lines upon oltipraz treatment which results in blocked 
adipogenesis314; as well as in primary macaque macrophages and human leukemic monocyte 
lymphoma cell line in which CUGBP1 is shown to be required for interferon beta (IFNβ)-mediated 
induction of LIP isoform316.  
CUGBP1 has also been shown to be involved in induction of internal ribosome entry sites (IRES), 
although with distinct effects depending on the gene, namely, favoring the translation of the serine 
hydroxymethyltransferase 1 (SHMT1)325 while repressing p27326 in MCF7 cell line, but the precise 
mechanisms underlying these opposing effects are unclear. Translation-associated positive or 
negative effects of CUGBP1 in cancer are not well understood, and addressing this question in 
melanoma is also a global objective of this PhD Thesis. 
4.3.3. CUGBP1 as an mRNA Decay Modulator 
Various studies have been performed to assess CUGBP1 roles and targets (see Table 4). For 
mRNA decay, high throughput studies to identify roles of CUGBP1 as an mRNA decay modulator 
have been only reported by RNA-immunoprecipitation followed by microarrays in HeLa cells and 
resting and activated T-cells284,327. In these studies, CUGBP1 was shown to be responsible for the 
destabilization of the target mRNAs by binding to 3’UTR-located GREs, a process weakened if 
CUGBP1 is phosphorylated327, supporting results in yeast289. A proposed mechanism for mRNA 
destabilization has been related to the recruitment of the poly(A)-specific ribonuclease (PARN), 
with the subsequent poly(A) tail shortening and degraded by 3’-to-5’ exonucleases328. However, 
emphasizing the complexity of CUGBP1 functions, this protein can also stabilize mRNA transcripts, 
for example interfering with microRNAs (i.e. as the case for miR-122 in hepatocellular 
carcinoma)329. In summary, CUGBP1 can recognize multiple mRNAs and at multiple sites, but the 
ultimate impact of this binding may be gene, tissue and context dependent.  
Intriguingly, and as we will show in the Figure 12F of the results section, the overlap in the 
targets whose stability are controlled by CUGBP1 in HeLa284 and T-cells327 is minimal (just 1% of 
common genes).  
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Table 4: High throughput analyses of CUGBP1. n.d. not determined. 
SYSTEM METHOD FUNCTION # TARGETS VALIDATED TARGETS REF. 
X. tropicalis 
egg extracts 
RIP + 
Microarray 
Binding 162 genes Lmo4, Cdk1, Cdk2, CPEB, 
ZMPste24 
330 
Myelogenous 
leukemia cell line 
RIP-ChIP Binding 2359 Genes -- 331 
Lymphoblastoid 
cell line  
RIP-ChIP Binding 147 Genes -- 331 
Embryonic chicken 
heart 
CLIP Binding 
and 
Splicing 
170 genes MYH7B, HOPX 
332 
C2C12 mouse 
muscle cell line 
HITS-CLIP Splicing n.d. Sox4, Wtap, MHC, Erbb2ip, 
Ctage5, Ddr1, Dst, Ktn1, Abi1, 
Ciz1, Itga6, Mtap4, Ndrg4, 
Rhot1 
283 
Heart and muscle 
specific CUGBP1 
overexpressing 
mice 
CLIP Splicing 540 exons in heart 
388 exons in 
muscle 
Clcn1 
333 
Embryonic chicken 
cardiomyocytes 
RNA-seq 
upon 
siCUGBP1 
RNA-Seq 8552 transcripts -- 
334 
C2C12 mouse 
muscle cell line 
RIP + 
Microarray 
mRNA 
Decay 
881 transcripts cJun, Rnd3, Smad7, Ppp1r15b, 
Myod1 
335 
HeLa RIP + 
Microarray 
mRNA 
Decay 
328 Genes JunD, TOP1, UBE3A 284 
T-Cells RIP + 
Microarray 
mRNA 
Decay 
1137 Genes JunB, AKT, EPHA4, NDUFS2, 
GSN,PPIC 
327 
 
5. CUGBP1 AND CANCER 
CUGBP1 is emerging as a relevant modulator of tumor cell progression and/or survival, although 
detailed analyses of the involved targets are still limited (see Table 5 for summary). Initial reports 
related to non-small cell lung carcinoma (NSCLC) has shown that CUGBP1 was linked to worse 
postsurgical survival, in part due to enhanced brain metastasis329. Moreover, retrospective 
analyses suggested reduced overall survival in cases with high CUGBP1 expression336,337. In 
addition, studies in hepatocellular338 and gastric339 carcinoma cell lines demonstrated that short-
hairpin RNA (shRNA) mediated downregulation of CUGBP1 promoted cell cycle arrest. In both cell 
lines, CUGBP1 depletion led to downregulation of cyclin B1338,339. However, cyclin D1, another key 
factor in cell proliferation, was upregulated by CUGBP1 depletion in hepatocellular carcinoma cell 
line338, but downregulated it in the gastric carcinoma cell line339. Data in other cancer types relate 
BIRC5 in esophageal cancer cell lines340. On the other hand, CUGBP1 has been shown to destabilize 
CD9 in HeLa and acute lymphocytic leukemia; and c-Fos in HeLa cell line341. Also C/EBPα 
modulation in non-small cell lung cancer cells342 has been shown.  
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Table 5: Cancer related roles of CUGBP1 in different cancer types. 
SYSTEM TARGET/FINDING REF. 
NSCLC patient biopsies and follow-up Negative correlation with post surgical 
survival 
337 
NSCLC patient biopsies Positive correlation with brain metastasis 336 
HepG2 - hepatocellular carcinoma  
CCNB1 downregulation 
CCND1 upregulation 
338 
MGC-803 - gastric cancer  
CCNB1 downregulation 
CCND1 downregulation 
339 
TE7 & TE10 - esophageal cancer  
BIRC5 stabilization 
Protection against apoptosis 
340 
HeLa - cervical cancer 
REH - acute lymphocytic leukemia  
CD9 destabilization 
c-Fos 
341 
A549 - NSCLC  C/EBPα downregulation 342 
 
To date, no published data is available regarding neither the expression nor the function of CUG 
repeat binding protein family members in melanoma. In addition, identified CUGBP1 targets fail to 
be consistent in different settings and comprehensive CUGBP1-controlled networks have not been 
published. With this background, the main purpose of this PhD thesis is to identify the expression 
levels of RBPs in melanoma; and in particular to understand the function of CUGBP1 in this disease 
by unraveling the gene networks that it controls. 
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Melanoma is a paradigm of histopathologically complex tumors, proceeding with the highest 
mutational rate known to date, and accumulating a plethora of changes in their transcriptome and 
proteome. Yet, RNA binding proteins, factors which have the inherently ability to impinge on a 
broad spectrum of oncogenic and suppressive signaling cascades, remain poorly understood in this 
disease. A comprehensive mining of all 692 RBPs described to date failed to suggest consistent 
mutations of copy number alterations in human melanoma specimens. Therefore, we turned to 
comparative transcriptomic profiles that could reveal differential RBP expression in melanoma cells 
vs. normal melanocytes. This analysis identified CUGBP1 as a putative novel melanoma-associated 
factor. The Specific Aims of this study were therefore as follows: 
1. To perform a histological characterization of CUGBP1 expression in melanoma progression 
(normal skin, benign nevi and malignant clinical specimens) 
2. To define the requirement and functional impact of CUGBP1 in melanoma cells. 
3. To dissect the gene networks regulated by CUGBP1, integrating RNA immunoprecipitation, 
transcriptomic and proteomic analyses. 
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1. CELL CULTURE 
The human melanoma cell lines SK-Mel-5, SK-Mel-19, SK-Mel-28, SK-Mel-29, SK-Mel-103, SK-
Mel-147, G-361, UACC-62, WM-1366 and LU-1205 (see Table 6 for mutation status) and non-
melanoma tumor cell lines 639V (bladder cancer), A549 (non-small cell lung cancer), BT549 (breast 
cancer), HCT116 (colorectal cancer), HeLa (cervical cancer), MiaPaca-2 (pancreatic cancer), U251 
(glioma) and 293FT (transformed human embryonic kidney cells) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Lonza, cat. no. BE12-604F/U1) supplemented with 10% fetal 
bovine serum (FBS, Lonza, cat. no. DE14-801F) and 100 μg/mL Penicillin/Streptomycin (Invitrogen, 
cat. no. 15070-063). Primary human melanocytes, keratinocytes and fibroblasts were isolated as 
described before343 from neonatal foreskins obtained from the Hospital Niño Jesús, Madrid, Spain. 
Melanocytes were cultured in Medium 254 (Invitrogen, cat. no. M-254CF-500) supplemented with 
1% melanocyte growth factors (HMGS, Invitrogen, cat. no. S-002-5), 0.2 mM CaCl2 and 100 μg/mL 
Penicillin/Streptomycin; keratinocytes were cultured in Epilife Medium (Invitrogen, cat. no. M-Epi-
500) supplemented with 1% keratinocyte growth factors (HKGS, Invitrogen, cat. no. S-001-5), 0.2 
mM CaCl2 and 100 μg/mL Penicillin/Streptomycin and fibroblasts were cultured in DMEM, 
supplemented with 10% FBS, and 100 μg/mL Penicillin/Streptomycin. 
 
Table 6: Human melanoma cell lines used in this PhD thesis study. 
(*: protein levels, WT: wild type, 
R
: repressed and nd: not determined) 
 
CELL LINE BRAF NRAS PTEN* TP53 DEK* 
SK-Mel-5 V600E WT + WT
R
 ++ 
SK-Mel-19 V600E WT + WT ++ 
SK-Mel-28 V600E WT + R273H ++ 
SK-Mel-29 V600E WT - WT ++ 
SK-Mel-103 WT Q61R + WT
R
 +++ 
SK-Mel-147 WT Q61R + WT
R
 ++ 
G-361 WT/V600E WT - WT
R
 + 
UACC-62 V600E WT - WT + 
WM-1366 WT Q61R nd nd +++ 
LU-1205 V600E WT nd nd + 
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2. PROTEIN IMMUNOBLOTTING 
Cells were harvested and total cell lysates were obtained using 1X Laemmli buffer (62.5 mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol and 5% β-mercaptoethanol) and boiled at 95°C for 7 minutes. 
Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories) 
according to manufacturer’s protocol. Protein immunoblots were performed by standard SDS-
PAGE electrophoresis in 10 or 12% polyacrylamide gels and subsequently transferred to 
Immobilon-P membranes (Millipore) using Mini Trans-Blot Cell system (Bio-Rad Laboratories). 
Transfer was performed at 100V during 1 hour at 4°C. Membranes were blocked with 5% milk in 
tris-buffered saline with 0.05% Tween-20 (TBS-T) for 1 hour at RT. Primary and secondary 
antibodies were diluted in 5% milk TBS-T incubated overnight at 4°C or 1 hour at RT. Primary 
antibodies used were: CUGBP1 (Abcam, ab9549), CUGBP2 (Sigma, AV40323), CCND1 (Santa Cruz 
Biotechnology, 8396), DEK (BD Transduction Laboratories, 610948), and Actin (Sigma-Aldrich, 
A5441). HRP-conjugated secondary antibodies used were anti-mouse and anti-rabbit (GE 
Healthcare) or anti-goat (Jackson Immunoresearch). When indicated, image J software was used to 
quantify protein band intensities.  
3. RNA EXTRACTION, PCR and RT-QPCR   
Total RNA was extracted and purified from cell pellets using RNeasy Mini-Kit (QIAGEN) following 
the manufacturer’s instructions. RNA concentration was determined by NanoDrop 
Spectrophotometer ND-100 (NanoDrop Biotechnologies). 1-2μg total RNA was reverse-transcribed 
into cDNA using the high capacity cDNA reverse transcriptase kit (Applied Biosystems), according to 
manufacturer´s protocol. 20 ng of the total cDNA were subjected to real-time quantitative 
polymerase chain reaction (RT-qPCR - 60°C annealing temperature) using Power SYBR® Green PCR 
Master Mix (Applied Biosystems). Assays were run in triplicates on the 7900HT Fast Real-Time PCR 
system (Applied Biosystems) or QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems). 
The primer sequences and annealing temperatures listed on Table 7. HPRT and GAPDH were used 
as loading control to normalize mRNA expression. 
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Table 7: List of primers used in this PhD thesis study (°C: annealing temperature). 
PCR/qPCR PRIMERS 
GENE FORWARD PRIMER (5’ – 3’) REVERSE PRIMER (5’ – 3’) °C 
CUGBP1 GTGGAAGACAGGAAGCTGTTT GCCGTCTGTGCCATGGCTCTTG 60 
DEK GCCATGTTAAAGAGCATCTGTG CAGAAGGCTTTGGATGCATTA 60 
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA 60 
GAPDH GAAGGTGAAGGTCGGAGTCAAC TGATTTTGGAGGGATCTCGCTC 60 
INSR CCAAAGACAGACTCTCAGAT AACATCGCCAAGGGACCTGC 54 
SERCA1 GATGATCTTCAAGCTCCGGGC CAGCTCTGCCTGAAGATGTG 54 
FXR1 GATAATACAGAATCAGATCAG CTGAAGGACCATGCTCTTCAA 54 
FAM188A GAGGAAACTGCTAGTATTTC CCAAATTTATTTCCCCACAT 54 
ANK2 TACCTCCAGACCCCAACATCC TCTTTACCACGGTGTGTCCAT 54 
ACTN1 CGGGCCTCCTTCAACCACTTT TCCACAATGCTCATGATGCGG 54 
MEF2A GAATGAACAGTAGGAAACCAG GCTGGTCAGTGAATAATCAGT 54 
PPFIBP1 TAGTGAAATGGACAGTGAGA CAATTTTTCTTGTAGCCTTT 54 
DEK 3’UTR 
Fragment 1 
see FLAG Forward Primer GGTCAGCAGTAAGTTCTACTAAC 58 
DEK 3’UTR 
Fragment 2 
see FLAG Forward Primer CATCTGTCACTTTTGTCATGCTG 58 
DEK 3’UTR 
Fragment 3 
see FLAG Forward Primer GTGCTTGTACTTAATCCCACCC 58 
DEK 3’UTR 
Fragment 4 
see FLAG Forward Primer CCTTTCCCTAGTGTCTGAGTAAC 58 
FLAG GATTACAAGGATGACGACGATAAG  58 
CLONING PRIMERS 
FRAGMENT FORWARD PRIMER (5’ – 3’) REVERSE PRIMER (5’ – 3’) °C 
DEK 3’UTR 
Fragment 1 
AGCCCTCGAGGATTACAAGGATGACGA 
CGATAAGGATAGAGGACAGAGAAGAT 
TAGGGGATCCCACACTGACAGAGA 
TGTGTATTC 
58 
DEK 3’UTR 
Fragment 2 
AGCCCTCGAGGATTACAAGGATGACGA 
CGATAAGAAAATTCAGCGGCAGTGTG 
TAGGGGATCCGGGTAACTGTTCCT 
TCAGTGTTGCC 
58 
DEK 3’UTR 
Fragment 3 
AGCCCTCGAGGATTACAAGGATGACGA 
CGATAAGTGCTTTGCCTCGAAAGTGT 
TAGGGGATCCGGTGCAACAAATG 
TGTCATTGTGTC 
58 
DEK 3’UTR 
Fragment 4 
AGCCCTCGAGGATTACAAGGATGACGACG 
ATAAGAATTAAGTGTTGAAAAATATCTTTGC 
TAGGGGATCCTGGTGATACATCC 
ATTTAATAAGTGTGCG 
58 
 
4. CLONING OF DEK 3’UTR FRAGMENTS 
DEK 3’UTR fragments were amplified with the indicated primers listed on Table 7 to obtain the 
following fragments (estimated UG repeats underlined). 
Fragment 1 
gauagaggacagagaagaugacucguucccauagauuugaagaucugauuuauaccauuauaccagcaaagagaauguauuucc
uuuucuaaauccuuguuaagcaacguuaguagaacuuacugcugaccuuuuuaucuugaguguuaugugaauuugaguuugc
uguuuuaaauugcauuucuaugccauuuuuaguuuaaaaucuugcauggcauuaauuguuccuugcuuuuauaguuguauu
uuguacauuuuggauuucuuuauauaaggucauagauucuugagcuguugugguuuuuagugcacuuaauauuagcuugcu
uaaggcauacuuuuaaucaaguagaacaaaaacuauuaucaccaggauuuauacauacagagauuguaguauuuaguauauga
aauauuuugaauacacaucucugucagugug  
   
Fragment 2 
aaaauucagcggcaguguguccaucauauuaaaaauauacaagcuacaguuguccagaucacugaauuggaacuuuucuccugc
auguguauauaugucaaauugucagcaugacaaaagugacagauguuauuuuuguauuuuuaaaaaacaauugguuguauau
aaaguuuuuuuauuucuuuugugcagaucacuuuuuaaacucacauagguagguaucuuuauaguuguagacuauggaaugu
caguguucagccaaacaguaugauggaacagugaaagucaauucagugauggcaacacugaaggaacaguuaccc 
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Fragment 3 
ugcuuugccucgaaagugucaucaauuuguaauuuuaguauuaacucuguaaaagugucuguagguacguuuuauauuauau
aaggacagaccaaaaaucaaccuaucaaagcuucaaaaacuuugggaaagggugggauuaaguacaagcacauuuggcuuacag
uaaaugaacugauuuuuauuaacugcuuuugcccauauaaaaugcugauauuuacuggaaaccuagccagcuucacgauuaug
acuaaaguaccagauuauaaugccagaauauaaugugcaggcaaucguggaugucucugacaaagugugucucaaaaauaaua
uacuuuuacauuaaagaaauuuaauguuucucuggaguuggggcucuuggcuuucagaguuugguuaaucaguguugauucu
agaugaucaacauaauggaccacuccugaaugagacuuaauuuugucuuucaaauuuacugucuuaaaucaguuuauuaaauc
ugaauuuuaaaacaugcuguuuaugacacaaugacacauuuguugcacc  
   
Fragment 4 
aauuaaguguugaaaaauaucuuugcaucauagaacagaaauauauaaaaauauauguugaauguuaacagguauuuucaca
gguuuguuucuugauaguuacucagacacuagggaaagguaaauacaagugaacaaaauaagcaacuaaaugagaccuaauaa
uuggccuucgauuuuaaauauuuguucuuauaaaccuugucaauaaaaauaaaucuaaaucacugguguuuuaagucacuug
cauuugauaucuuauagguguauauagcauuuccuuauggggaauaauucugaaaagggauuuuuaaauugauucagcccua
uaaccuauacaauuuggaauacucuuuugugguaauggaccauuuucuuggagugacuucacaaaacugaauaauuaagguua
auuuuaugaccauuugcuauaaagaagguaaguagucaugcauagaguauuuggaagugaggaaauggaguuguucuguaug
aaaguucuugaugaguacgcacacuuauuaaauggauguaucacca 
 
PCR products were purified with PCR purification kit (Qiagen, cat. no. 28106) following 
manufacturer instructions. Amplified fragments and empty pLV-CMV-SV40-Puro vector were 
digested by XhoI (NEB Inc, cat. no. R0146) and BamHI (NEB Inc, cat. no. R0136) with NEBuffer 3 
(NEB Inc, cat. no. B7003) and BSA (NEB Inc, cat. no. B9001). Ligation was performed (3:1, 
insert:vector molar ratio) with T4 DNA Ligase (NEB Inc, cat. no. M0202). Insertion was checked by 
sequencing. 
5. GENE SILENCING VIA LENTIVIRAL TRANSDUCTION OF shRNAs 
CUGBP1 expression was inhibited by lentiviral-driven gene silencing using two previously 
reported shRNAs344, kindly donated by Roger Romis. Target sequences were; shCUGBP1-1: 
GCTGCATTAGAAGCTCAGAAT (Sigma-Aldrich-TRCN0000017284) and shCUGBP1-2: 
CGAGTCATGTTCTCTTCGTTT (Sigma-Aldrich-TRCN0000017285). As control, non-targeting shRNA 
from Sigma: CAACAAGATGAAGAGCACCAA was used. Viruses were produced in 293FT cells and 
infections were performed as previously described91. Downregulation efficiency was determined 
after puromycin selection (1µg/mL) by protein immunoblotting or RT-qPCR.  
6. CELL PROLIFERATION ASSAYS 
6.1. GROWTH CURVES 
For growth curves, 1x103 melanoma cells were plated in 96-well optical bottom plates at day 6 
after lentiviral transduction. At the indicated time intervals (Day 0 is the following day after 
seeding), cells were fixed with 4% paraformaldehyde (Electron Microscopy Sciences) and stained 
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with DAPI (Invitrogen). For each time point, total cell number was quantified in triplicates by 
automated high throughput confocal detection of DAPI-stained nuclei using the OPERA HCS 
platform and the Acapella Analysis Software (Perkin Elmer). 
6.2. COLONY FORMATION 
Low confluency colony formation assays were performed seeding 1x103 (SK-Mel-103, SK-Mel-
147, 639V, A549, HeLa, HCT116, MiaPaca2 and U251) or 5x103 (SK-Mel-5, SK-Mel-19, SK-Mel-28, 
SK-Mel-29, UACC-62, LU-1205 and BT-549) cells per well onto 6-well plates. Cells were allowed to 
grow for 10-14 days for low density assays, fixed with cold methanol for 10 minutes and the 
colonies were stained with 0.4g/L crystal violet (Sigma). Number of colonies was quantified by 
counting using ImageJ software.  
7. CELL CYCLE PROFILE ANALYSIS BY FLOW CYTOMETRY 
7.1. CELL SYNCHRONIZATION 
For cell synchronization at G1/S border, control or shCUGBP1 depleted SK-Mel-103 cells were 
treated with 2.5 mM thymidine (Sigma) for 18 hours. Cells were fixed (see below) at 0, 4 and 8 
hours after release of the thymidine block. 
7.2. BRDU PULSE LABELING 
For BrdU pulse, exponentially growing control or shCUGBP1 depleted SK-Mel-103 cells were 
incubated with 10µM BrdU (Sigma) for one hour. Cells were fixed with ice cold 70% ethanol and 
processed following the acidic protocol described before345. S-phase BrdU positive cells were 
stained with FITC-conjugated anti-BrdU antibody (BD Pharmigen), and DNA was counterstained 
with 50µg/mL propidium iodide (Sigma). 
7.3. FLOW CYTOMETRY 
Data was acquired using a FACS Calibur flow cytometer (Becton Dickinson). Cell aggregates were 
excluded using pulse processing and a minimum of 20000 single events were measured. Data was 
analyzed using FlowJo 9.6.4 software (Treestar). Cell percentages at G0/G1, S or G2/M phases in 
synchronized cells were calculated using Watson model346. 
8. TISSUE IMMUNOSTAINING, TISSUE IMMUNOFLUORESCENCE AND MICROSCOPY 
8.1. IMMUNOHISTOCHEMISTRY (IHC) 
Tissue microarrays containing a total of 185 (47 benign, 138 malignant) human specimens were 
stained with CUGBP1 antibody (Abcam, ab9549) using BondTM Automated System (Leica 
Microsystems) by the Monoclonal Antibodies Unit of CNIO. After automated dewaxing and 
rehydration of the samples, heat-induced antigen retrieval was performed using Bond Epitope 
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Retrieval Solution 2 (Leica Biosystems) and immunodetection was performed with BondTM 
Polymer Refine Detection (Leica Microsystems) following the manufacturer’s instructions. CUGBP1 
protein expression was scored blinded according to staining intensity by two independent 
dermatologists. The score system used for staining intensity was: 0 (no detectable), 1 
(intermediate) and 2 (high). Digital images of IHC-stained sections were obtained at 40x 
magnification (0.12μm/ pixel) using a whole slide scanner (Mirax scan, Zeiss) fitted with a 40x/0.95 
Plan Apochromat objective lens (Zeiss). 
8.2. IMMUNOFLUORESCENCE (IF) 
Paraffin embedded malignant melanoma tissues were processed as previously described347 for 
CUGBP1 (Abcam, ab129115) and DEK (BD Transduction Laboratories, cat. no. 610948) co-staining. 
Antigen retrieval was performed using 10 mmol/L sodium citrate buffer at pH 6. Secondary 
antibodies used were anti-rabbit Alexa Fluor 555 and anti-mouse Alexa Fluor 488 (Life 
Technologies) and DNA was counterstained with DAPI. Negative controls were obtained by 
omitting the primary antibody. Image mosaics were acquired at 40xHCX PL APO 1.2 N.A. oil 
immersion objective using a confocal TCS-SP5 (AOBS-UV) confocal microscope and “intelligent 
matrix screening remote control” (iMSRC) tool348. Images were subsequently analyzed with 
Definiens XD software to determine CUGBP1 and DEK nuclear intensities per cell. The signal 
intensities were quantified in maximum range of RGB color scale (0-255). Data points were pseudo-
colored based on red/green signal intensity ratio (red, ratio≥2; green, ratio≤0.5; yellow, 
0.5<ratio<2). 
9. RNA STABILITY (ACTINOMYCIN D TREATMENT) ASSAYS  
Control or CUGBP1 depleted (shRNA) cells were seeded on day 4 after infection (250000 
cells/6cm plate). Cells were treated with Actinomycin D (Sigma Aldrich, A9415) at 5 μg/ml 
concentration. After 30 minutes of pre-treatment, cells were washed with ice cold PBS and 
collected via scraping at indicated time points (0, 1, 2, 4 and 6 hour). RNA extraction, 
quantification, reverse transcription and qPCR were performed as described previously. 
10. ANIMAL EXPERIMENTS  
Mouse xenograft models were generated by subcutaneous implantation of 1.0x106 (SK-Mel-103) 
or 2x106 (UACC-62, LU-1205) cells in athymic nude (Crl:NU(NCr)-Foxn1nu) female mice (Charles 
Rivers). Cells were harvested at day 4 after transduction with control or CUGBP1 shRNAs, 
resuspended in Matrigel (BD Bioscience) at 1:3 ratio in PBS  and injected in the back of the animals 
(n=5 per group). Tumor growth was measured blinded to the experimental conditions at the 
indicated time intervals. Tumor volume was estimated using a caliper and calculated as V= 
axb2xπ/6, where “a” stand for the bigger and “b” for the smaller diameter of the tumor. When 
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control tumors exceeded 1cm3 size mice were sacrificed and xenografts were surgically excised and 
processed for histopathological and protein detection studies. All experiments with mice met the 
Animal Welfare guidelines and were performed in accordance with protocols approved by the 
Institutional Ethics Committee of CNIO. 
11. RNA IMMUNOPRECIPITATION AND SEQUENCING (RIP-SEQ) 
11.1. RNA IMMUNOPRECIPITATION 
For RNA immunoprecipitation, non-infected cells at 80% confluence were fixed in 1% 
formaldehyde for 10 minutes at room temperature (RT), and fixation was stopped by adding 1M 
Glycine for 5 minutes at room temperature. After washing with ice cold PBS, cells were collected 
by scraping and lysed with in NT2 buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1mM MgCl2, 0.5% 
Nonidet P-40 and 1 mM EDTA) supplemented with protease and RNase inhibitors (Applied 
Biosystems). For the solubilization of crosslinked complexes, lysates were sonicated in a Bioruptor 
Standard (Diagenode) for 10 minutes at medium intensity. After preclear by protein A Dynabeads 
for 30 minutes at 4°C, samples were immunoprecipitated using CUGBP1 antibody or mouse IgG 
coupled to protein A Dynabeads (Invitrogen) for 3h at 4°C. Immunoprecipitates were washed 6-8 
times extensively and resuspended in NT2 buffer containing 50µg proteinase K (Roche Applied 
Science), 1% SDS, 200mM NaCl and 10mM EDTA. Sample was split into two (1:4 for protein, 3:4 for 
RNA extraction). Protein fraction was mixed with loading dye, boiled at 95°C for 5 minutes and 
supernatant was collected. RNA elution was done by consecutive incubations at 55°C for 30 
minutes and at 65°C for 45 minutes. Supernatants were collected and digested with DNaseI for 10 
minutes at RT. RNA was extracted with TRI Reagent (Sigma) following manufacturer´s protocol. For 
validation, independent RIP assays were performed. The total amount of RNA immunoprecipitated 
and 1µg of RNA extracted from inputs were retrotranscribed using cDNA reverse transcriptase kit 
and qPCR were performed as described before. Fold binding enrichment of target mRNAs in the 
immunoprecipitated fraction was calculated after normalization with the gene expression from the 
inputs. The primers used for RIP-qPCR are listed Table 7. 
11.2. SEQUENCING AND BIOINFORMATICS ANALYSIS 
RNA sequencing was performed by Genomics Unit from CNIO. Integrity of RNA was evaluated by 
Agilent 2100 Bioanalyzer using RNA 6000 Pico kit following manufacturer’s recommendations. An 
estimated mass of 20 ng RNA per sample (1 μg for input samples) was processed with Ribo-Zero 
Gold Kit (Epicentre, cat. no. RZHM11106/RZG1224) for ribosomal RNAs removal. RNAs were 
randomly fragmented, converted to double stranded cDNA and processed through subsequent 
enzymatic treatments of end-repair, dA-tailing, ligation to adapters and amplification by PCR with 
Illumina PE primers. The purified cDNA library was applied to an Illumina flow cell for cluster 
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generation (TruSeq cluster generation kit v5) and sequenced on Illumina Genome Analyzer IIx with 
SBS TruSeq v5 reagents following manufacturer’s protocols. Fastq349 files with 40-nt single-end 
sequenced reads were quality-checked with FastQC350 and aligned to the human genome 
(GRCh37/hg19) with TopHat-2.0.4351, using Bowtie 0.12.7352 and Samtools 0.1.16353, allowing two 
mismatches. For each read, only the alignment with the best score was considered. RIP-seq peaks 
were called with Piranha 1.2.1354 using the ZeroTruncatedPoissonRegression distribution, with a 
bin size of 20 and 0.05 FDR. From the total number of peaks obtained, only those with more than 
30 reads were considered for further analysis. Peak annotation was performed with PeakAnalyzer 
1.4355, using the Homo sapiens GRCh37.72 annotation from Ensembl356. Common peaks among the 
three samples were obtained with BEDtools 2.16.2357, and their corresponding nucleotide 
sequences were retrieved with the Ensembl API. CUGBP1 binding sequences in the binding region 
of the target was searched by Sequence Searcher358 allowing two mismatches. Motifs enriched in 
the peaks were discovered with DREME359. 
12. CUSTOMIZED SPLICING SENSITIVE MICROARRAY 
Melanoma cell lines SK-Mel-19 and SK-Mel-103; and primary human melanocytes were grown as 
indicated above. Melanoma cells were harvested by trypsination at a confluency of approximately 
70% and the pellets were stored at -80°C. Melanocytes were harvested by trypsination at a 
confluency of approximately 70% confluency. Melanocytes derived from three different donors 
were pooled and the pellets stored at -80°C. Total RNA was purified using RNeasy Mini kit (Qiagen, 
74104) and digested with DNase RNase free (Qiagen, 79254). Quality assessment of Total RNA 
samples were analyzed using the Agilent Bioanalyzer 2100 and the RNA 6000 LabChip Kit (Agilent) 
with the Eukaryote Total RNA Nano Assay (Agilent). Cy5-Cy3 labelled cRNA were generated from 
the total RNA using the Agilent Low RNA Input fluorescent linear amplification kit (Agilent, 5184-
3526) and cyanine 5-CTP and cyanine 3-CTP (Perkin-Elmer NEL580, NEL581); the cRNA was purified 
using the RNeasy Mini kit (Qiagen, 74104). Quality control assessed by Agilent Bioanalyzer 2100. 
6μg of each cRNA were used for the hybridization following Agilent In situ Hybridization Kit Plus, 
(Agilent, 5184-3568). Three biological replicates were hybridized, with both direct and dye-reversal 
hybridizations. Agilent hybridization oven was set to 60°C. Fluorescent images were obtained using 
the G2565BA Microarray Scanner System (Agilent) with 100% laser power and 100% PMT settings 
and 16-bit TIFF images, one for each channel, were quantified using GenePix Pro 6.0 microarray 
analysis software (Molecular Devices, www.moleculardevices.com). Mean foreground and 
background intensities were extracted from the red (Cy5) and green (Cy3) channels for every spot 
on the microarray. The background intensities are used to correct the foreground intensities for 
local variation on the array surface, resulting in corrected red and green intensities. Raw data were 
processed using SAPO (http://bioinfo.ciberehd.org/SAP.ang.htm) and CGEM (http://bioinfo. 
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ciberehd.org/CGEM.ang.html) alternative splicing analysis tools, obtaining lowess normalized log2 
ratios. General gene expression values represent the average of log2 ratios for all the probes of a 
locus. Statistical analyses were carried out with Linear Models for Microarray Data360,361. The 
background correction method used in the analysis was Normexp362. Locally weighted linear 
regression (LOWESS) analysis was used as a normalization method363. 
13. HUMAN JUNCTION ARRAY (HJAY) 
13.1. RNA LABELING AND HYBRIDIZATION 
Affymetrix Human Junction Arrays (HJAY) were hybridized by GenoSplice Technology according 
to Affymetrix (Santa Clara, USA) labelling and hybridization recommendations. Microarrays were 
hybridized, washed and scanned using Affymetrix instruments. Total RNAs RIN values were 
between 9.8 and 10.0 (average: 9.98). Raw data are controlled with Expression console 
(Affymetrix). 
13.2. MICROARRAY DATA ANALYSIS 
Affymetrix HJAY dataset analysis was performed by GenoSplice technology. Data were 
normalized using quantile normalization. Background corrections were made with antigenomic 
probes and probes were selected according to their %GC, cross-hybridization status and potential 
overlap with repeat region as previously described364,365. Only probes targeting exons and exon-
exon junctions annotated from FAST DB® transcripts (release fastdb_2013_1) were selected366,367. 
Only probes with a DABG P value ≤0.05 in at least half of the arrays were considered for statistical 
analysis364,365. Only genes expressed in at least one compared condition were analyzed. To be 
considered to be expressed, the DABG p-value was selected to be ≤0.05 for at least half of the gene 
probes. Student’s t-test was performed to compare gene intensities between experimental 
conditions. Genes were considered significantly regulated when fold-change was ≥1.5 and p-value 
≤0.05 (unadjusted p-value). Analysis at the splicing level was first performed taking into account 
only exon probes in order to potentially detect new alternative events that could be differentially 
regulated (i.e. without taking into account exon-exon junction probes). Analysis at the splicing level 
was also performed by taking into account exon-exon junction probes using the FAST DB® splicing 
patterns annotation (i.e. for each gene, all possible splicing patterns were defined and analyzed). 
Expression and alternative splicing analyses were performed using unpaired Student's t-test on the 
splicing-index as previously described364,365. Results were considered statistically significant for 
unadjusted p-values ≤ 0.05 and fold-changes ≥ 1.5 for alternative splicing analysis; and unadjusted 
p-values ≤ 0.05 and fold-changes ≥ 2.0 for expression analysis.  
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14. ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUANTITAION (iTRAQ) 
Pellets obtained from control and CUGBP1 depleted SK-Mel-103 and UACC-62 cells were washed 
3 times with cold PBS containing protease inhibitors (Halt™ Protease & Phosphatase inhibitor 
cocktail, EDTA-free) and resuspended in 500 μL of ice-cold RIPA lysis buffer (150 mM NaCl, 1.0% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 50 mM Tris, pH 8.0 plus 
protease inhibitors) and 0.1% Benzonase Nuclease (Novagen). Samples were vortexed, sonicated 
and clarified by centrifugation at 4°C for 15 minutes. The supernatants containing the protein 
fraction were collected and cleaned-up by methanol-chloroform precipitation. Pellets were 
dissolved in 7M urea 2M tiourea. Protein concentration was determined using the Pierce 660nm 
Protein Assay (Bio-Rad) using BSA as standard. Proteins were digested using the FASP protocol. 
Peptides were labeled with 4-plex iTRAQ reagents and samples were pooled. Then, the complex 
mixture was subjected to IEF fractionation. The resulting fractions were separated by on-line nano-
LC and analyzed by electrospray MS/MS using a LTQ Orbitrap Velos mass spectrometer (Thermo 
Scientific). Raw files were searched against UniProtKB / Swiss-Prot human database (20,584 
entries) using SequestHT as the search engine through the Proteome Discoverer (Thermo 
Scientific) software. Results were validated with Percolator and filtered to 1% FDR (peptide-level). 
15. GSEA, NETWORKS, HEATMAPS and VENN DIAGRAMS 
Significantly enriched (p≤0.05) GO Biological Processes (database 02.10.2015) between 
melanoma cells and primary melanocytes were identified by using Cytoscape v3.2.1368 and the 
ClueGO v2.1.7 plug-in369. 
Gene Set Enrichment Analysis (GSEA) was performed using annotations from the Reactome 
pathways. Genes were ranked using the t statistic. After Kolmogorov-Smirnoff correction for 
multiple testing, only those pathways bearing a FDR <0.25 were considered significant370. Heatmap 
and correlation graphs for RNA and protein levels were created by Perseus v1.5.1.6. Protein 
networks were created by using Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING)371 and Cytoscape v3.2.1. Venn diagrams were created by using online tools Venny v2.0372 
and jvenn373. 
16. STATISTICAL ANALYSES 
CUGBP1 expression in human benign and malignant melanocytic lesions and cell proliferation 
curves were evaluated by two-tailed unpaired Student´s t-test. In all the cases p<0.05 was 
considered significant. CUGBP1 and DEK co-expression in human melanoma specimens was 
evaluated by Pearson test. R stands for Pearson correlation value. 
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1. GLOBAL ANALYSIS OF RNA BINDING PROTEINS IN MELANOMA CELLS 
A recent census study has reported 692 mRNA binding proteins (mRBP) in human cells218. Given 
the potential of these factors to exert broad effects on gene expression, we decided to perform an 
unbiased analysis of their mutational status and allelic content in melanoma tumors. To this end, 
cBioPortal was used to mine the Cancer Genome Atlas (TCGA), which contains 478 annotated 
human melanoma specimens374. As summarized in Figure 7, none of the mRBPs appeared to be a 
frequent target of genomic alterations in this disease (see Table S1 for full detail on the individual 
genes and alteration rate). 
Therefore, we chose to perform comparative analyses of transcriptomic profiles of melanoma 
cell lines versus normal melanocytes as an initial strategy to screen for potential novel contributors 
to melanoma progression. While the large set of mRBPs listed in Figure 7 were extracted from 
computational analyses that mined for factors that contain bona fide RNA binding domains 
(RBDs)218, only a fraction of these genes have been functionally addressed in cancer cells. 
Therefore, to increase the likelihood of identifying physiologically-relevant of melanoma genes, we 
chose to focus on RBPs with mechanistic evidence for key roles on mRNA polyadenylation, 
maturation, stability and/or translational control (n=180). These included mainly mRBPs, as well as 
factors known to recognize snRNAs, snoRNA, ncRNA and tRNA, for a more global analysis of the 
RNA binding family (see Table S2 for detailed information on the selected genes). A series of 302 
cell signaling, proliferation, adhesion and apoptosis modulators with reported cancer-associated 
posttranscriptional gene regulation were also included in the array (Figure 8A) to guide in 
subsequent functional studies of identified RNA binding candidates (a strategy we have previously 
validated for gene discovery in Hodgkin lymphoma cells and in other systems)375. Total RNA was 
isolated from the well characterized SK-Mel-19 and SK-Mel-103 melanoma cell lines, used as 
Figure 7: Genomic landscape of mRNA binding proteins in human melanoma. Shown is the frequency 
(%) of melanoma patients with mutations and/or copy number alterations (deletions or amplifications) 
in all known mRNA binding proteins (mRBPs, n=692), classified according to their RNA binding domains 
(Pfam nomenclature). Data was retrieved from the melanoma TCGA database (n=478 specimens) using 
cBioPortal and manual curation. BRAF, NRAS and NF1 are included as references for classical melanoma-
associated oncogenes, and PTEN as a classical melanoma-associated tumor suppression gene. 
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representative examples of cases bearing the BRAFV600E and NRASQ61R characteristic mutations in 
this disease (see Table 6)376. Hybridizations were performed using pools of primary melanocytes as 
a reference (see Methods section for additional detail). Gene Ontology (GO) functional term 
enrichment analyses were performed by Cytoscape and the ClueGO plug-in for maximum p value 
of 0.05. Interestingly, we identified a selective deregulation of 29% (50/180) of RBPs in melanoma 
cells (Figure 8B and Table S3) with enriched functions in RNA splicing and spliceosome formation, 
ribonucleoprotein (RNP) complex assembly, mRNA 3’end processing and termination of RNA 
transcription (see gene clusters 1-22 in Figure 8C).  Among the cancer-associated genes we 
identified changes in 19.5% of the analyzed cases (59/302) which intriguingly clustered 
preferentially around cell cycle, chromosome organization and mitotic cell cycle checkpoints 
(clusters 23-75 in Figure 8C; see Table S4 for details of the specific GO terms and the genes on each 
cluster). We then set to investigate these 75 GO clusters for candidate selection.  
 
Figure 8: Global analysis of RBPs and post-transcriptionally regulated cancer-associated genes in 
melanoma vs. normal melanocytes. A, Schematic representation of experimental design. B, 
Differentially expressed cancer- and RNA biology related genes in melanoma cells compared to the 
primary melanocytes with specific detail on changes in the indicated RBP families. Dark colors 
represent differential regulation. C, Network of enriched GO terms in SK-Mel-19 and SK-Mel-103 cell 
lines. Size of the nodes reversely reflects the statistical significance of the terms (p<0.0005, p<0.005 or 
p<0.05). Bold bordered terms refer to GO terms containing CUGBP1. mRNA: messenger RNA, snRNA: 
small nuclear RNA, ncRNA: non-coding RNA, snoRNA: small nucleolar RNA, tRNA: transfer RNA. 
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2. CUGBP1 IS AN EARLY-INDUCED RBP IN MELANOMA CELL LINES AND MALIGNANT TISSUES 
Given the inherent pleiotropic nature of RBPs, we considered essential a detailed validation that 
integrated histological assessment of expression in clinical biopsies, functional studies in cultured 
cells and in animal models, and genome-wide transcriptomic/proteomic analyses for the 
identification of direct targets. Given the challenge of performing such a comprehensive 
characterization for each of the 50 RBPs described above in Figure 8B (Table S2), an additional 
filtering step was performed with the following criteria: (i) no reported link to melanoma, (ii) 
participation in the melanoma-enriched GO-terms associated with RNA metabolism (i.e. networks 
labeled in blue in Figure 8C), and (iii) relationship to the cancer-related categories with a particular 
deregulation in the melanoma cell lines tested (Clusters 23-75 in Figure 8C). Among the top genes 
in this list (Table S4) we chose to focus on CELF1 (CUG repeat binding protein, Elav-like family 
member 1), also referred to as CUGBP1 for its ability to bind GU-rich elements (GREs) in target 
mRNAs. As mentioned in the introduction, CUGBP1 has the attractive feature of being able to act 
on pre-mRNAs (modulating alternative splicing) and on mature mRNAs, controlling translation and 
transcript stability. CUGBP1 is best known for its contribution to post-transcriptional events in 
muscle differentiation and myotonic dystrophy. Nevertheless, a few studies in gastric carcinoma339, 
hepatocellular carcinoma338 and oesophageal340  carcinoma have reported a requirement of 
CUGBP1 for proper tumor cell proliferation. No common CUGBP1 cellular targets have been 
identified from these studies (see additional detail below), offering the possibility of gene 
discovery.  
Our customized microarray revealed an increased CUGBP1 mRNA expression melanoma cell lines 
compared to primary melanocytes. To start defining the impact of this deregulation at the protein 
level, total cell extracts were prepared from a panel of melanoma cell lines that recapitulate main 
genetic alterations in this disease (see BRAF, NRAS, PTEN and p53 status in Table 6 in Materials and 
Methods section). Immunoblots were then performed using as a reference normal skin cells 
(including various independent isolates of primary melanocytes and as well as fibroblasts and 
keratinocytes). As shown in Figure 9A, all melanoma cells displayed a marked upregulation of 
CUGBP1 compared to normal controls. Of note, this differential expression was not detected for 
CUGBP2, another member of the CUG binding protein family (Figure 9A). Additional comparative 
analyses were performed with respect to the well known Mel-STV immortalized melanocytes377. 
Interestingly, Mel-STV, which has been used in the field as surrogates for early transformation 
events377,378 showed also higher CUGBP1 than normal melanocytes, to levels similar to melanoma 
cell lines (Figure 9B). These results therefore, suggest an early activation of CUGBP1 during 
melanoma progression. To confirm this hypothesis, a retrospective series of benign nevi (n=47) and 
clinically annotated melanoma (n=138) paraffin-embedded biopsies (see Methods for additional 
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details on the number of primary and metastatic specimens analyzed) were processed by 
immunohistochemistry, using a 0-2 scoring for CUGBP1 on the basis of negative, intermediate or 
high expression (Figure 9C; see the Methods section). As summarized in Figures 9D and 9E, a 
significant enrichment for high expression of CUGBP1 was found in malignant lesions (p<0.005), 
particularly on vertical growth phase (VGP) cutaneous melanomas (see examples in Figure 9E). 
Together, these results identify CUGBP1 as a new RBP with an early induction during melanoma 
progression.  
Figure 9: CUGBP1 overexpression in melanoma. A, Differential expression of CUGBP1 in normal skin 
cells (fibroblasts, keratinocytes and three independent pools of melanocytes) and the indicated 
melanoma cell lines. CUGBP2 was indicated as a reference for another ELAV-family member. B, CUGBP1 
expression in immortalized Mel-STV melanocytes shown in comparison to normal melanocytes and two 
melanoma cell lines. C, Representative examples of paraffin-embedded melanomas stained for CUGBP1 
(brown) to illustrate negative, intermediate and high-expressors (i.e. scoring 0-2, respectively). D, 
Distribution of benign and malignant specimens (% of analyzed cases) separated as a function of 
CUGBP1 scoring, performed as in C, and pooled for vertical growth phase melanoma, skin metastasis 
and lymph node metastasis (separated as a function of scoring intensity: 0 - negative, 1 - medium and 2 
- high). E, Representative micrographs of nevi and primary (VGP) and metastatic melanomas, showing a 
heightened CUGBP1 expression (brown staining) during tumor progression. Nuclei were counterstained 
in blue with Hematoxilin. 
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3. DEFECTIVE PROLIFERATIVE CAPACITY OF MELANOMA CELLS DEPLETED FOR CUGBP1 
To deplete CUGBP1 and define functional impact in melanoma cells, we used a lentiviral-based 
gene transfer of two previously reported short hairpin interfering RNAs (shRNA)344. These 
constructs, allowing for puromycin-based selection of infected cells, were used to transduce SK-
Mel-103 (NRASQ61R mutated) and UACC-62 (BRAFV600E) (see downregulation efficacy in Figure 10A). 
Cell proliferation was monitored at different time points after infection by DAPI-based nuclei count 
(see Methods). Both cell lines responded to CUGBP1 depletion with a marked inhibition of cell 
proliferation (Figure 10B). To further characterize the effect of CUGBP1 on proliferation, SK-Mel-
103 cells were infected with control or CUGBP1-shRNA expressing lentiviruses. Two days after 
puromycin selection, cells were synchronized at G1/S phase of the cell cycle by a standard 
thymidine block. Propidium iodide staining was then performed for assessment of DNA content by 
flow cytometry. While control shRNA-cells recovered a normal proliferation within 8h after 
releasing from the block, CUGBP1-shRNA cells showed a significant G1 phase accumulation, with a 
concomitant reduction in S-phase proliferating cells (see flow cytometry profiles in Figure 10C and 
quantification in Figure 10D). 
Figure 10: Cell cycle arrest after CUGBP1 depletion in melanoma cells. A, Downregulation of CUGBP1 
levels in SK-Mel-103 and UACC-62 by lentiviral-based transfer of CUGBP1 depleting shRNAs 
(shCUGBP1-1 and 2) visualized by immunoblotting with respect to cells expressing control shRNA. 
Error bars correspond to SEM of three experiments in triplicate.  B, Impaired growth of SK-Mel-103 
and UACC-62 cells upon CUGBP1 depletion. Time points indicate the days after seeding. C, Cell cycle 
profiles and quantification (D) of shControl and shCUGBP1 transduced cells. Time points indicate 
release from the thymidine block. 
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To determine whether impaired cell proliferation is a general feature of CUGBP1-depleted 
melanoma cells, long-term colony formation assays were performed in panel of 8 independent cell 
lines (n=8, see CUGBP1 downregulation in Figure 11A). Interestingly, albeit with different efficacies, 
all melanoma cell lines tested responded to CUGBP1 shRNA with an inhibited proliferative capacity 
(see Figure 11B for crystal violet-stained colonies 10-14 days after seeding and Figure 11C for 
quantification). To further define the physiological relevance of these results, control- and 
CUGBP1-depleted melanoma cells (SK-Mel-103 or UACC-62) were injected subcutaneously into the 
flanks of 7 week-old athymic nude (Crl:NU(NCr)-Foxn1nu) female mice. While some CUGBP1-
depleted lesions were observed with a marked reduction in growth (Figures 11D and 11E), most 
tumors recovered CUGBP1 expression which may indicate that tumors could not be formed 
without CUGBP1. Thus, post-mortem analyses (protein immunoblotting and immunohistochemical 
Figure 11: Impaired proliferative potential of CUGBP1-depleted melanoma cells. A, Downregulation 
of CUGBP1 by lentiviral-mediated transduction of CUGBP1 shRNA (1) in the indicated cell lines, defined 
by immunoblotting 2 days after puromycin selection of positively-transduced cells. B, Colony 
formation of the cell populations in (A) determined by crystal violet 12 days after cell seeding. C, 
Quantification of inhibited colony formation activity. Data are represented as the ratio of inhibition 
with respect to control shRNA-transduced cells (for simplicity here shown as a gray bar only for SK-
Mel-5). Error bars correspond to SEM of two experiments in duplicates. D, E, Depletion of CUGBP1 in 
the indicated cell lines (D) for subcutaneous implantation in nude mice (E). Shown are photographs 
and images of excised lesions generated by the indicated cell populations showing the impact of 
sustained CUGBP1 depletion. 
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stainings) revealed that intriguingly, actively growing melanoma xenografts selected for cells that 
retained CUGBP1 expression (data not shown). Together, these in vitro and in vivo results support 
a relevant impact of CUGBP1 on the tumorigenic potential of melanoma cells.  
4. KNOWN CUGBP1 TARGETS ARE NOT SHARED BY MELANOMA  
Next, we interrogated CUGBP1 targets that may underline the inhibited proliferative capacity of 
melanoma cells when this factor is depleted. As indicated in the introduction, one the main 
functions of CUGBP1 is the regulation of alternative splicing303,305. Characteristically-regulated 
CUGBP1 splicing targets are INSR302-304, SERCA1305, FXR1305, FAM188A305, ANK2305, ACTN1306,307, 
MEF2A306,307 and PPFIBP1306,307, among others (see Figures 12A and 12B for the corresponding exon 
inclusion/exclusion events). Therefore, a panel of 8 melanoma cell lines was transduced with 
control or shCUGBP1-1 for isoform analysis by semi quantitative PCR.  Spliced variants of INSR, 
Figure 12: Known CUGBP1 targets are not shared by melanoma cells. A, Ratio of splicing variants of the 
indicated genes in melanoma cell lines transduced with control or CUGBP1-1 shRNAs. Data correspond 
to quantification of semi-quantitative PCRs (with concrete examples in panel B, visualized after 
electrophoretic separation in agarose gels). C, CCND1 protein levels in the indicated populations of 
melanoma cells, detected by immunoblotting. D, Venn diagrams to assess the overlap of CUGBP1 
binding targets in the indicated cell lines. The table below lists this overlap as percentages. 
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SERCA1, FXR1, FAM188A, and ANK2 were found in the melanoma cell lines tested, but however, no 
consistent changes in isoform ratio were observed after CUGBP1 depletion (see quantifications in 
Figure 12A and representative examples of electrophoretic analyses in Figure 12B). For ACTN1, 
MEF2A and PPFIBP1, only one isoform was detected by RT-PCR, with no obvious changes in 
expression in CUGPB1-depleted cells (Figure 12B). Similar lack of selective changes in splicing 
variants was detected for other tumor cell types, indicating that these factors may not be frequent 
downstream targets of CUGBP1 (Figures 19A and 19B).  We then tested cyclin D1  (CCND1) for its 
known roles in cell cycle control, but also an example of a gene which can be either upregulated or 
downregulated by CUGBP1 depending on the system (i.e. in HepG2 hepatocellular carcinoma338 
and MGC-803 gastric cancer339 cell lines, respectively). As shown in Figure 12C, most melanoma 
cells tested responded to CUGBP1 depletion by increasing CCND1 protein levels, a feature 
consistent with delayed S-phase progression379. However, these changes in CCND1 were variable 
and indeed not consistent among cell lines (see for example negligible changes in LU-1205, Figure 
12C).  We therefore chose to pursue a genome-wide characterization of CUGBP1 targets in 
melanoma. 
Gene sets corresponding to the two RNA immunoprecipitation (RIP)-based assessment of 
CUGBP1 targets reported to our knowledge in human cells (i.e, in HeLa284 and in T-cells327) were 
then mined to identify commonly modulated factors that could be used as a guideline in 
melanoma. A search in the ENCODE project331 was also performed, identifying two additional cell 
lines, K562 (myelogenous leukemia) and GM12878 (an EBV-transformed B-cells), were there 
unpublished, but available data for CUGBP1 binding. Intriguingly, maximum overlap among these 
data sets was less than 6% (in T cells vs. K562 cells, Figure 12D). Notably, no gene was found to be 
shared by these 4 studies (Figure 12D). Together, these results further emphasize the need for a 
comprehensive unbiased search for novel CUGBP1 targets in melanoma.    
 
5. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES IDENTIFY CUGBP1 REGULATED GENES 
As mentioned before CUGBP1 is an RNA binding protein with wide range of functions, ranging 
from the modulation of splicing302-307, to transcriptional activation/repression285,309,313,314,322-325 or 
mRNA stability modulation284,327-329. In order to explore all these functions we used two high 
throughput systems: (i) Human Junction Array (HJAY), which allows to monitor both changes in 
mRNA levels and alternative splicing events by using a high coverage of probes for the detection of 
constitutive exons and retained/excluded exons (5.4 million probes), and (ii) isobaric tags for 
relative and absolute quantification (iTRAQ) for global assessment of proteomic profiles. As model 
systems, we used SK-Mel-103 and UACC-62 melanoma cell lines, which were processed for RNA 
and total protein isolation 4 days after infection with lentiviral-driven control or CUGBP1 shRNA 
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(i.e. time points before cell cycle arrest). HJAY identified 1361 and 698 altered genes by CUGBP1 
depletion in SK-Mel-103 and UACC-62, respectively (Figure 13A). Of those changes, the vast 
majority (96.4 and 95%) corresponded to differential gene expression, with just a minority of 
factors with additional alteration of splicing sites (Figure 13B). Therefore, we focused on iTRAQ 
proteomic analyses, which to our knowledge have not been previously performed for CUGBP1 
targets. 
  
Figure 13: Genome-wide transcriptomic and proteomic analysis (HJAY and iTRAQ LC-MS/MS, 
respectively) for the identification of CUGBP1-regulated cellular targets. A, Venn diagrams showing 
differentially expressed (DE) and alternatively spliced (AS) genes identified by HJAY in SK-Mel-103 and 
UACC-62 cells upon shCUGBP1-1 transduction. B, Genes undergoing differential mRNA expression and 
splicing regulation in CUGBP1 shRNA melanoma cells. C, Volcano plots showing up- and downregulated 
proteins identified by iTRAQ LC-MS/MS analyses in SK-Mel-103 and UACC-62 cells upon shCUGBP1-1 
transduction. Factors indicated in green and red are those with significant changes in protein 
expression. D, Enriched biological processes identified from significant changes in the proteome 
(p<0.05) of the indicated cell lines defined by monitoring Panther database. E, Correlation scatter plots 
of global changes in RNA and protein levels upon CUGBP1 depletion in SK-Mel-103 and UACC-62 
melanoma cell lines. F, Overlap in RNA and protein level changes between these two cell lines. 
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Setting proteomic changes to be significant for p<0.05 and 1.5-fold deviation with respect to 
shRNA controls we identified 1020 and 532 CUGBP1-regulated proteins in SK-Mel-103 and UACC-
62 cell lines, respectively (see Volcano plots in Figure 13C). Enrichment analyses using Panther 
databases revealed a preferential enrichment for biological processes related to DNA replication, 
chromatin architecture, mitosis, cell cycle and various stress-related programmes (Figure 13D). Of 
note, these differentially expressed proteins were found to reflect changes in mRNA expression 
(Figure 13E), with a significant overlap in the two cell lines tested (RNA, r=0.43; and protein, 
r=0.38; Figure 13F). Together, these results support a broad spectrum of proteins whose 
expression is modulated by CUGBP1 in melanoma as a result of defining mRNA levels, rather than 
acting as a regulator of alternative splicing. 
6. IDENTIFICATION OF CUGBP1-REGULATED NETWORKS 
To further address CUGBP1 targets in melanoma, transcriptomic and proteomic datasets 
reported above were subjected to gene set enrichment analyses through Reactome databases for 
pathway (network) identification (Figures 14A and 14B).  DNA synthesis/replication and cell cycle 
related pathways were downregulated in both cell lines at both RNA and protein levels (Figure 
14A). Interestingly, the impact of CUGBP1 in these cellular processes appeared to be broad, but 
selective (i.e. only a fraction of genes in each functional category was significantly deregulated by 
CUGBP1 shRNA (Figure 14B). To identify key hubs in these processes, functional networks were 
then built using the STRING database with the Cytoscape v3.2.1 for visualization. As shown in 
Figure 14C a series of highly interconnected proteins were revealed by this analysis to be 
deregulated both at the protein and RNA levels (mostly by inhibition in expression, green columns) 
in the two cell lines (the direction and magnitude of these changes are indicated in the insets of 
Figure 14C as columns labeled A-D). Validating this approach, CCNB1 and POLA1, two genes 
required for cell cycle progression and reported as CUGBP1 targets in hepatocellular338 carcinomas, 
gastric carcinomas339 and myeloid leukemia331 (unpublished data), respectively, were also found 
modulated by CUGBP1 in both melanoma cell lines. Nevertheless, the rest of the factors and 
network interactions uncovered by our comprehensive transcriptomic and proteomic analyses had 
not been previously linked to CUGBP1, further emphasizing the significance of our results. Focusing 
on newly-identified cell cycle and DNA synthesis/replication networks that could underlie the 
phenotype of CUGBP1-depleted melanoma cells (Figure 10), our analyses revealed various MCM 
proteins (MCM-2, -3, -4, -5, -6, -7) as well as other well known DNA synthesis and replication 
factors such as RPA-2 and RPA-3 (Figure 14C). Other downregulated genes included FANCA, FAND2 
and FANC1 (Figure 14C), likely reflecting DNA damage associated to replicative stress. An additional 
gene unknown to be modulated by CUGBP1 and identified in our analysis was the chromatin 
remodeler DEK (Figure 14C), an oncogene upregulated in multiple tumor types165-170, including 
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melanoma185, where we had previously demonstrated critical for cell cycle progression and cell 
survival185. In summary, these studies further expand our knowledge on CUGBP1 roles in the 
regulation of key cancer-associated signaling networks. 
 
Figure 14: CUGBP1-modulated signaling hubs identified by HJAY and iTRAQ in melanoma cells. A, 
Heatmap of gene sets found enriched (Reactome pathway database) both at RNA and protein levels in 
shCUGBP1-1 expressing melanoma cells, listed as a function of FDR values. B, Close up of the most 
downregulated pathways found in the two cell lines analyzed. Indicated are enriched gene sets, total 
number of genes in each category, and those deregulated in both cell lines. Blue rows: cell cycle-related 
pathways; pink rows: DNA synthesis and replication-related pathways. C, Interaction maps of identified 
factors corresponding to cell cycle (left) and DNA synthesis/replication (right) revealed by STRING. Bar 
charts below gene nodes refer to changes in RNA and protein levels in CUGBP1 shRNA vs. control shRNA 
cells (A: SK-Mel-103 - RNA, B: UACC-62 - RNA, C: SK-Mel-103 - Protein, D: UACC-62 - Protein). Darker 
nodes: genes indicated with darker color (blue or red) are controlled also by the DEK Oncogene (see 
Table S5). 
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7. RIP-SEQ ASSAYS IDENTIFY NOVEL DIRECT CUGBP1 TARGETS IN MELANOMA 
Next, RNA immunoprecipitation followed by sequencing of retrieved transcripts (RIP-seq) was 
performed to determine which of the genes whose expression is modulated by CUGBP1 are indeed 
direct targets of this protein. To this end, RNAs binding to the endogenous CUGBP1 were 
precipitated after crosslinking with a CUGBP1 antibody in SK-Mel-103 and UACC-62 (three 
biological replicates). This was followed by RNA-Seq with 20 million reads per sample, using inputs 
as a reference. Validating this approach, we identified higher number of reads  in CUGBP1 IP 
samples compared to input at the 3’UTR of CCND1 (see an example for SK-Mel-103 in Figure 15A 
visualized on the UCSC genome browser), which was validated by RIP and qPCR in additional 
melanoma cell lines (Figure 15B). Factors with FDR value smaller than 0.05 (n=2024) were then 
compared to the reported RIP studies for HeLa284 and T-cells327 mentioned above as well as the 
candidates we had identified as CUGBP1 targets in K562 and GM12878 in unpublished data from 
ENCODE. The overlap with these datasets was rather low: with only 8.5% and 13.7% of targets 
shared with K562 and T-cells and a global minimal binding conservation (Figure 15C, Table S6). 
Thus, we uncovered transcripts of 1197 (out of 2024) unreported CUGBP1-bound genes in 
melanoma (Figure 15C). Peak calling was then performed with the Piranha software354 to identify 
regions of statistically significant read enrichment. In order to minimize false positive results by 
using a large bin size, instead a bin size of 20 was used considering that canonical CUGBP1 binding 
sequences are typically 11-mers284. The distribution of binding regions on target mRNA indicated 
that CUGBP1 bound the majority its targets (59%) on their 3’UTRs (Figure 15D, left pie charts). 
Sequence Searcher358 was used to mine for the common CUGBP1 recognition sites 
UGUGUGUGUGU and UGUUUGUUUGU284,323 allowing up to two mismatches. As shown in Figure 
15D, right chart, 78% of targets in our RIP-Seq indeed contained CUGBP1 sites in their regions of 
CUGBP1 binding. The motif discovery DREME algorithm359 was then applied to further define the 
CUGBP1-binding sites enriched in both SK-Mel-103 and UACC-62 CUGBP1 RIP-Seq. Importantly, 5 
significant motifs were found, all of which were UG rich sequences, with p values ranging from 10-7 
to 10-40 (Figure 15E).  
In conclusion, the results above identify a broad spectrum of novel cellular targets that CUGBP1 
binds preferentially at 3’UTR-containing UG-rich repeats. This 3’UTR binding is consistent with 
global effects on mRNA stability, therefore, providing a mechanistic explanation for the changes in 
mRNA expression (Figure 13) discovered in CUGBP1-depleted melanoma cells (i.e. rather than 
involving intron/exon binding and modulation of RNA splicing). 
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Figure 15: Identification of direct targets of CUGBP1 by RIP-Seq analyses. A, Validation of the 
crosslinking/immunoprecipitation of CUGBP1-bound transcripts in SK-Mel-103 showing the enrichment 
identified for the 3’UTR of CCND1 in CUGBP1-IP samples (blue), with respect to input (orange); the 
CUGBP1-IP/Input ratio (green). B, Confirmation of CCND1 3’UTR pulldown by RIP for the indicated 
melanoma cell lines. C, Venn diagrams to assess the overlap of RIP-based analyses in melanoma cells (SK-
Mel-103 and UACC-62) versus the indicated cell populations. D, Left chart, peak calling distribution 
defined by the Piranha algorithm indicating preferential binding of CUGBP1 to 3’UTR sites in both SK-
Mel-103 and UACC-62. Right chart, results obtained by Sequence Searcher for classical CUGBP1 11-mers 
as defined in the text, represented for the total of 2024 RIP-Seq identified transcripts. E, Enriched 
sequences from the melanoma CUGBP1 RIP-Seq data defined by the DREME algorithm (p<0.005).  
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8. VALIDATION OF DEK AS A FUNCTIONAL DOWNSTREAM TARGET OF CUGBP1 IN MELANOMA  
Next, the RIP-Seq data was 
integrated with our 
transcriptomic and proteomic 
analyses. Of note, a fraction, 
but not all key cell cycle/DNA 
synthesis interacting networks 
controlled at mRNA levels by 
CUGBP1 are indeed direct 
targets of this RBP (see genes 
marked with gray boxes in 
Figure 16). Therefore, we 
questioned whether any of 
these direct interactors (i.e. CCNB1, CKS1B, DEK, MCM2, MCM3, MCM7, PRKDC or UBE2C) could in 
turn act downstream of CUGBP1, broadening its spectrum of action. We hypothesized of DEK as a 
likely candidate, since as indicated above, it is an oncogenic RNA-190,191 and chromatin-
interacting171,172 factor with key roles in cycle progression and modulation of apoptosis in 
melanoma cells186. Therefore, a further detailed mechanistic and computational analysis was 
performed (i) to validate DEK as a CUGBP1-modulated factor; (ii) define how CUGBP1 regulates 
DEK expression, (iii) demonstrate physiological relevance by modulating DEK and rescuing CUGBP1 
shRNA-related effects, and if the case (iv) assess co-expression of CUGBP1 and DEK in vivo (human 
melanoma specimens). To start answering the objectives indicated above, a panel of melanoma 
cell lines was infected with lentiviruses coding for CUGBP1 shRNA, and the subsequent effect on 
DEK protein expression was determined by immunoblotting. As summarized in Figs. 17A and B, 
DEK levels were clearly reduced in 5 of the 6 CUGBP1-downregulated melanoma cell lines. 
Therefore, CUGBP1 is required to sustain a high expression of DEK. A further characterization of 
the RIP-Seq data described in Figure 15 revealed CUGBP1 bound to the 3’UTR of DEK (Figure 17C), 
a feature confirmed by independent immunoprecipitation and amplification of this whole genomic 
region by semi-quantitative RT-PCR (see data for SK-Mel-103 and UACC-62 in Figs. 17D, E, and 
similar supportive results for additional melanoma cell lines in Figs. 17F, G). 
Figure 16: CUGBP1 targets (grey boxes) undergoing changes in 
mRNA and protein levels as indicated in Figure 14C. Genes under 
the control of DEK as defined by cDNA arrays are marked with green 
dashed lines. See text for detail. 
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further assess CUGBP1 recognition. I, Input and immunoprecipitated CUGBP1 in UACC-62 expressing 
the indicated DEK 3’ UTR fragments. As a control for specificity of the CUGBP1 antibodies, similar 
pulldowns were performed in cells expressing CUGBP1 siRNA. J, Amplification of the corresponding 
DEK 3’UTR fragments determined by semi-quantitative RT-PCR fragments to further assess CUGBP1 
recognition. K, Quantification of data as in J. 
Figure 17: DEK is a direct target of CUGBP1. A, B, 
Downregulation of DEK protein expression by 
CUGBP1 depletion (shRNAs) in the indicated 
melanoma cell lines visualized by immunoblotting 
with respect to control shRNA transduced 
counterparts. C, Results of RIP-seq identifying 
enriched CUGBP1 binding at the 3’UTR of the DEK 
mRNA. D, Immunoprecipitation of CUGBP1 for 
subsequent analysis of qPCR-based retrieval DEK 
3’UTR (E). F, G, similar studies as in D, E, but with 
additional melanoma cell lines to show data 
reproducibility. H, Cloned DEK 3’UTR fragments to 
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We have identified 13 UG-rich areas at the DEK 3’UTR (red boxes in Figure 17H). A PCR-based 
amplification was then set to clone these sites (distributed into 4 fragments; Figure 17H) for 
expression via lentiviral vectors. Four isogenic UACC-62 populations were therefore generated to 
individually express these DEK 3’UTR fragments. In turn, each of these populations was divided in 
two sets, for transduction of control or CUGBP1 siRNAs (the latter for a negative control for the 
selectivity of the CUGBP1 antibodies; Figure 17I). As shown in Figure 17J, K, this strategy revealed a 
significant and preferential binding of CUGBP1 to the central area of the 3’UTR of DEK. Together, 
these data confirm DEK as a new class of bona-fide CUGBP1 targets. 
9. CUGBP1 ALSO CONTROLS PROLIFERATION AND DEK EXPRESSION IN OTHER TUMOR TYPES  
As mentioned above, published genome-wide analyses for CUGBP1 targets are only available for 
HeLa and T-cells. Interestingly, mining the corresponding datasets, we identified DEK bound by 
CUGBP1 in T-cells, supporting our data in melanoma. However, there was no information for 
CUGBP1-DEK RIP in HeLa, nor additional information in other cancer types. Therefore, a panel of 
cell lines from different tumor types was analyzed to define to which our results in melanoma were 
applicable to other malignancies. Interestingly, and as summarized in Figure 18A, a variety of cell 
lines from multiple tumor types expressed CUGBP1 levels comparable to those in melanoma cell 
lines (i.e. higher than in normal skin cells). Moreover, CUGBP1 depletion also compromised cell 
proliferation as demonstrated by impaired colony formation ability (Figures 18B and 18C).  
Figure 18: CUGBP1 in other tumor 
types. A, Comparative expression of 
CUGBP1 protein levels across the 
indicated cell types, using normal 
melanocytes as a reference. B, Impact 
of CUGBP1 depletion (shRNA) on colony 
formation of the indicated cell lines. C, 
Quantification of results in (B). 
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Of note, no significant changes in isoform levels of known CUGBP1 targets as a splicing regulator, 
neither on CCND1 protein expression were detected after CUGBP1 depletion in these cell lines 
(Figures 19A and 19B). Instead, CUGBP1 downregulation resulted in a clearly identifiable reduction 
in DEK in 4 out of the 7 lines analyzed (Figure 19C). Therefore, these data expand the spectrum of 
tumor types with DEK as a downstream target of CUGBP1. 
 
10. CUGBP1 STABILIZES DEK mRNA 
Next, we interrogated how CUGBP1 binding to the DEK mRNA affected gene expression. As this 
binding was found to occur at the 3’ UTR region, we hypothesized effects on mRNA stability. 
Therefore, we compared the half life of the DEK mRNA in melanoma and non-melanoma cell lines. 
To this end, transcription was blocked with Actinomycin D in control and CUGBP1 shRNA-
expressing cells, and DEK mRNA half life was measured thereafter. Importantly, in those lines 
where CUGBP1 depletion reduced DEK protein expression, DEK mRNA half life was significantly 
Figure 19: CUGBP1-dependent regulation 
of DEK in other tumor cell types. A, 
Impact of CUGBP1 shRNA on the splicing 
of the indicated genes, with isoform 
quantification in (B). C,  DEK protein levels 
in control vs. CUGBP1-depleted cell lines. 
CCND1 was also included as a reference. 
Figure 20: CUGBP1 stabilizes DEK mRNA. A, CUGBP1 depletion efficiency (left) and remaining DEK mRNA 
levels after Actinomycin D treatment in UACC-62 melanoma cell line. B, CUGBP1 depletion efficiency 
(left) and remaining DEK mRNA levels after Actinomycin D treatment in U251 glioblastoma cell line. 
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shortened (see data for the melanoma UACC-62 in Figure 20A, and for the glioblastoma U251 in 
Figure 20B).   Therefore, while other regulatory mechanisms may modulate DEK expression192-
194,198, our data supports an unanticipated control of its mRNA stability (and consequently protein 
levels) by CUGBP1 in a large fraction of tumor cell lines. 
11. DEK OVEREXPRESSION RESCUES CUGBP1 DEPLETION-DEPENDENT PHENOTYPE 
As indicated above, one of the main findings of this PhD thesis is the identification of a broad 
spectrum of proteomic and transcriptomic changes induced by CUGBP1 depletion. Therefore, we 
questioned to which extent DEK depletion was ultimately responsible for main effect of CUGBP1 
depletion, namely, impairment in the defective proliferative capacity of melanoma cells.  
Therefore, the DEK coding sequence was cloned in lentiviral vectors for stable transduction in 
representative cell lines.  This ectopically expressed DEK (which not having the 3’UTR was not 
downregulated by CUGBP1 depletion; Figure 21A) largely counteracted the inhibitory effect of 
CUGBP1 shRNA on colony formation ability (Figures 21B and 21C). Therefore, this data solidifies 
the concept of DEK as a functionally-relevant target of CUGBP1. 
 
12. POSITIVE CORRELATION BETWEEN CUGBP1 AND DEK EXPRESSION IN VIVO  
A corollary of our findings is that DEK and CUGBP1 expression should be positively correlated in 
human melanoma biopsies. Supporting this hypothesis, mRNA levels of both genes showed a 
relevant Pearson correlation (R=0.35) in the n=278 melanomas of the TCGA database (Figure 22A).  
This correlation was even stronger when analyzing the expression of both proteins by automated 
single-cell analysis of co-immunostained sections of malignant human melanoma biopsies. An 
example of this dual DEK/CUGBP1 visualization (green and red fluorescence, respectively) can be 
found in Figure 22B in a representative melanoma skin metastasis.  Similarly significant 
coexpression was identified in vertical growth phase, and LN metastasis (Figure 23C, see also 
additional examples for skin metastases).  Together, these provide further physiological support for 
a tight interplay between DEK and CUGBP1 expression.   
Figure 21: Functional impact of DEK downstream of CUGBP1. A, Expression of the indicated protein in 
SK-Mel-103 transduced with GFP-expressing lentiviruses either empty or coding for the coding region 
of DEK (lacking 5’ or 3’ UTRs). B, Crystal violet staining of colonies formed in the indicated cell 
populations infected with control or shCUGBP1-1. C, Quantification of data in (B).  
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Figure 22: Positive correlation between CUGBP1 and DEK expression in vivo. A, Correlation plots of DEK 
vs. CUGBP1 mRNA in melanoma patients (data obtained from TCGA, n=278). B, CUGBP1 (red) and DEK 
(green) protein levels in a skin metastasis human biopsy sample. Chart below: the quantification of 
nuclear staining of CUGBP1 and DEK in the human biopsy. Images on the right show higher magnification 
of selected areas of the lesion. C, Immunofluorescence staining of CUGBP1 and DEK in malignant 
melanoma lesions of human biopsies (a-c, VGP; d-e, skin metastasis; f-h, lymph node metastasis). Charts 
show the quantification of nuclear staining of CUGBP1 and DEK in each biopsy (R, Pearson correlation 
coefficient; n, total number of quantified cells in whole tissue).  
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Melanomas are prime examples of aggressive tumors that proceed with massive changes in the 
transcriptome and proteome126-129. RNA regulatory mechanisms are attractive as key contributors 
to this complexity for their potential to modulate multiple pro-tumorigenic signaling 
cascades243,246,247. Yet, knowledge on the expression and function of RNA binding proteins (RBPs) 
are puzzlingly incomplete. Here we identify CUGBP1/CELF1 as an early-induced melanoma factor 
required for proper cell cycle progression. Target identification was then performed by genome-
wide RIP-Seq, transcriptomic and proteomic analyses. This integrated approach, to our knowledge, 
the first in class for human RBPs, revealed a relatively minor set of genes controlled by CUGBP1 in 
the context of alternative splicing. These results therefore separate melanomas from 
developmental processes (i.e. in muscle cells) where this gene has been better characterized285,286. 
Instead, CUGBP1 was found to regulate mRNA levels (and their protein expression) of a broad 
spectrum of cellular factors, enriched for an interconnected network of key cell cycle/DNA 
replication modulators. Canonical UG rich domains were identified at 3’UTR of CUGBP1 bound 
transcripts, supporting a key role of this RBP in the control of mRNA stability.  A novel CUGBP1-
target discovered with these 3’UTR-associated features was the oncogene DEK. The physiological 
relevance of DEK as a downstream effector of CUGBP1 was supported by rescue experiments, and 
further emphasized by histological analyses in human clinical specimens. Interestingly, DEK was 
found under the control of CUGBP1 in cell lines from various additional cancer types. Together, 
these data provide new insights on mechanisms of RNA regulation in melanoma, identifying new 
roles and functions of CUGBP1, with unanticipated links to the oncogenic DEK that may have a 
broader impact on tumor development. 
1. RBPs IN MELANOMA AND BEYOND: CUGBP1 IN CELL CYCLE CONTROL 
The starting point of this PhD thesis was the finding that despite the almost 80000 somatic 
mutations and the plethora of chromosomal reorganizations reported for human melanoma 
specimens217, mRBPs (with more than 650 family members) are not a frequent subject of 
mutations or copy number variations. Hypothesizing a post-transcriptional control, we exploited an 
array specifically designed for a high coverage survey of functionally annotated representatives of 
main RBP families (i.e. recognition to mRNA, snRNA, snoRNA and ncRNA)218. This microarray also 
contained probes for 302 cancer-related factors, which ultimately guided our validation efforts 
towards the analysis of RBPs able to both modulate cell cycle control checkpoints and chromatin 
organizers. This strategy revealed 50 RBPs with an enhanced mRNA expression with respect to 
normal melanocytes. Of those, only 9 (C1QBP, DEK, DYRK1A, EIF6, MAGOH, PTBP1, SNRPD1, SNRPE 
and SRSF3 – see Table 8 for details) had been previously found with key roles in melanoma. 
Therefore our new discoveries have important basic and translational implications.  
VII. Discussion/Discusión 
 
100 
 
Table 8: RBPs enriched in melanoma melanocyte microarray with defined functions in melanoma. 
GENE FINDING REF 
C1QBP 
C1QBP driven enhanced migration and tumor growth of B16F10 melanoma 
cells in C57/BL6 mice through MT1-MMP and MMP-2 activation. 
380 
DEK DEK dependent melanoma growth and chemoresistance. 
185 
DYRK1A Higher DYRK1A levels in primary melanoma compared to nevi. 
381 
EIF6 
Cell migration and invasion enhancement in eIF6 overexpressing 
melanoma cell lines through activation of cdc42. 
382 
MAGOH MAGOH-regulated proliferation of melanoblasts in the dermis. 383 
PTBP1 
PTBP1 dependent CD44v6 (brain metastasis driver) overexpression in 
advanced melanomas. 
384 
SNRPD1 
SNRPD1 depletion dependent reduction of cell viability in melanoma cell 
lines. 
385 
SNRPE 
SNRPE depletion dependent reduction of cell viability in melanoma cell 
lines through increased autophagy. 
385 
SRSF3 SRSF3-dependent MDM4-driven melanoma growth. 
386 
 
With the objective of providing insight into novel mechanisms of gene regulation in melanoma, 
we focused on genes not previously reported to this disease.  CUGBP1 was of interest for its recent 
links to hepatocellular carcinoma, non-small cell lung cancer, esophageal carcinoma and gastric 
cancer336-342, although genome-wide analyses for regulated transcripts have yet to be defined 
(Table 5). Finding CUGBP1 induced in semi-transformed melanocytes (Mel-STV) and at early stages 
of melanoma progression thus further emphasizes tumor-associated roles of RBPs. Moreover, our 
data showing a high protein expression of CUGBP1 (and functional impact) in cell lines from 
bladder, breast, colon, glioma, lung and prostate cancer cell lines (Figure 18) further expands the 
breadth of malignancies where high throughput analyses of CUGBP1 targets may prove highly 
informative. In addition, we anticipate the identification of upstream modulators of CUGBP1 as a 
useful strategy to further link pro-oncogenic events to global regulators of gene expression. In this 
context, it is interesting to note that an E-box motif has been identified at the CUGBP1 promoter: 
analyses in normal and differentiated myoblasts reported binding of the TCF3, CBP and p300 
transcription factors294, also with reported links to malignancy. The development of inducible 
CRISPR-Cas9 now offers the possibility of assessing not only upstream modulators of CUGBP1, but 
also to define cooperating (or antagonistic) effects in vivo of the additional RBPs we found 
deregulated in melanoma cells.  
2. SYSTEM-DEPENDENT ROLES OF CUGBP1 
One of the most unanticipated result was the relatively modest overlap of the CUGBP1-bound 
transcripts we discovered in melanoma, with respect to the two genome-wide analyses available in 
the literature for HeLa and T-cells284,327. This minor overlap was also obvious for information 
available through ENCODE on the K562 and GM12878 cell lines331. The mechanisms underlying this 
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variability will have to be defined in future studies. However, it is tempting to speculate the 
involvement of alternative 3’UTRs that are differentially used depending on the cellular 
context387,388. Additionally, the differential outcome of CUGBP1 in different cellular settings may 
reflect the expression of other RBPs which may act in a compensatory manner. Competition and 
collaboration between different RBPs and microRNAs has been reported in several studies389-391. In 
particular for CUGBP1, this agonistic and antagonistic functions have been demonstrated for 
MBNL1283,333 and HuR392. The extent to which these compensatory proteins act in melanoma cells is 
unclear, but preliminary studies from our lab suggest an important contribution of MBNL1 
(unpublished data).  
3. NOVEL CUGBP1 TARGETS IN MELANOMA CELLS 
Regarding the mechanism of action of CUGBP1 in melanoma, our initial studies aimed to assess 
alternative splicing. The rationale stemmed from the large body of literature for CUGBP1 in the 
modulation of isoform selection in the context of physiological and pathogenic developmental 
processes in muscle cells294,303,332,334,393.  However, we found that CUGBP1 shRNA had a minor 
impact on known CUGBP1 targets such as exon 11 or INSR302-304, exon 22 of SERCA1305, exon 17 of 
FXR1305, exon 5 of FAM188A305 and exon 20 of ANK2305. In addition, we failed to detect the splicing 
event of exon 7a MEF2A and exon 9 of PPFIBP1 in cancer cell lines tested. Moreover, genome-wide 
analyses using Human Junction Arrays (HJAY), which cover a total of 5.4 million probes, revealed a 
surprisingly small number of genes found to show changes in splicing in both cell lines upon 
CUGBP1 depletion (see Table 9).  
Table 9: Common alternative splicing events observed in both SK-Mel 103 and UACC-62 cells 
upon CUGBP1 depletion. 
 
SK-MEL 103 UACC-62  
 GENE Fold Index GENE Fold Index EXON EVENT 
ATP5G3 3.14 ATP5G3 2.11 ae4 intron retention 
CLDND1 3.04 CLDND1 3.07 e2 alternative first exon, exon skipping 
CLSPN 2.22 CLSPN 2.21 ae1 alternative first exon 
CSNK1G1 3.00 CSNK1G1 2.01 e5 alternative last exon, exon skipping 
DHX40P1 3.04 DHX40P1 2.41 e10 unknown 
DHX40P1 2.77 DHX40P1 2.27 e8 unknown 
DHX40P1 2.52 DHX40P1 2.48 e12 unknown 
DHX40P1 2.27 DHX40P1 2.22 ae5 unknown 
DHX40P1 2.07 DHX40P1 2.21 e7 unknown 
EIF4E2 3.07 EIF4E2 2.40 ae6 alternative last exon 
MACF1 3.09 MACF1 2.87 e41 alternative first exon, exon skipping 
MBNL1 2.02 MBNL1 2.14 e3 exon skipping 
RREB1 2.44 RREB1 3.60 ae6 intron retention 
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In the light of the small number of genes with altered splicing, we decided to proceed to an 
unbiased transcriptomic and proteomic analysis. Interestingly, a significant correlation between 
mRNA and protein levels, supporting the concept that CUGBP1 controls gene expression by 
modulating translation285,309,322 and mRNA stability284,327. Another objective of this work was to 
unravel and build network of genes regulated by CUGBP1 in melanoma cells. Enrichment analyses 
revealed cell cycle and DNA replication/cellular stress as key signaling cascades modulated by 
CUGBP1. Interestingly, and while both cellular processes are modulated by a large set of cellular 
factors, CUGBP1 appear to modulate mRNA and protein expression of a selective set of highly 
interacting signaling hubs.  In particular, we identified an unexpected coordinated regulation of 
minichromosome maintenance proteins (MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7), 
replication factor C protein complex (RFC4 and RCF5) and DNA polymerase alpha complex (POLA1 
and POLA2). This indicates an aberration in the DNA synthesis initiation and elongation. 
Downregulation of these genes upon CUGBP1 depletion might explain the delayed progression 
through the G1 phase of the cycle phase. In addition, GINS family members (GINS2 and GINS4) 
essential for initiation of DNA replication, and progression of DNA replication forks were also found 
as CUGBP1 modulating factors. DNA replication stress has been proposed to be one of the 
hallmarks of cancer, which is a source of DNA strand breaks and genomic instability394. The 
deregulation of FANCA, FANCD2 or FANCC1 (Figure 16) may further contribute to replicative stress 
and a subsequent impairment of tumor progression. The inability of CUGBP1-depleted melanoma 
cells to grow efficiently as xenografts further supports the requirement of this RBP to avoid 
detrimental effects related to aberrant proliferation.  
Intriguingly, RIP-Seq identified various MCMs (i.e. MCM2, MDCM3 and MCM7) as well as other 
cell cycle and DNA synthesis modulators such as CCNB1, UBE2C or PRKDC (Figure 16) as direct 
binding targets of CUGBP1 in melanoma cells. However, this was not the case for multiple 
additional controllers of cell proliferation that CUGBP1 modulates at the protein and mRNA levels. 
In this context, finding that chromatin organization and chromatin architecture were enriched 
terms identified in microarrays and whole genome transcriptomic and proteomic analysis was 
found critical to identify CUGBP1 “intermediaries” that broaden the control of pro-tumorigenic 
factors with no consensus UG-rich sites in their mRNA. Thus, integrating all these unbiased 
analyses ultimately revealed the chromatin binding factor DEK as a direct CUGBP1 target. 
Moreover, we identified 13 UG-rich repeats at the 3’UTR of DEK. Of those, repeats contained in 
between nucleotides 442-1311 in this region appear to define recognition by CUGBP1. This binding 
of CUGBP1 extended the half life of the DEK transcript. While additional studies are required to 
determine how CUGBP1 stabilizes and protects DEK and other targets from degradation, a possible 
mechanism involve competing for other mRNA binding proteins such as HuR, ARE-BP and/or PABP 
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thus inhibiting the formation of destabilizing complex which would enable the PARN to degrade 
the target mRNA.  
The power of genome-wide analyses was also illustrated in the identification of downstream 
effectors of DEK (Table S5). We had previously linked the oncogenic functions of DEK to the control 
of cell cycle progression and modulation of cell survival. Here we now identified specific proteins 
that may mediate these functions of DEK. Certainly, given the inherent pleiotropic nature of RPBs, 
it would not be expected that DEK would completely restore the deficient proliferation of CUGBP1-
depleted melanoma cells. Therefore, finding that a significant recovery of colony formation was 
possible after rescuing DEK expression in CUGBP1 shRNA-expressing melanoma cells is highly 
significant (Figure 21). In this context, it is important to note that DEK has been shown to 
counteract replication stress and ensure cell proliferation by resolving DNA and/or chromatin 
structures at the replication fork due to its function on changing the DNA topology395. The 
physiological relevance of DEK is emphasized by its overexpression in human melanoma 
specimens185, and the finding demonstrated here of a positive correlation with CUGBP1. 
Histopathological validation in human melanoma tissues is supported by the identification of DEK 
as a downstream modulator of CUGBP1 in other cell types. 
In summary, these findings presented in this PhD thesis helped us to expand the information on 
the functional impact of CUGBP1 in cancer, and in more detail in melanoma. Importantly, we have 
identified a large set of novel CUGBP1-bound transcripts which expand spectrum of targets (and 
functions) of this gene. Together, this information furthers our knowledge on the crosstalk 
between cell cycle, DNA synthesis and chromatin organization, via the RNA binding features of 
CUGBP1, incorporating DEK as a fundamental mediator of these processes. 
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CONCLUSIONS 
In the light of the results represented in this PhD thesis we withdraw the following conclusions: 
1. RNA binding proteins (RBPs) are not a frequent mutational target in melanoma. However, a 
subset of 50 members of this family was found to undergo selective deregulation at the mRNA 
level in melanoma cell lines. 
2. From these newly-identified melanoma-overexpressed RBPs, the CUG repeat binding protein 1, 
CUGBP1, was found upregulated at early stages of tumor progression, being required to 
maintain cell proliferation (in vitro and in vivo). Depletion of CUGBP1 in melanoma cells results 
in delayed cell cycle, resulting from defective G1-S cell cycle progression. 
3. Genome-wide analyses (transcriptomic and proteomic analyses) identified a highly 
interconnected network of novel CUGBP1 regulated genes. In particular, enrichment studies 
uncovered cell cycle and DNA synthesis/replication modulators previously unknown to be 
modulated by CUGBP1 at protein and mRNA levels.  
4. RIP-seq revealed a large set of direct binding targets of CUGBP1, which contained GU-rich 
repeats preferentially at 3’UTR sites. A key characteristic target of CUGBP1 with these features 
is the DEK chromatin organizer. The binding occurs between bases 433-1311 of 3’UTR of DEK 
mRNA, representing an unanticipated mechanism of regulation for this oncogene. 
5. DEK is a functionally-relevant CUGBP1 target, alleviating inhibitory effects of CUGBP1 shRNA in 
clonogenic capacity. 
6. CUGBP1 and DEK levels (RNA and protein) positively correlate in human melanoma biopsies. 
7. The interplay between CUGBP1-DEK and cell cycle proliferation/DNA synthesis identified in 
melanoma, was also demonstrated to apply to other tumor types, expanding the roles and 
mechanistic impact of RBPs in cancer. 
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CONCLUSIONES  
A raíz de los resultados presentados en la presente Tesis Doctoral, concluimos lo siguiente: 
1. Las proteínas de unión a ARN (RBPs) no representan una diana mutacional frecuente en el 
melanoma. Sin embargo, aquí identificamos una serie de 50 miembros de esta familia que 
sufren una regulación particular a nivel de ARNm en el melanoma humano. 
2. Entre estas nuevas RBPs enriquecidas en el melanoma, la “CUG repeat binding protein 1”, 
CUGBP1, se identificó como un factor sobre-expresado en fases iniciales de esta enfermedad, 
requerido para mantener la proliferación celular (in vitro and in vivo). La depleción de CUGBP1 
en células de melanoma conduce a una reducción en la capacidad proliferativa derivada de una 
progresión deficiente a través de las fases G1-S del ciclo celular. 
3. Análisis de perfiles transcriptómicos y proteómicos correspondientes al genoma completo  
revelaron una red altamente interconectada de nuevos genes regulados por CUGBP1. En 
particular, estudios de enriquecimiento resultaron en el descubrimiento de reguladores de 
ciclo celular y de síntesis/replicación del ADN, previamente desconocidos como dianas 
reguladas por CUGBP1 a nivel de ARNm y proteína.  
4. RIP-seq reveló un gran grupo de dianas directas de CUGBP1, conteniendo repeticiones ricas en 
UG preferentemente en sitios 3’UTR. Uno de los genes con esta característica es el organizador 
de cromatina DEK. CUGBP1 reconoce los residuos 433-1311 de 3’UTR en el ARNm de DEK, 
representando un mecanismo de regulación desconocido para este oncogén. 
5. DEK ejerce un efecto funcionalmente relevante como efector de CUGBP1, disminuyendo los 
efectos inhibidores de CUGBP1 shRNA  en la capacidad clonogénica de las células del 
melanoma. 
6. Los niveles de CUGBP1 y DEK (ARN and proteína) correlacionan de forma positiva en biopsias 
de melanoma humano.  
7. La interconexión entre CUGBP1, DEK y proliferación celular/síntesis de ADN identificada en el 
melanoma se demostró aplicable a otros tipos tumorales, reforzando y expandiendo el 
impacto fisiológico de las RBPs en el cáncer.  
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1. SUPPLEMENTARY TABLES 
Supplementary Table 1: List of mRNA binding proteins (n=692), their domains and counts of the domains 
in the protein structure are indicated. %: Percentage of melanoma patients with mutations or copy number 
variations (n=478, data retrieved from TCGA). 
GENE DOMAIN [COUNT] % 
A1CF RRM_1[2],DND1_DSRM[1],RRM_6[1] 7.32 
ABCF1 ABC_tran_2[1],ABC_tran[2] 4.81 
ABT1 RRM_6[1] 4.18 
ACIN1 SAP[1],RRM_5[1] 2.51 
ACO1 Aconitase_C[1],Aconitase[1] 2.51 
ADAD1 A_deamin[1],dsrm[1] 3.13 
ADAD2 A_deamin[1],dsrm[1] 2.51 
ADAR A_deamin[1],z-alpha[2],dsrm[3] 4.18 
ADARB1 A_deamin[1],dsrm[2] 2.51 
ADARB2 A_deamin[1],dsrm[2] 4.39 
AFF1 AF-4[1] 3.55 
AFF2 AF-4[1] 5.64 
AFF3 AF-4[1] 5.23 
AFF4 AF-4[1] 5.02 
AGFG1 ArfGap[1] 1.67 
AKAP1 TUDOR[1],KH_1[1],DUF3552[1] 5.23 
AKAP17A . 1.04 
AKAP8 AKAP95[1] 1.67 
AKAP8L AKAP95[1] 1.25 
ALKBH1 2OG-FeII_Oxy_2[1] 1.46 
ALKBH5 2OG-FeII_Oxy_2[1] 1.04 
ALYREF FoP_duplication[1],RRM_1[1],FYTT[1] 4.18 
ANGEL1 Exo_endo_phos[1] 2.71 
ANGEL2 Exo_endo_phos[1] 3.13 
APEX1 Exo_endo_phos[1] 0.62 
API5 API5[1] 0.83 
APOBEC1 APOBEC_N[1] 1.88 
APOBEC2 APOBEC_N[1] 3.97 
APOBEC3F APOBEC_N[2] 1.88 
APOBEC3G APOBEC_N[2] 2.3 
APOBEC4 APOBEC_N[1] 2.92 
AQR AAA_11[1],AAA_12[1] 4.6 
ARHGEF28 PH[1],RhoGEF[1],C1_1[1] 3.97 
ARL6IP4 SR-25[1] 1.04 
ATXN1 ATXN-1_C[1],AXH[1] 8.78 
ATXN1L AXH[1] 0.41 
ATXN2 PAM2[1],LsmAD[1],SM-ATX[1] 2.09 
ATXN2L PAM2[1],LsmAD[1],SM-ATX[1] 2.3 
AUH ECH[1] 0.2 
BCLAF1 THRAP3_BCLAF1[1] 12.55 
BICC1 SAM_1[1],KH_1[3] 3.97 
BOLL RRM_1[1] 0.83 
BUD13 Bud13[1] 4.18 
BZW1 W2[1] 0.41 
BZW2 W2[1] 2.92 
C12orf65 RF-1[1] 0.62 
C1QBP MAM33[1] 1.04 
CACTIN CactinC_cactus[1],Cactin_mid[1] 1.46 
CALR Calreticulin[1] 0.83 
CAPRIN1 Caprin-1_C[1] 1.67 
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GENE DOMAIN [COUNT] % 
CAPRIN2 C1q[1],Caprin-1_C[1] 3.13 
CARHSP1 CSD[1] 0.41 
CASC3 Btz[1] 2.51 
CCAR1 SAP[1],DBC1[1],MIP-T3[1],S1-like[1] 1.25 
CCAR2 DBC1[1],S1-like[1] 3.13 
CDC40 WD40[5] 3.55 
CDC5L Myb_Cef[1],Myb_DNA-bind_6[1] 3.97 
CELF1 RRM_1[3] 1.04 
CELF2 RRM_1[3] 0.62 
CELF3 RRM_1[3] 3.34 
CELF4 RRM_5[1],RRM_1[2] 3.13 
CELF5 RRM_1[3] 1.67 
CELF6 RRM_1[3] 1.67 
CHERP G-patch[1],Surp[1],CTD_bind[1] 2.71 
CHTOP FoP_duplication[1] 3.55 
CIRBP RRM_1[1] 0.62 
CLASRP DRY_EERY[1] 1.25 
CLK1 Pkinase[1] 1.04 
CLK2 Pkinase[1] 4.39 
CLK3 Pkinase[1] 1.88 
CLK4 Pkinase[1] 1.25 
CLP1 MobB[1],Clp1[1] 1.04 
CMTR1 G-patch[1],FtsJ[1] 5.02 
CMTR2 FtsJ[1] 2.51 
CNBP zf-CCHC[7] 0.62 
CNOT1 DUF3819[1],Not1[1] 4.81 
CNOT10 TPR_1[2],BLOC1_2[1] 2.51 
CNOT11 DUF2363[1] 0.2 
CNOT2 NOT2_3_5[1] 3.76 
CNOT3 Not3[1],NOT2_3_5[1] 1.25 
CNOT4 RRM_5[1],zf-RING_4[1] 6.06 
CNOT6 LRR_8[1],Exo_endo_phos[1] 2.3 
CNOT6L LRR_8[1],Exo_endo_phos[1] 1.67 
CNOT7 CAF1[1] 2.3 
CNOT8 CAF1[1] 1.04 
CNP CNPase[1],AAA_33[1] 0.2 
CPEB1 RRM_1[1],RRM_6[1] 2.71 
CPEB2 RRM_1[1] 1.88 
CPEB3 RRM_1[1] 1.04 
CPEB4 RRM_1[1] 2.3 
CPSF1 MMS1_N[1],CPSF_A[1] 7.53 
CPSF2 RMMBL[1],Beta-Casp[1],Lactamase_B[1],CPSF100_C[1] 0.83 
CPSF3 RMMBL[1],Beta-Casp[1],Lactamase_B[1],CPSF73-100_C[1] 1.04 
CPSF3L RMMBL[1],Beta-Casp[1],Lactamase_B[1] 2.71 
CPSF4 zf-CCHC[1],zf-CCCH[3] 1.67 
CPSF4L zf-CCCH[3] 3.55 
CPSF6 RRM_6[1] 4.81 
CPSF7 RRM_1[1] 0.83 
CRNKL1 HAT[4] 3.97 
CRYZ ADH_N[1],ADH_zinc_N[1] 1.67 
CSDC2 CSD[1] 2.92 
CSDE1 SUZ-C[1],CSD[5] 4.18 
CSTF1 WD40[4] 2.71 
CSTF2 RRM_1[1],CSTF2_hinge[1],CSTF_C[1] 1.25 
CSTF2T RRM_1[1],CSTF2_hinge[1],CSTF_C[1] 2.09 
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GENE DOMAIN [COUNT] % 
CSTF3 Suf[1],TPR_16[1] 1.46 
CTIF MIF4G[1] 3.13 
CWC15 Cwf_Cwc_15[1] 2.92 
CWC22 MIF4G[1],MA3[1],CAF-1_p150[1] 1.04 
CWC25 Cir_N[1],CWC25[1] 1.46 
CWC27 Pro_isomerase[1] 1.88 
CWF19L1 Metallophos_3[1],CwfJ_C_1[1],CwfJ_C_2[1] 0.62 
CWF19L2 CwfJ_C_1[1],CwfJ_C_2[1] 4.18 
CXorf23 THRAP3_BCLAF1[1] 2.09 
DAZ1 RRM_1[3] 0 
DAZ2 RRM_1[1] 0.2 
DAZ3 RRM_1[1] 0 
DAZ4 RRM_1[2] 0 
DAZAP1 RRM_1[2] 1.67 
DAZL RRM_1[1] 2.3 
DBR1 Metallophos[1],DBR1[1] 1.67 
DCP1A DCP1[1] 0.83 
DCP1B DCP1[1] 2.51 
DCP2 DCP2[1],NUDIX[1] 2.51 
DCPS DcpS[1],DcpS_C[1] 2.92 
DDX1 Helicase_C[1],DEAD[1] 0.62 
DDX17 Helicase_C[1],DEAD[1] 4.39 
DDX19A Helicase_C[1],DEAD[1] 0.41 
DDX19B DEAD[1] 0.62 
DDX25 Helicase_C[1],DEAD[1] 3.76 
DDX26B VWA_2[1],INT_SG_DDX_CT_C[1] 1.46 
DDX39A Helicase_C[1],DEAD[1] 1.25 
DDX39B Helicase_C[1],DEAD[1] 4.81 
DDX3X Helicase_C[1],DEAD[1] 4.81 
DDX3Y Helicase_C[1],DEAD[1] 0.62 
DDX4 Helicase_C[1],DEAD[1] 2.92 
DDX41 Helicase_C[1],DEAD[1] 2.92 
DDX42 Helicase_C[1],DEAD[1] 5.43 
DDX43 Helicase_C[1],DEAD[1],KH_1[1] 4.81 
DDX5 P68HR[2],Helicase_C[1],DEAD[1] 4.81 
DDX53 Helicase_C[1],DEAD[1],KH_1[1] 3.34 
DDX59 zf-HIT[1],Helicase_C[1],DEAD[1] 5.64 
DDX6 Helicase_C[1],DEAD[1] 2.92 
DEK SAP[1],DEK_C[1] 5.23 
DENR SUI1[1] 0.41 
DGCR14 Es2[1] 3.97 
DHX15 OB_NTP_bind[1],DUF1777[1],HA2[1],Helicase_C[1],DEAD[1] 2.71 
DHX29 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 3.13 
DHX30 OB_NTP_bind[1],HA2[1],Helicase_C[1],dsrm[1],DEAD[1] 1.67 
DHX32 OB_NTP_bind[1],HA2[1] 1.88 
DHX33 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 1.67 
DHX34 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 2.92 
DHX35 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 2.3 
DHX36 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 2.51 
DHX38 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 2.51 
DHX40 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1] 4.81 
DHX57 OB_NTP_bind[1],HA2[1],Helicase_C[1],DEAD[1],RWD[1] 1.88 
DHX8 OB_NTP_bind[1],S1[1],Helicase_C[1],DEAD[1] 2.92 
DND1 RRM_1[1],DND1_DSRM[1] 1.04 
DQX1 OB_NTP_bind[1],HA2[1],AAA_22[1] 2.51 
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GENE DOMAIN [COUNT] % 
DRG1 MMR_HSR1[1],TGS[1] 0.41 
DRG2 MMR_HSR1[1],TGS[1] 1.25 
DUSP11 DSPc[1] 0.41 
DYNC1H1 
Dynein_heavy[1],AAA_9[1],DHC_N1[1],DHC_N2[1],MT[1],AAA_6[1],AAA_5[1],
AAA_7[1],AAA_8[1] 
5.02 
DYNLL1 Dynein_light[1] 0.41 
DZIP1 Dzip-like_N[1],zf-C2H2[1] 5.43 
DZIP1L Dzip-like_N[1] 1.67 
DZIP3 zf-RING_2[1] 2.51 
EDC3 LSM14[1],YjeF_N[1] 2.3 
EDC4 WD40[1] 3.55 
EEF2K Alpha_kinase[1] 2.09 
EIF1 SUI1[1] 0.2 
EIF1AD eIF-1a[1] 1.67 
EIF1AX eIF-1a[1] 1.25 
EIF1AY eIF-1a[1] 0 
EIF1B SUI1[1] 1.04 
EIF2AK1 Pkinase[2] 3.76 
EIF2AK3 PQQ_2[1],Pkinase[2] 4.6 
EIF2B1 IF-2B[1] 0.83 
EIF2B2 IF-2B[1] 0.83 
EIF2B3 NTP_transferase[1] 1.46 
EIF2B4 IF-2B[1] 0.41 
EIF2B5 Hexapep[1],NTP_transferase[1],W2[1] 1.46 
EIF3A PCI[1] 2.3 
EIF3B eIF2A[2],RRM_1[1] 4.18 
EIF3C eIF-3c_N[1],PCI[1] 0.2 
EIF3CL eIF-3c_N[1],PCI[1] 0 
EIF3D eIF-3_zeta[1] 1.88 
EIF3E eIF3_N[1],PCI[1] 4.18 
EIF3G RRM_1[1],eIF3g[1] 0.62 
EIF3H XkdN[1],JAB[1] 4.81 
EIF3I WD40[4] 1.46 
EIF3J eIF3_subunit[1] 1.88 
EIF3K PCI_Csn8[1] 0.83 
EIF3L Paf67[1] 2.92 
EIF3M PCI[1] 0.2 
EIF4A1 Helicase_C[1],DEAD[1] 1.25 
EIF4A2 Helicase_C[1],DEAD[1] 1.46 
EIF4A3 Helicase_C[1],DEAD[1] 5.02 
EIF4B RRM_1[1] 1.25 
EIF4E IF4E[2] 1.04 
EIF4E1B IF4E[1] 1.88 
EIF4E2 IF4E[1] 0.62 
EIF4E3 IF4E[1] 3.13 
EIF4ENIF1 EIF4E-T[1] 0.83 
EIF4G1 MIF4G[1],MA3[1],W2[1] 4.18 
EIF4G2 MIF4G[1],MA3[1],W2[1] 1.25 
EIF4G3 MIF4G[1],MA3[1],W2[1] 4.81 
EIF4H RRM_1[1] 1.88 
EIF5 eIF-5_eIF-2B[1],W2[1] 1.46 
EIF5A KOW[1],eIF-5a[1] 0.41 
EIF5A2 KOW[1],eIF-5a[1] 0.83 
EIF5AL1 eIF-5a[1] 0.83 
EIF6 eIF-6[1] 1.46 
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ELAVL1 RRM_1[3] 0.83 
ELAVL2 RRM_1[3] 9.41 
ELAVL3 RRM_1[3] 1.88 
ELAVL4 RRM_1[3] 3.34 
ENOX1 RRM_1[1] 1.88 
ENOX2 RRM_1[1] 1.67 
ERN1 PQQ_2[1],Pkinase[1],Ribonuc_2-5A[1] 6.27 
ERN2 PQQ_2[1],Pkinase[1],Ribonuc_2-5A[1] 5.02 
ESRP1 RRM_6[3] 7.74 
ESRP2 RRM_6[3] 1.88 
ETF1 eRF1_1[1],eRF1_2[1],eRF1_3[1] 0.83 
EWSR1 zf-RanBP[1],RRM_6[1] 2.71 
FAM103A1 RAM[1] 1.04 
FAM120A . 1.46 
FAM98A DUF2465[1] 0.62 
FASTK FAST_1[1],FAST_2[1],RAP[1] 4.6 
FASTKD1 FAST_1[1],FAST_2[1],RAP[1] 1.04 
FASTKD2 FAST_1[1],FAST_2[1],RAP[1] 0.83 
FASTKD3 FAST_1[1],FAST_2[1],RAP[1] 3.13 
FASTKD5 FAST_1[1],FAST_2[1],RAP[1] 3.13 
FIP1L1 Fip1[1],Pkinase_Tyr[1] 3.55 
FMR1 Agenet[1],FXR1P_C[1],KH_1[2] 1.46 
FRG1 FRG1[1] 3.55 
FRG1BP FRG1[1] 11.29 
FTO FTO_CTD[1],FTO_NTD[1] 1.04 
FUBP1 DUF1897[2],KH_1[4] 1.88 
FUBP3 KH_1[4] 1.46 
FUS zf-RanBP[1],RRM_1[1] 0.62 
FXR1 Agenet[1],FXR1P_C[1],KH_1[2] 1.88 
FXR2 Agenet[1],FXR1P_C[1],KH_1[2] 0.83 
FYTTD1 FYTT[1] 1.88 
G3BP1 RRM_1[1],NTF2[1] 1.46 
G3BP2 RRM_1[1],NTF2[1] 1.04 
GAPDH Gp_dh_C[1],Gp_dh_N[1] 1.67 
GCFC2 GCFC[1] 1.46 
GFM1 EFG_C[1],GTP_EFTU_D2[1],EFG_IV[1],EFG_II[1],GTP_EFTU[1] 1.46 
GFM2 EFG_C[1],GTP_EFTU_D2[1],EFG_IV[1],EFG_II[1],GTP_EFTU[1] 1.67 
GLE1 GLE1[1] 0.62 
GPATCH1 G-patch[1],Cwf_Cwc_15[1],DUF1604[1] 3.34 
GRSF1 RRM_6[3] 0.83 
GSPT1 PAM2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 1.46 
GSPT2 PAM2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 2.92 
GTF2F1 TFIIF_alpha[1] 1.25 
GTPBP1 GTP_EFTU_D2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 4.18 
GTPBP2 GTP_EFTU_D2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 3.34 
GUF1 EFG_C[1],GTP_EFTU_D2[1],LepA_C[1],EFG_II[1],GTP_EFTU[1] 1.88 
HABP4 HABP4_PAI-RBP1[1] 0.41 
HBS1L HBS1_N[1],GTP_EFTU_D2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 2.71 
HDLBP KH_1[14] 3.34 
HELZ PAM2[1],AAA_19[1],AAA_11[1],zf-CCCH[1],AAA_12[1] 5.64 
HELZ2 AAA_11[2],RNB[1],AAA_12[2] 6.9 
HNRNPA0 RRM_1[1],RRM_6[1] 0.62 
HNRNPA1 HnRNPA1[1],RRM_1[2] 0.83 
HNRNPA1L2 HnRNPA1[1],RRM_1[2] 1.04 
HNRNPA2B1 RRM_1[1],RRM_6[1] 2.09 
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HNRNPA3 RRM_1[1],RRM_6[1] 0.41 
HNRNPAB RRM_1[2],CBFNT[1] 1.67 
HNRNPC RRM_1[1] 0.62 
HNRNPCL1 RRM_1[1] 8.15 
HNRNPD RRM_1[2],CBFNT[1] 0.62 
HNRNPDL RRM_1[2],CBFNT[1] 0.2 
HNRNPF zf-RNPHF[1],RRM_1[1],RRM_6[2] 1.67 
HNRNPH1 zf-RNPHF[1],RRM_6[3] 2.09 
HNRNPH2 zf-RNPHF[1],RRM_6[3] 0.62 
HNRNPH3 RRM_6[2] 0.2 
HNRNPK ROKNT[1],KH_1[3] 1.04 
HNRNPL RRM_5[3] 2.51 
HNRNPLL RRM_5[2],RRM_6[1] 0.62 
HNRNPM HnRNP_M[1],RRM_1[3] 2.71 
HNRNPR RRM_1[3] 3.55 
HNRNPU SAP[1],SPRY[1],AAA_33[1] 4.6 
HNRNPUL1 SAP[1],SPRY[1],AAA_33[1] 1.67 
HNRNPUL2 SAP[1],SPRY[1],AAA_33[1] 0.83 
HTATSF1 RRM_5[1],RRM_1[1] 1.88 
IGF2BP1 RRM_1[1],KH_1[4],RRM_6[1] 4.6 
IGF2BP2 RRM_1[2],KH_1[4] 1.46 
IGF2BP3 RRM_1[1],KH_1[4],RRM_6[1] 3.76 
ILF2 DZF[1] 3.76 
ILF3 dsrm[2],DZF[1] 2.09 
IPO11 IBN_N[1],Xpo1[1] 2.3 
IPO13 IBN_N[1],Xpo1[1] 1.88 
IPO4 IBN_N[1],HEAT_2[1],HEAT_EZ[1] 2.51 
IPO5 IBN_N[1],HEAT_2[1],HEAT[1] 4.39 
IPO7 Cse1[1],IBN_N[1] 2.09 
IPO9 IBN_N[1],Xpo1[1] 5.64 
IREB2 Aconitase_C[1],Aconitase[2] 3.34 
ISY1 Isy1[1] 0.41 
JAKMIP1 . 6.27 
KHDC1 . 4.6 
KHDC1L . 3.34 
KHDRBS1 KH_1[1] 2.51 
KHDRBS2 KH_1[1] 8.57 
KHDRBS3 KH_1[1] 5.85 
KHNYN RNase_Zc3h12a[1] 1.25 
KHSRP DUF1897[2],KH_1[4] 0.62 
KPNB1 IBN_N[1],HEAT_EZ[1] 1.25 
L1TD1 Transposase_22[2] 5.43 
LARP1 La[1] 3.55 
LARP1B La[1] 1.88 
LARP4 La[1],RRM_6[1] 2.71 
LARP4B La[1],RRM_5[1] 3.76 
LARP6 SUZ-C[1],La[1] 2.09 
LIN28A zf-CCHC[1],CSD[1] 1.46 
LIN28B zf-CCHC[1],CSD[1] 4.18 
LRPPRC PPR_2[2],PPR[1] 3.97 
LSM12 AD[1] 0.41 
LSM14A LSM14[1],FDF[1] 2.09 
LSM14B LSM14[1],FDF[1] 2.09 
LUC7L LUC7[1] 1.25 
LUC7L2 LUC7[1] 4.81 
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LUC7L3 LUC7[1] 2.92 
LUZP4 FYTT[1] 1.46 
MAGOH Mago_nashi[1] 0.62 
MAGOHB Mago_nashi[1] 1.46 
MATR3 RRM_5[2] 2.09 
MBNL1 zf-CCCH[1] 1.46 
MBNL2 zf-CCCH[2] 1.25 
MBNL3 zf-CCCH[2] 0.62 
MECP2 MBD[1] 2.09 
METTL14 MT-A70[1] 0.83 
METTL3 MT-A70[1] 0.83 
MEX3A KH_1[2],zf-C3HC4_3[1] 2.71 
MEX3B KH_1[2],zf-C3HC4_3[1] 1.04 
MEX3C KH_1[2],zf-C3HC4_3[1] 0.83 
MEX3D KH_1[2],zf-C3HC4_3[1] 0.41 
MIF4GD MIF4G[1] 3.97 
MKRN1 zf-C3HC4[1],zf-CCCH[3] 5.02 
MKRN2 zf-RING_2[1],zf-CCCH[4] 1.88 
MKRN3 zf-C3HC4[1],zf-CCCH[1] 4.39 
MOV10 AAA_19[1],AAA_11[1],AAA_12[1] 3.55 
MOV10L1 AAA_11[2],AAA_12[1],S1-like[1] 7.11 
MRTO4 Ribosomal_L10[1] 1.25 
MSI1 RRM_1[2] 1.04 
MSI2 RRM_1[2] 3.76 
MTHFSD RRM_1[1],5-FTHF_cyc-lig[1] 1.46 
MTIF3 IF3_C[1],IF3_N[1] 0.62 
MTPAP GOLGA2L5[1],PAP_assoc[1] 1.04 
MTRF1 PCRF[1],RF-1[1] 0.83 
MTRF1L PCRF[1],RF-1[1] 1.46 
MYEF2 RRM_1[3] 1.88 
NAA38 LSM[1] 3.34 
NANOS1 zf-nanos[1] 0.83 
NANOS2 zf-nanos[1] 0.83 
NANOS3 zf-nanos[1] 1.25 
NCBP1 MIF4G_like_2[1],MIF4G[1],MIF4G_like[1] 0.2 
NCBP2 RRM_5[1] 1.25 
NCBP2L RRM_1[1] 0.41 
NELFE RRM_1[1] 5.02 
NFX1 R3H[1],zf-NF-X1[7] 2.51 
NGDN Sas10_Utp3[1] 1.46 
NMD3 NMD3[1] 1.46 
NOCT Exo_endo_phos[1] 1.04 
NOL3 CARD[1] 1.25 
NOVA1 KH_1[3] 4.6 
NOVA2 KH_1[3] 0.62 
NR0B1 Hormone_recep[1],NR_Repeat[4] 1.04 
NSRP1 DUF2040[1] 1.46 
NUDT21 NUDIX_2[1] 1.25 
NUFIP2 NUFIP2[1] 1.67 
NUPL2 zf-CCCH[1] 2.51 
NUTF2 NTF2[1] 0.2 
NXF1 LRR_4[1],Tap-RNA_bind[1],NTF2[1],TAP_C[1] 1.25 
NXF2 LRR_4[1],Tap-RNA_bind[1],NTF2[1],TAP_C[1] 1.25 
NXF2B LRR_4[1],Tap-RNA_bind[1],NTF2[1],TAP_C[1] 1.04 
NXF3 Tap-RNA_bind[1],NTF2[1] 3.13 
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NXF5 LRR_4[1],Tap-RNA_bind[1] 2.09 
NXT1 NTF2[1] 0.83 
NXT2 NTF2[1] 0.41 
PABPC1 RRM_1[4],PABP[1] 4.81 
PABPC1L RRM_1[4],PABP[1] 1.88 
PABPC1L2A RRM_1[2] 1.04 
PABPC1L2B RRM_1[2] 1.04 
PABPC3 RRM_1[4],PABP[1] 2.3 
PABPC4 RRM_1[4],PABP[1] 2.09 
PABPC4L RRM_1[4] 1.25 
PABPC5 RRM_1[4] 1.67 
PABPN1 RRM_1[1] 0.83 
PABPN1L RRM_1[1] 0.83 
PAIP1 PAM2[1],MIF4G[1] 3.34 
PAIP2 PAM2[1] 1.04 
PAIP2B PAM2[1] 0.2 
PAN2 RNase_T[1],UCH_1[1] 3.13 
PAN3 Pkinase[1],zf-CCCH[1] 1.88 
PAPD4 PAP_assoc[1],NTP_transf_2[1] 2.09 
PAPOLA PAP_RNA-bind[1],PAP_central[1] 1.25 
PAPOLB PAP_RNA-bind[1],PAP_central[1] 4.18 
PAPOLG PAP_RNA-bind[1],PAP_central[1] 1.46 
PARK7 DJ-1_PfpI[1] 1.67 
PARN CAF1[2],RNA_bind[1] 2.3 
PARP1 BRCT[1],WGR[1],PARP_reg[1],zf-PARP[2],PARP[1],PADR1[1] 4.39 
PATL1 PAT1[1] 2.51 
PATL2 PAT1[1] 2.09 
PCBP1 KH_1[3] 0.2 
PCBP2 KH_1[3] 1.04 
PCBP3 KH_1[3] 1.67 
PCBP4 KH_1[3] 0.62 
PCF11 CTD_bind[1] 4.6 
PDCD4 MA3[2] 1.88 
PDE12 Exo_endo_phos[1] 1.46 
PELO eRF1_1[1],eRF1_2[1],eRF1_3[1] 1.04 
PHF5A PHF5[1] 3.34 
PHRF1 PHD[1],zf-RING_2[1] 2.92 
PLRG1 WD40[6] 2.3 
PNLDC1 . 2.71 
PNN Pinin_SDK_N[1],Pinin_SDK_memA[1] 1.25 
PNRC2 PNRC[1] 1.46 
POLDIP3 RRM_1[1] 3.97 
POLR2A 
RNA_pol_Rpb1_3[1],RNA_pol_Rpb1_R[1],RNA_pol_Rpb1_2[1],RNA_pol_Rpb1
_1[1],RNA_pol_Rpb1_5[1],RNA_pol_Rpb1_4[1] 
2.71 
POLR2B 
RNA_pol_Rpb2_7[1],RNA_pol_Rpb2_4[1],RNA_pol_Rpb2_1[1],RNA_pol_Rpb2
_3[1],RNA_pol_Rpb2_5[1],RNA_pol_Rpb2_6[1] 
3.97 
POLR2D RNA_pol_Rpb4[1] 0.41 
POLR2E RNA_pol_Rpb5_N[1],RNA_pol_Rpb5_C[1] 0.62 
POLR2F RNA_pol_Rpb6[1] 2.51 
POLR2G S1[1],SHS2_Rpb7-N[1] 0 
POLR2H RNA_pol_Rpb8[1] 1.04 
POLR2I RNA_POL_M_15KD[1],TFIIS_C[1] 1.25 
POLR2J RNA_pol_L_2[1] 1.88 
POLR2J2 RNA_pol_L_2[1] 1.67 
POLR2J3 . 1.67 
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POLR2K DNA_RNApol_7kD[1] 3.13 
POLR2L RNA_pol_N[1] 0.2 
POLRMT RPOL_N[1],RNA_pol[1] 1.67 
PPAN 7tm_1[1],Brix[1] 0.2 
PPIE RRM_1[1],Pro_isomerase[1] 0.62 
PPIH Pro_isomerase[1] 1.04 
PPIL3 Pro_isomerase[1] 0.41 
PPIL4 RRM_1[1],Pro_isomerase[1] 1.46 
PPRC1 RRM_1[1] 3.34 
PPWD1 Pro_isomerase[1],WD40[2] 1.25 
PQBP1 WW[1] 0.83 
PRDX1 AhpC-TSA[1],1-cysPrx_C[1] 1.67 
PRKDC PI3_PI4_kinase[1] 7.74 
PRPF18 PRP4[1],Prp18[1] 1.25 
PRPF19 Prp19[1],U-box[1],WD40[4] 0.83 
PSIP1 LEDGF[1],PWWP[1] 3.13 
PTBP1 RRM_5[3],RRM_6[1] 1.25 
PTBP2 RRM_5[3],RRM_6[1] 1.67 
PTBP3 RRM_5[2],RRM_1[1],RRM_6[1] 0.83 
PTCD2 MRP-S27[1] 1.88 
PTCD3 PPR_2[1],PPR_3[1] 1.25 
PUF60 RRM_5[1],RRM_1[2] 5.85 
PUM1 Shadoo[1],PUF[8] 3.55 
PUM2 PUF[8] 1.67 
PUM3 CPL[1] 2.09 
PURA PurA[1] 1.25 
PURB PurA[1] 0.41 
PURG PurA[1] 2.51 
PYM1 Mago-bind[1] 1.25 
QKI KH_1[1] 2.71 
RAE1 WD40[3] 1.88 
RALY RRM_1[1] 2.3 
RALYL RRM_1[1] 5.43 
RAN Ras[1] 0.62 
RANBP17 IBN_N[1],CRM1_C[1] 5.85 
RANBP2 TPR_1[1],IR1-M[2],zf-RanBP[8],Ran_BP1[4],Pro_isomerase[1] 6.69 
RANBP6 HEAT_2[2] 3.13 
RAVER1 RRM_1[1],RRM_6[2] 2.09 
RAVER2 RRM_1[2],RRM_6[1] 1.88 
RBBP6 DWNN[1],zf-CCHC[1],zf-C3HC4_2[1] 4.6 
RBFOX1 Fox-1_C[1],RRM_1[1] 7.32 
RBFOX2 Fox-1_C[1],RRM_1[1] 2.09 
RBFOX3 Fox-1_C[1],RRM_1[1] 4.6 
RBM10 G-patch[1],zf-RanBP[1],RRM_6[2] 1.88 
RBM11 RRM_1[1] 4.39 
RBM12 RRM_1[1],RRM_6[4] 3.76 
RBM12B RRM_6[5] 5.02 
RBM14 RRM_1[2] 3.13 
RBM15 RRM_5[2],RRM_1[1],SPOC[1] 2.3 
RBM15B RRM_5[1],RRM_1[2],SPOC[1] 1.46 
RBM17 G-patch[1],RRM_5[1] 0.83 
RBM18 RRM_1[1] 0.41 
RBM20 RRM_5[1] 0.62 
RBM22 FYVE[1],RRM_1[1],zf-CCCH[1] 3.13 
RBM23 RRM_1[2],RBM39linker[1] 1.67 
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RBM24 RRM_6[1] 5.02 
RBM25 RRM_1[1],PWI[1] 2.51 
RBM26 RRM_5[1],PWI[1],zf-CCCH[1],RRM_6[1] 2.71 
RBM27 RRM_5[1],PWI[1],zf-CCCH[1] 2.92 
RBM3 RRM_1[1] 0.62 
RBM33 RRM_6[1] 4.81 
RBM34 RRM_1[2] 3.76 
RBM38 RRM_1[1] 2.09 
RBM39 RRM_5[1],RRM_1[2],RBM39linker[1] 1.88 
RBM4 RRM_1[2],zf-CCHC[1] 2.09 
RBM41 RRM_1[1] 0.62 
RBM42 RRM_1[1] 1.46 
RBM43 RRM_6[1] 0.62 
RBM44 RRM_1[1] 2.3 
RBM45 RRM_5[1],RRM_1[3] 1.04 
RBM46 RRM_1[3],DND1_DSRM[1] 5.02 
RBM47 RRM_1[3] 3.76 
RBM48 RRM_5[1] 1.67 
RBM4B RRM_1[2],zf-CCHC[1] 2.09 
RBM5 G-patch[1],zf-RanBP[1],RRM_6[2] 2.71 
RBM6 G-patch[1],RRM_6[2] 2.51 
RBM7 RRM_1[1] 3.55 
RBM8A RRM_1[1] 4.39 
RBMS1 RRM_1[2] 1.25 
RBMS2 RRM_1[2] 2.3 
RBMS3 RRM_1[2] 2.51 
RBMX RBM1CTR[1],RRM_1[1] 1.88 
RBMX2 RRM_1[1] 0.62 
RBMXL1 RBM1CTR[1],RRM_1[1] 2.3 
RBMXL2 RBM1CTR[1],RRM_1[1] 3.13 
RBMXL3 RRM_1[1] 0.41 
RBMY1A1 RBM1CTR[1],RRM_1[1] 0 
RBMY1B RBM1CTR[1],RRM_1[1] 0 
RBMY1D RBM1CTR[1],RRM_1[1] 0 
RBMY1E RBM1CTR[1],RRM_1[1] 0.2 
RBMY1F RBM1CTR[1],RRM_1[1] 0 
RBMY1J RBM1CTR[1],RRM_1[1] 0 
RBPMS RRM_1[1] 1.67 
RBPMS2 RRM_1[1] 0.62 
RC3H1 zf-CCCH[1],zf-RING_UBOX[1] 4.81 
RC3H2 zf-RING_5[1],zf-CCCH[1] 2.51 
RNF17 TUDOR[5] 9.62 
RNGTT mRNA_cap_C[1],mRNA_cap_enzyme[1],DSPc[1] 3.13 
RNMT Pox_MCEL[1] 1.46 
RNPS1 RRM_1[1] 0.41 
RPUSD3 PseudoU_synth_2[1] 1.04 
RPUSD4 PseudoU_synth_2[1] 3.97 
RQCD1 Rcd1[1] 2.3 
RRBP1 Rib_recp_KP_reg[1],IncA[1] 1.88 
RSRC1 THRAP3_BCLAF1[1] 1.88 
RTF1 Plus-3[1],SYF2[1] 2.09 
RUVBL1 TIP49[1] 0.62 
RUVBL2 TIP49[1] 1.25 
SAFB SAP[1],RRM_6[1] 2.09 
SAFB2 SAP[1],RRM_1[1] 1.25 
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GENE DOMAIN [COUNT] % 
SAMD4A SAM_1[1] 1.67 
SAMD4B PHAT[1],SAM_1[1] 1.25 
SAP18 SAP18[1] 0.83 
SARNP SAP[1] 0.83 
SCAF1 . 4.39 
SCAF11 zf-RING_2[1] 2.71 
SCAF4 RRM_1[1],CTD_bind[1] 2.09 
SCAF8 RRM_1[1],CTD_bind[1] 3.76 
SECISBP2 Ribosomal_L7Ae[1] 1.46 
SECISBP2L Ribosomal_L7Ae[1] 2.51 
SERBP1 HABP4_PAI-RBP1[1] 1.04 
SETX AAA_11[1],AAA_12[1] 3.76 
SF1 zf-CCHC[1],KH_1[1] 2.3 
SF3B1 HEAT_2[1],SF3b1[1] 3.34 
SF3B14 RRM_1[1] 0.62 
SF3B2 SAP[1],DUF382[1],PSP[1] 3.76 
SF3B3 MMS1_N[1],CPSF_A[1] 2.09 
SF3B4 RRM_1[2] 3.34 
SF3B5 SF3b10[1] 1.67 
SFPQ RRM_1[2],NOPS[1] 1.46 
SFSWAP Surp[2],DRY_EERY[1] 2.51 
SKIV2L Helicase_C[1],rRNA_proc-arch[2],DSHCT[1],DEAD[1] 7.32 
SLBP SLBP_RNA_bind[1] 1.46 
SLTM SAP[1],RRM_1[1] 2.71 
SLU7 Slu7[1] 2.09 
SMG1 PI3_PI4_kinase[1],FATC[1] 3.55 
SMG5 PIN_4[1],EST1_DNA_bind[2],EST1[1] 3.55 
SMG6 PIN_4[1],EST1[1],EST1_DNA_bind[1] 2.51 
SMG7 EST1_DNA_bind[1] 5.43 
SMG8 DUF2146[2] 4.6 
SMG9 DUF2146[1] 0.83 
SMNDC1 SMN[1] 0.62 
SND1 SNase[5],TUDOR[1] 6.48 
SNW1 SKIP_SNW[1] 0.83 
SON G-patch[1],DND1_DSRM[1] 2.71 
SPATS2 DUF1387[1] 1.88 
SPATS2L GVQW[1],DUF1387[1] 1.04 
SPEN RRM_5[1],RRM_1[3],SPOC[1] 8.78 
SREK1 RRM_1[1],RRM_6[1] 1.67 
SRPK2 Pkinase[2] 3.13 
SRRM1 PWI[1] 3.76 
SRRM2 cwf21[1] 5.85 
SRRM3 cwf21[1],SRRM_C[1] 1.67 
SRRM4 SRRM_C[1] 2.51 
SRSF1 RRM_1[2] 3.55 
SRSF10 RRM_1[1] 1.67 
SRSF11 RRM_1[1] 1.46 
SRSF12 RRM_1[1] 2.71 
SRSF2 RRM_1[1] 5.23 
SRSF3 RRM_1[1] 3.97 
SRSF4 RRM_1[2] 1.67 
SRSF5 RRM_1[2] 1.25 
SRSF6 RRM_1[2] 2.09 
SRSF7 RRM_1[1],zf-CCHC[1] 1.25 
SRSF8 RRM_1[1] 2.71 
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GENE DOMAIN [COUNT] % 
SRSF9 RRM_1[2] 0.83 
SSU72 Ssu72[1] 2.51 
STAU1 dsrm[3] 3.97 
STAU2 dsrm[4] 4.18 
STRAP WD40[5] 1.25 
STRBP dsrm[2],DZF[1] 1.04 
SUB1 PC4[1] 3.34 
SUGP1 G-patch[1],Surp[2] 2.51 
SUGP2 G-patch[1],Surp[2] 3.97 
SUPT4H1 Spt4[1] 3.34 
SUPT5H KOW[3],CTD[1],Spt5-NGN[1],Spt5_N[1] 2.09 
SUPT6H S1[1],DLD[1],SH2_2[1],YqgF[1],HTH_44[1],Tex_N[1],HHH_7[1],SPT6_acidic[1] 4.39 
SUPV3L1 Helicase_C[1],SUV3_C[1] 1.25 
SWT1 PIN_4[1] 4.6 
SYF2 SYF2[1] 1.46 
SYMPK DUF3453[1],Cohesin_HEAT[1],Symplekin_C[1] 2.09 
SYNCRIP RRM_1[3] 3.34 
TAF15 zf-RanBP[1],RRM_1[1] 1.67 
TARBP1 SpoU_methylase[1] 6.9 
TARBP2 dsrm[2] 0 
TARDBP RRM_1[2] 2.3 
TBRG4 FAST_1[1],FAST_2[1],RAP[1] 1.46 
TCERG1 FF[6],WW[3] 3.55 
TDRD3 TUDOR[1],DUF1767[1],UBA[1] 2.09 
TDRD7 TUDOR[3],OST-HTH[1] 2.09 
TEFM HHH_3[1] 0.62 
TEX13A zf-RanBP[1],TEX13[1] 3.76 
TFAM HMG_box[1],HMG_box_2[1] 1.88 
TFIP11 G-patch[1],TIP_N[1],GCFC[1] 2.71 
THOC1 efThoc1[1],Death[1] 1.25 
THOC2 Tho2[1],Thoc2[1] 5.02 
THOC3 WD40[4] 1.67 
THOC5 FimP[1] 1.67 
THOC6 WD40[1] 0.62 
THOC7 THOC7[1] 2.09 
THRAP3 THRAP3_BCLAF1[1] 3.97 
TIA1 RRM_1[3] 0.2 
TIAL1 RRM_1[3] 1.04 
TNPO1 IBN_N[1],HEAT_2[1],HEAT_EZ[1],HEAT[1] 2.3 
TNPO2 IBN_N[1],HEAT_2[1],Arm[1],HEAT_EZ[1],HEAT[1] 0.83 
TNPO3 Xpo1[1] 6.06 
TNRC6A RRM_5[1],Ago_hook[1] 2.92 
TNRC6B RRM_5[1],Ago_hook[1] 7.32 
TNRC6C RRM_5[1],M_domain[1],Ago_hook[1] 8.15 
TOP3B Topoisom_bac[1],Toprim[1] 2.92 
TPR TPR_MLP1_2[2] 4.39 
TRA2A RRM_1[1] 1.67 
TRA2B RRM_1[1] 1.67 
TRIM25 SPRY[1],PRY[1],zf-C3HC4_4[1],zf-B_box[1] 3.55 
TSFM EF_TS[1],UBA[1] 3.13 
TTF2 zf-GRF[1],Helicase_C[1],SNF2_N[1] 3.97 
TUFM GTP_EFTU_D2[1],GTP_EFTU_D3[1],GTP_EFTU[1] 1.67 
U2AF1 RRM_5[1],zf-CCCH[2] 0.41 
U2AF1L4 RRM_5[1],zf-CCCH[2] 1.25 
U2AF2 RRM_1[2],Transformer[1],RRM_6[1] 1.25 
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GENE DOMAIN [COUNT] % 
UBA1 UBACT[2],UBA_e1_C[1],UBA_e1_thiolCys[1],ThiF[2] 0.83 
UBAP2 DUF3697[1],UBA[1] 2.51 
UBAP2L DUF3697[1],UBA[1] 5.23 
UHMK1 RRM_5[1],Pkinase[1] 3.34 
UPF1 AAA_11[1],AAA_12[1],UPF1_Zn_bind[1] 3.13 
UPF2 MIF4G[3],Upf2[1] 4.6 
UPF3A Smg4_UPF3[1] 1.88 
UPF3B Smg4_UPF3[1] 2.3 
USP10 PAM2[1],UCH[1] 2.71 
WBP4 WW[2],zf-U1[1] 1.04 
WDR61 WD40[6] 1.04 
WDR83 WD40[3] 0.62 
XAB2 TPR_2[1],TPR_12[1] 1.67 
XPO1 IBN_N[1],Xpo1[1],CRM1_C[1] 1.04 
XPO4 CRM1_C[1] 2.3 
XPO6 IBN_N[1],Xpo1[1] 1.88 
XPO7 IBN_N[1],CRM1_C[1] 3.34 
XRCC6 SAP[1],Ku[1],Ku_C[1],Ku_N[1] 3.13 
YBX1 CSD[1] 1.67 
YBX2 CSD[1] 2.3 
YBX3 CSD[1] 2.09 
YTHDC1 YTH[1] 2.71 
YTHDC2 OB_NTP_bind[1],Ank_2[1],HA2[1],Helicase_C[1],YTH[1],R3H[1],DEAD[1] 3.97 
YTHDF1 YTH[1] 5.23 
YTHDF2 YTH[1] 2.3 
YTHDF3 YTH[1] 2.51 
ZC3H14 zf-CCCH_2[3] 1.88 
ZC3H3 zf-CCCH[3] 9.2 
ZCCHC13 zf-CCHC[4] 2.09 
ZCCHC8 zf-CCHC[1],PSP[1] 1.04 
ZFP36 zf-CCCH[2] 0.83 
ZFP36L1 Tis11B_N[1],zf-CCCH[2] 0.83 
ZFP36L2 Tis11B_N[1],zf-CCCH[2] 1.67 
ZNF326 AKAP95[1] 1.67 
ZNF385A GVQW[1],zf-met[2] 1.04 
ZNF598 . 2.3 
ZNF638 RRM_5[2],zf-C2H2_jaz[1],RRM_6[1] 4.6 
ZRANB2 zf-RanBP[2] 0.83 
ZRSR1 RRM_5[1],zf-CCCH[2] 2.71 
ZRSR2 RRM_5[1],zf-CCCH[2] 0.83 
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Supplementary Table 2: List of RNA binding proteins (and their RNA binding domains) included in the 
melanoma cell lines vs. melanocytes microarray. Pink: upregulated genes, green: downregulated genes (for 
regulation levels, see Table S3). N/A: not available. Data extracted from ref
218
. 
GENE FAMILY # DOMAINS DOMAINS 
ACIN1 mRNA 2 SAP[1],RRM_5[1] 
AFF2 mRNA 1 AF-4[1] 
BUB3 mRNA N/A N/A 
BUD13 mRNA 1 Bud13[1] 
BUD31 snRNA N/A N/A 
C1QBP mRNA 1 MAM33[1] 
CCNT2 ncRNA 1 Cyclin_N[1] 
CDC40 mRNA 5 WD40[5] 
CDK9 ncRNA 1 Pkinase[1] 
CELF1 mRNA 3 RRM_1[3] 
CELF2 mRNA 3 RRM_1[3] 
CLASRP mRNA 1 DRY_EERY[1] 
CLK1 mRNA 1 Pkinase[1] 
CLK2 mRNA 1 Pkinase[1] 
CLK3 mRNA 1 Pkinase[1] 
CLK4 mRNA 1 Pkinase[1] 
CPSF1 mRNA 2 MMS1_N[1],CPSF_A[1] 
CPSF2 mRNA 4 RMMBL[1],Beta-Casp[1],Lactamase_B[1],CPSF100_C[1] 
CPSF4 mRNA 4 zf-CCHC[1],zf-CCCH[3] 
CRNKL1 mRNA 4 HAT[4] 
DDX11 mRNA N/A N/A 
DDX23 mRNA 2 Helicase_C[1],DEAD[1] 
DDX39B mRNA 2 Helicase_C[1],DEAD[1] 
DDX46 mRNA 2 Helicase_C[1],DEAD[1] 
DDX5 mRNA 4 P68HR[2],Helicase_C[1],DEAD[1] 
DEK mRNA 2 SAP[1],DEK_C[1] 
DHX15 mRNA 5 OB_NTP_bind[1],DUF1777[1],HA2[1],Helicase_C[1],DEAD[1] 
DHX9 mRNA 6 OB_NTP_bind[1],HA2[1],Helicase_C[1],dsrm[2],DEAD[1] 
DNAJC8 snRNA N/A N/A 
DUSP11 mRNA 1 DSPc[1] 
DYRK1A diverse N/A N/A 
EFTUD2 tRNA 5 EFG_C[1],GTP_EFTU_D2[1],EFG_IV[1],EFG_II[1],GTP_EFTU[1] 
EIF6 mRNA 1 eIF-6[1] 
ELAVL1 mRNA 3 RRM_1[3] 
ELAVL2 mRNA 3 RRM_1[3] 
ELAVL4 mRNA 3 RRM_1[3] 
ERG diverse N/A N/A 
EWSR1 mRNA 2 zf-RanBP[1],RRM_6[1] 
FMR1 mRNA 4 Agenet[1],FXR1P_C[1],KH_1[2] 
FNBP1 mRNA N/A N/A 
FRG1 mRNA 1 FRG1[1] 
FUBP1 mRNA 6 DUF1897[2],KH_1[4] 
FUS mRNA 2 zf-RanBP[1],RRM_1[1] 
FXR1 mRNA 4 Agenet[1],FXR1P_C[1],KH_1[2] 
FXR2 mRNA 4 Agenet[1],FXR1P_C[1],KH_1[2] 
GEMIN2 snRNA 1 SIP1[1] 
HNRNPA1 mRNA 3 HnRNPA1[1],RRM_1[2] 
HNRNPA2B1 mRNA 2 RRM_1[1],RRM_6[1] 
HNRNPDL mRNA 3 RRM_1[2],CBFNT[1] 
HNRNPF mRNA 4 zf-RNPHF[1],RRM_1[1],RRM_6[2] 
HNRNPH3 mRNA 2 RRM_6[2] 
HNRNPK mRNA 4 ROKNT[1],KH_1[3] 
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GENE FAMILY # DOMAINS DOMAINS 
HNRNPM mRNA 4 HnRNP_M[1],RRM_1[3] 
HNRNPR mRNA 3 RRM_1[3] 
ISY1 mRNA 1 Isy1[1] 
KHDRBS1 mRNA 1 KH_1[1] 
KHDRBS3 mRNA 1 KH_1[1] 
KHSRP mRNA 6 DUF1897[2],KH_1[4] 
LSM1 snRNA 1 LSM[1] 
LSM4 snRNA 1 LSM[1] 
LSM7 snRNA 1 LSM[1] 
LUC7L mRNA 1 LUC7[1] 
LUC7L3 mRNA 1 LUC7[1] 
MAGOH mRNA 1 Mago_nashi[1] 
MBNL1 mRNA 1 zf-CCCH[1] 
MBNL2 mRNA 2 zf-CCCH[2] 
NAA38 snoRNA 1 LSM[1] 
NCBP1 mRNA 3 MIF4G_like_2[1],MIF4G[1],MIF4G_like[1] 
NCBP2 mRNA 1 RRM_5[1] 
NHP2L1 snRNA 1 Ribosomal_L7Ae[1] 
NOL4 mRNA N/A N/A 
NONO mRNA 3 RRM_1[2],NOPS[1] 
NOP56 snoRNA 3 NOP5NT[1],Nop[1],NOSIC[1] 
NOSIP mRNA N/A N/A 
NOVA1 mRNA 3 KH_1[3] 
NOVA2 mRNA 3 KH_1[3] 
NUDT21 mRNA 1 NUDIX_2[1] 
NUMA1 mRNA N/A N/A 
PABPC1 mRNA 5 RRM_1[4],PABP[1] 
PABPC4 mRNA 5 RRM_1[4],PABP[1] 
PCBP2 mRNA 3 KH_1[3] 
PPIE mRNA 2 RRM_1[1],Pro_isomerase[1] 
PPIL2 mRNA N/A N/A 
PPIL3 mRNA 1 Pro_isomerase[1] 
PPP1R8 diverse 1 FHA[1] 
PRPF18 mRNA 2 PRP4[1],Prp18[1] 
PRPF19 mRNA 6 Prp19[1],U-box[1],WD40[4] 
PRPF3 snRNA 3 DUF1115[1],PRP3[1],PWI[1] 
PRPF31 snRNA 3 Nop[1],Prp31_C[1],NOSIC[1] 
PRPF4B mRNA 1 Pkinase[1] 
PRPF8 snRNA 8 
PROCN[1],RRM_4[1],U6-
snRNA_bdg[1],PROCT[1],PRO8NT[1],PRP8_domainIV[1],U5_2-
snRNA_bdg[1],JAB[1] 
PSIP1 mRNA 2 LEDGF[1],PWWP[1] 
PTBP1 mRNA 4 RRM_5[3],RRM_6[1] 
PTBP2 mRNA 4 RRM_5[3],RRM_6[1] 
PTK6 diverse N/A N/A 
PUF60 mRNA 3 RRM_5[1],RRM_1[2] 
QKI mRNA 1 KH_1[1] 
RALY mRNA 1 RRM_1[1] 
RAVER1 mRNA 3 RRM_1[1],RRM_6[2] 
RBFOX2 mRNA 2 Fox-1_C[1],RRM_1[1] 
RBM10 mRNA 4 G-patch[1],zf-RanBP[1],RRM_6[2] 
RBM15 mRNA 4 RRM_5[2],RRM_1[1],SPOC[1] 
RBM17 mRNA 2 G-patch[1],RRM_5[1] 
RBM39 mRNA 4 RRM_5[1],RRM_1[2],RBM39linker[1] 
RBM5 mRNA 4 G-patch[1],zf-RanBP[1],RRM_6[2] 
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GENE FAMILY # DOMAINS DOMAINS 
RBM6 mRNA 3 G-patch[1],RRM_6[2] 
RBM7 mRNA 1 RRM_1[1] 
RBM8A mRNA 1 RRM_1[1] 
RBMS1 mRNA 2 RRM_1[2] 
RNPS1 mRNA 1 RRM_1[1] 
SAFB mRNA 2 SAP[1],RRM_6[1] 
SF1 mRNA 2 zf-CCHC[1],KH_1[1] 
SF3A1 snRNA 4 ubiquitin[1],PRP21_like_P[1],Surp[2] 
SF3A2 snRNA 2 CactinC_cactus[1],zf-met[1] 
SF3A3 snRNA 3 Telomere_Sde2_2[1],SF3a60_bindingd[1],DUF3449[1] 
SF3B1 mRNA 2 HEAT_2[1],SF3b1[1] 
SF3B14 mRNA 1 RRM_1[1] 
SF3B3 mRNA 2 MMS1_N[1],CPSF_A[1] 
SF3B4 mRNA 2 RRM_1[2] 
SLU7 mRNA 1 Slu7[1] 
SMN1 snRNA 1 SMN[1] 
SMN2 snRNA 1 SMN[1] 
SMNDC1 mRNA 1 SMN[1] 
SNRNP200 snRNA 6 Helicase_C[2],Sec63[2],DEAD[2] 
SNRNP40 mRNA 7 WD40[7] 
SNRNP70 snRNA 2 RRM_1[1],U1snRNP70_N[1] 
SNRPA snRNA 2 RRM_1[2] 
SNRPA1 snRNA 1 LRR_9[1] 
SNRPB snRNA 1 LSM[1] 
SNRPC snRNA 1 zf-U1[1] 
SNRPD1 snRNA 1 LSM[1] 
SNRPD2 snRNA 1 LSM[1] 
SNRPD3 snRNA 1 LSM[1] 
SNRPE snRNA 1 LSM[1] 
SNRPN snRNA 1 LSM[1] 
SNW1 mRNA 1 SKIP_SNW[1] 
SRC mRNA N/A N/A 
SRP54 ncRNA 3 SRP_SPB[1],SRP54[1],SRP54_N[1] 
SRP9 ncRNA 1 SRP9-21[1] 
SRPK2 mRNA 2 Pkinase[2] 
SRRM1 mRNA 1 PWI[1] 
SRRM2 mRNA 1 cwf21[1] 
SRSF1 mRNA 2 RRM_1[2] 
SRSF10 mRNA 1 RRM_1[1] 
SRSF11 mRNA 1 RRM_1[1] 
SRSF12 mRNA 1 RRM_1[1] 
SRSF14 mRNA N/A N/A 
SRSF2 mRNA 1 RRM_1[1] 
SRSF3 mRNA 1 RRM_1[1] 
SRSF4 mRNA 2 RRM_1[2] 
SRSF5 mRNA 2 RRM_1[2] 
SRSF6 mRNA 2 RRM_1[2] 
SRSF7 mRNA 2 RRM_1[1],zf-CCHC[1] 
SRSF8 mRNA 1 RRM_1[1] 
SRSF9 mRNA 2 RRM_1[2] 
SSRP1 mRNA N/A N/A 
STAU1 mRNA 3 dsrm[3] 
SUGP1 mRNA 3 G-patch[1],Surp[2] 
SUPT16H mRNA N/A N/A 
SYNJ1 mRNA N/A N/A 
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GENE FAMILY # DOMAINS DOMAINS 
TAF15 mRNA 2 zf-RanBP[1],RRM_1[1] 
TCERG1 mRNA 9 FF[6],WW[3] 
THOC1 mRNA 2 efThoc1[1],Death[1] 
THOC3 mRNA 4 WD40[4] 
TIA1 mRNA 3 RRM_1[3] 
TIAL1 mRNA 3 RRM_1[3] 
TOPORS diverse N/A N/A 
TRA2A mRNA 1 RRM_1[1] 
TRA2B mRNA 1 RRM_1[1] 
U2AF1 mRNA 3 RRM_5[1],zf-CCCH[2] 
U2AF2 mRNA 4 RRM_1[2],Transformer[1],RRM_6[1] 
U2SURP snRNA 4 cwf21[1],RRM_1[1],Surp[1],CTK3[1] 
UPF1 mRNA 3 AAA_11[1],AAA_12[1],UPF1_Zn_bind[1] 
UPF2 mRNA 4 MIF4G[3],Upf2[1] 
USP39 snRNA 2 UCH[1],zf-UBP[1] 
WT1 mRNA N/A N/A 
YTHDC1 mRNA 1 YTH[1] 
ZBP1 mRNA N/A N/A 
ZNF207 mRNA N/A N/A 
ZRSR2 mRNA 3 RRM_5[1],zf-CCCH[2] 
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Supplementary Table 3: List of genes regulated in melanoma cell lines vs. melanocyte microarray (at least 
in one cell line) with fold change values. FC: Fold change. 
UPREGULATED GENES 
 
DOWNREGULATED GENES 
        GENE FC 
 
Gene FC 
 
Gene FC 
TGFBI 4.100 
 
RBM17 1.489 
 
CASP1 0.164 
SNRPE 3.417 
 
EFTUD2 1.482 
 
CDH1 0.421 
CDKN2A 2.477 
 
E2F4 1.471 
 
CTNNB1 0.458 
EIF6 2.278 
 
U2AF1 1.470 
 
TFDP2 0.465 
NME1 2.188 
 
TRA2B 1.469 
 
CUGBP2 0.472 
SNRPD1 2.167 
 
SRSF2 1.468 
 
FOS 0.476 
DDX39B 2.152 
 
HNRNPDL 1.462 
 
FN1 0.484 
SF3B14 2.057 
 
STAU1 1.457 
 
FAP 0.491 
SNRPA1 2.017 
 
LSM7 1.435 
 
MYH10 0.532 
MAGOH 1.991 
 
PSIP1 1.411 
 
MYC 0.573 
NOP56 1.903 
 
LSM1 1.411 
 
POLB 0.586 
GADD45A 1.820 
 
MAPK6 1.406 
 
ATM 0.589 
CCNA2 1.818 
 
MAP3K7 1.406 
 
CASP4 0.599 
C1QBP 1.806 
 
NUDT21 1.406 
 
FGFR1 0.630 
SNRPD2 1.795 
 
PLK1 1.388 
 
CTSL2 0.674 
SSRP1 1.788 
 
PTBP1 1.379 
 
MAPK3 0.678 
NHP2L1 1.781 
 
KHDRBS1 1.371 
 
MYD88 0.685 
SRSF7 1.757 
 
MCL1 1.371 
 
KAI1 0.692 
HNRNPA1 1.707 
 
DDX46 1.363 
 
MAP3K6 0.695 
SF3A3 1.696 
 
HNRNPK 1.361 
 
CD164 0.697 
BUB3 1.696 
 
PRPF4B 1.356 
 
ETS1 0.705 
SNRPB 1.693 
 
BUB1B 1.355 
 
FNBP1 0.711 
DEK 1.684 
 
FAF1 1.350 
 
LMNA 0.714 
PLK2 1.682 
 
SRRM1 1.338 
 
PDCD8 0.726 
LMNB1 1.671 
 
CCNC 1.337 
 
C21orf33 0.731 
SRSF3 1.661 
 
HIF1A 1.331 
 
CCND3 0.735 
MBNL1 1.648 
 
DHX15 1.330 
 
PTEN 0.736 
SMN2 1.630 
 
SNRNP200 1.328 
 
PTGS2 0.741 
CDC2 1.605 
 
CELF1 1.326 
 
ENAH 0.743 
TFPI2 1.594 
 
VEGFA 1.322 
 
DYRK1A 0.744 
MSH6 1.585 
 
ABL1 1.317 
 
APBB1 0.750 
SUPT16H 1.573 
 
PABPC4 1.311 
 
ZNF198 0.750 
MYBL2 1.564 
 
FUBP1 1.309 
 
SCUBE2 0.755 
SRSF9 1.543 
 
RBM7 1.286 
 
NME5 0.759 
AATF 1.543 
 
CDK9 1.276 
 
SPTAN1 0.765 
MSH2 1.495 
 
SKP2 1.275 
 
PTK2 0.774 
PDCD2 1.491 
       
X. Appendices/Apéndices 
 
 
151 
 
Supplementary Table 4: List of genes regulated in each Gene Ontology Terms found to be significantly 
enriched in melanoma melanocyte microarray. 
 
NODE GENE ONTOLOGY TERM 
GENE 
ONTOLOGY 
# 
GENES P-VALUE REGULATED GENES 
1 
Spliceosomal Complex 
Assembly 
GO:0000245 11 3.89E-14 
CUGBP1, CUGBP2, DDX39B, 
MBNL1, PSIP1, SF3A3, SNRNP200, 
SNRPD1, SNRPD2, SNRPE, SRSF9 
2 
Ribonucleoprotein Complex 
Biogenesis 
GO:0022613 19 2.37E-12 
AATF, C1QBP, CDKN2A, CUGBP1, 
CUGBP2, DDX39B, EIF6, MBNL1, 
NHP2L1, NOP56, PSIP1, PTEN, 
SF3A3, SNRNP200, SNRPB, 
SNRPD1, SNRPD2, SNRPE, SRSF9 
3 mRNA Splice Site Selection GO:0006376 6 2.69E-08 
CUGBP1, CUGBP2, MBNL1, PSIP1, 
SF3A3, SRSF9 
4 
Ribonucleoprotein Complex 
Assembly 
GO:0022618 14 3.14E-11 
C1QBP, CUGBP1, CUGBP2, 
DDX39B, EIF6, MBNL1, PSIP1, 
SF3A3, SNRNP200, SNRPB, 
SNRPD1, SNRPD2, SNRPE, SRSF9 
5 
mRNA Splicing, via 
Spliceosome 
GO:0000398 33 2.76E-34 
C1QBP, CUGBP1, CUGBP2, 
DDX39B, DDX46, DYRK1A, 
EFTUD2, HNRNPA1, HNRNPK, 
LSM7, MAGOH, MBNL1, NHP2L1, 
NUDT21, PRPF4B, PSIP1, PTBP1, 
RBM17, SF3A3, SF3B6, 
SNRNP200, SNRPA1, SNRPB, 
SNRPD1, SNRPD2, SNRPE, 
SRRM1, SRSF2, SRSF3, SRSF7, 
SRSF9, TRA2B, U2AF1 
6 RNA Splicing GO:0008380 35 1.31E-31 
C1QBP, CUGBP1, CUGBP2, 
DDX39B, DDX46, DHX15, DYRK1A, 
EFTUD2, HNRNPA1, HNRNPK, 
LSM1, LSM7, MAGOH, MBNL1, 
NHP2L1, NUDT21, PRPF4B, PSIP1, 
PTBP1, RBM17, SF3A3, SF3B6, 
SNRNP200, SNRPA1, SNRPB, 
SNRPD1, SNRPD2, SNRPE, 
SRRM1, SRSF2, SRSF3, SRSF7, 
SRSF9, TRA2B, U2AF1 
7 RNA Processing GO:0006396 42 2.23E-28 
C1QBP, CDK9, CDKN2A, CUGBP1, 
CUGBP2, DDX39B, DDX46, 
DHX15, DYRK1A, EFTUD2, 
HNRNPA1, HNRNPDL, HNRNPK, 
KHDRBS1, LSM1, LSM7, MAGOH, 
MBNL1, NHP2L1, NOP56, 
NUDT21, PABPC4, PRPF4B, PSIP1, 
PTBP1, RBM17, SF3A3, SF3B6, 
SMN2, SNRNP200, SNRPA1, 
SNRPB, SNRPD1, SNRPD2, SNRPE, 
SRRM1, SRSF2, SRSF3, SRSF7, 
SRSF9, TRA2B, U2AF1 
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NODE GENE ONTOLOGY TERM 
GENE 
ONTOLOGY 
# 
GENES P-VALUE REGULATED GENES 
8 mRNA Metabolic Process GO:0016071 39 8.12E-29 
ATM, C1QBP, CDK9, CUGBP1, 
CUGBP2, DDX39B, DDX46, 
DHX15, DYRK1A, EFTUD2, 
HNRNPA1, HNRNPK, KHDRBS1, 
LSM1, LSM7, MAGOH, MBNL1, 
NHP2L1, NUDT21, PRPF4B, PSIP1, 
PTBP1, RBM17, SF3A3, SF3B6, 
SMN2, SNRNP200, SNRPA1, 
SNRPB, SNRPD1, SNRPD2, SNRPE, 
SRRM1, SRSF2, SRSF3, SRSF7, 
SRSF9, TRA2B, U2AF1 
9 
Spliceosomal snRNP 
Assembly 
GO:0000387 4 1.34E-04 SNRPB, SNRPD1, SNRPD2, SNRPE 
10 
Histone mRNA Metabolic 
Process 
GO:0008334 4 2.61E-05 ATM, LSM1, SNRPB, SNRPE 
11 
Alternative mRNA Splicing, 
via Spliceosome 
GO:0000380 8 7.38E-11 
DYRK1A, HNRNPA1, MAGOH, 
MBNL1, PTBP1, RBM17, SRSF2, 
TRA2B 
12 
Negative Regulation of 
mRNA Processing 
GO:0050686 6 3.32E-08 
C1QBP, CDK9, DYRK1A, PTBP1, 
SRSF7, SRSF9 
13 Regulation of RNA Splicing GO:0043484 10 3.79E-10 
C1QBP, CUGBP1, DYRK1A, 
MAGOH, MBNL1, PTBP1, SRSF2, 
SRSF7, SRSF9, TRA2B 
14 
Regulation of Alternative 
mRNA Splicing, via 
Spliceosome 
GO:0000381 6 2.17E-08 
DYRK1A, MAGOH, MBNL1, 
PTBP1, SRSF2, TRA2B 
15 
Regulation of mRNA 
Processing 
GO:0050684 10 3.79E-10 
C1QBP, CDK9, DYRK1A, MAGOH, 
MBNL1, PTBP1, SRSF2, SRSF7, 
SRSF9, TRA2B 
16 mRNA 3'-End Processing GO:0031124 11 4.20E-12 
CDK9, MAGOH, NUDT21, SNRPB, 
SNRPE, SRRM1, SRSF2, SRSF3, 
SRSF7, SRSF9, U2AF1 
17 RNA Export from Nucleus GO:0006405 10 2.75E-10 
DDX39B, HNRNPA1, KHDRBS1, 
MAGOH, SRRM1, SRSF2, SRSF3, 
SRSF7, SRSF9, U2AF1 
18 Nucleocytoplasmic Transport GO:0006913 18 2.02E-10 
C21orf33, CDH1, CDKN2A, 
DDX39B, EIF6, FAF1, HNRNPA1, 
KHDRBS1, LMNA, MAGOH, 
MAPK3, PTGS2, SRRM1, SRSF2, 
SRSF3, SRSF7, SRSF9, U2AF1 
19 
Termination of RNA 
Polymerase II Transcription 
GO:0006369 10 3.91E-13 
MAGOH, NUDT21, SNRPB, 
SNRPE, SRRM1, SRSF2, SRSF3, 
SRSF7, SRSF9, U2AF1 
20 Nuclear Export GO:0051168 12 2.13E-10 
CDKN2A, DDX39B, EIF6, 
HNRNPA1, KHDRBS1, MAGOH, 
SRRM1, SRSF2, SRSF3, SRSF7, 
SRSF9, U2AF1 
21 RNA Localization GO:0006403 11 1.72E-08 
DDX39B, HNRNPA1, KHDRBS1, 
MAGOH, SRRM1, SRSF2, SRSF3, 
SRSF7, SRSF9, STAU1, U2AF1 
22 
Ribonucleoprotein Complex 
Export from Nucleus 
GO:0071426 9 5.22E-09 
DDX39B, EIF6, MAGOH, SRRM1, 
SRSF2, SRSF3, SRSF7, SRSF9, 
U2AF1 
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NODE GENE ONTOLOGY TERM 
GENE 
ONTOLOGY 
# 
GENES P-VALUE REGULATED GENES 
23 
Negative Regulation of Cell 
Cycle 
GO:0045786 21 5.77E-12 
ABL1, APBB1, ATM, BUB1B, 
BUB3, CCNA2, CDK1, CDK9, 
CDKN2A, CTNNB1, DDX39B, ETS1, 
FAP, GADD45A, KHDRBS1, MSH2, 
MYC, PLK1, PLK2, PTEN, PTGS2 
24 
Anaphase-Promoting 
Complex-Dependent 
Proteasomal Ubiquitin-
Dependent Protein Catabolic 
Process 
GO:0031145 7 1.01E-05 
ATM, BUB1B, BUB3, CDK1, PLK1, 
PTEN, SKP2 
25 
Negative Regulation of 
Mitotic Cell Cycle Phase 
Transition 
GO:1901991 7 1.13E-04 
ATM, BUB1B, BUB3, CCNA2, 
CDK1, PLK1, PTEN 
26 
Regulation of Cyclin-
Dependent Protein 
Serine/Threonine Kinase 
Activity 
GO:0000079 7 2.81E-06 
CCNA2, CCNC, CCND3, CDKN2A, 
GADD45A, PLK1, PTEN 
27 
G2/M Transition of Mitotic 
Cell Cycle 
GO:0000086 9 4.47E-06 
ATM, CCNA2, CDK1, CDKN2A, 
GADD45A, KHDRBS1, MYBL2, 
PLK1, SKP2 
28 Mitochondrial Depolarization GO:0051882 3 3.34E-04 ABL1, CASP1, CDKN2A 
29 
Regulation of DNA Damage 
Response, Signal 
Transduction By P53 Class 
Mediator 
GO:0043516 3 1.34E-03 ATM, CDKN2A, DYRK1A 
30 
Regulation of Response to 
DNA Damage Stimulus 
GO:2001020 9 4.82E-07 
ABL1, ATM, CDK9, CDKN2A, 
DDX39B, DEK, DYRK1A, MCL1, 
MYC 
31 
Regulation of G2/M 
Transition of Mitotic Cell 
Cycle 
GO:0010389 4 4.10E-04 ATM, CCNA2, CDK1, CDKN2A 
32 
Regulation of Ubiquitin-
Protein Transferase Activity 
GO:0051438 8 2.03E-06 
ABL1, ATM, BUB1B, BUB3, CDK1, 
CDKN2A, PLK1, PTEN 
33 
Negative Regulation of 
Mitotic Cell Cycle 
GO:0045930 11 3.75E-07 
ABL1, ATM, BUB1B, BUB3, 
CCNA2, CDK1, CTNNB1, MSH2, 
PLK1, PLK2, PTEN 
34 Centrosome Organization GO:0051297 5 4.24E-04 
CDK1, CTNNB1, GADD45A, PLK1, 
PLK2 
35 
Mitotic Nuclear Envelope 
Disassembly 
GO:0007077 3 2.43E-03 CDK1, LMNA, PLK1 
36 
Regulation of Ubiquitin-
Protein Ligase Activity 
Involved in Mitotic Cell Cycle 
GO:0051439 6 4.25E-05 
ATM, BUB1B, BUB3, CDK1, PLK1, 
PTEN 
37 
Negative Regulation of 
Protein Modification By Small 
Protein Conjugation or 
Removal 
GO:1903321 7 4.46E-05 
ABL1, ATM, BUB1B, BUB3, 
CDKN2A, CTNNB1, PLK1 
38 
Regulation of Protein 
Modification By Small Protein 
Conjugation or Removal 
GO:1903320 12 2.07E-07 
ABL1, ATM, BUB1B, BUB3, CDK1, 
CDK9, CDKN2A, CTNNB1, PLK1, 
PTEN, PTK2, SKP2 
39 
Negative Regulation of 
Ubiquitin-Protein Transferase 
Activity 
GO:0051444 6 3.80E-05 
ABL1, ATM, BUB1B, BUB3, 
CDKN2A, PLK1 
40 
Regulation of Fibroblast 
Proliferation 
GO:0048145 4 2.06E-03 CCNA2, CTNNB1, FN1, MYC 
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NODE GENE ONTOLOGY TERM 
GENE 
ONTOLOGY 
# 
GENES P-VALUE REGULATED GENES 
41 Ureteric Bud Development GO:0001657 5 5.77E-04 
C21orf33, CTNNB1, FGFR1, MYC, 
VEGFA 
42 
Positive Regulation of Stem 
Cell Proliferation 
GO:2000648 6 6.22E-06 
CTNNB1, FGFR1, HIF1A, MYC, 
PDCD2, VEGFA 
43 Neuroblast Proliferation GO:0007405 4 4.69E-04 CTNNB1, FGFR1, HIF1A, VEGFA 
44 Organ Formation GO:0048645 4 8.59E-04 
C21orf33, CTNNB1, FGFR1, 
MAPK3 
45 
Positive Regulation of 
Mesenchymal Cell 
Proliferation 
GO:0002053 4 6.47E-05 CTNNB1, FGFR1, MYC, VEGFA 
46 Telomere Maintenance GO:0000723 4 2.06E-03 ATM, CTNNB1, MYC, PTEN 
47 Adherens Junction Assembly GO:0034333 4 1.73E-03 CTNNB1, PTEN, PTK2, VEGFA 
48 
Cell-Substrate Junction 
Assembly 
GO:0007044 4 2.43E-03 FN1, PTEN, PTK2, VEGFA 
49 
Regulation of Protein 
Ubiquitination Involved in 
Ubiquitin-Dependent Protein 
Catabolic Process 
GO:2000058 5 3.52E-04 CDK1, CDKN2A, PLK1, PTEN, PTK2 
50 
Positive Regulation of 
Chromosome Organization 
GO:2001252 6 3.20E-05 
CDK9, CTNNB1, MAPK3, PLK1, 
PTEN, VEGFA 
51 
Regulation of Chromosome 
Segregation 
GO:0051983 6 1.72E-05 
ATM, BUB1B, BUB3, CTNNB1, 
PLK1, PTEN 
52 
Negative Regulation of 
Cyclin-Dependent Protein 
Serine/Threonine Kinase 
Activity 
GO:0045736 3 1.03E-03 CDKN2A, PLK1, PTEN 
53 Cell Aging GO:0007569 5 4.44E-04 
ABL1, ATM, CDKN2A, LMNA, 
PTEN 
54 
Regulation of Cell-Matrix 
Adhesion 
GO:0001952 4 3.07E-03 CDKN2A, PTEN, PTK2, VEGFA 
55 
Regulation of Chromosome 
Organization 
GO:0033044 10 2.29E-06 
ATM, BUB1B, BUB3, CDK9, 
CTNNB1, MAPK3, MYC, PLK1, 
PTEN, VEGFA 
56 
Positive Regulation of 
Histone Modification 
GO:0031058 4 1.01E-03 CDK9, CTNNB1, MAPK3, VEGFA 
57 
Positive Regulation of 
Response to DNA Damage 
Stimulus 
GO:2001022 3 8.13E-03 ATM, CDKN2A, MYC 
58 
Cellular Component 
Disassembly Involved in 
Execution Phase of Apoptosis 
GO:0006921 8 1.89E-08 
AIFM1, CDH1, CDKN2A, CTNNB1, 
LMNA, LMNB1, PTK2, SPTAN1 
59 Execution Phase of Apoptosis GO:0097194 11 9.31E-11 
AIFM1, CASP1, CASP4, CDH1, 
CDKN2A, CTNNB1, FAP, LMNA, 
LMNB1, PTK2, SPTAN1 
60 
Regulation of Mitotic 
Metaphase/Anaphase 
Transition 
GO:0030071 5 2.79E-05 ATM, BUB1B, BUB3, PLK1, PTEN 
61 
Multicellular Organismal 
Aging 
GO:0010259 4 5.10E-05 ATM, CTSV, MSH2, MSH6 
62 
Somatic Diversification of 
Immune Receptors via 
Germline Recombination 
within a Single Locus 
GO:0002562 4 6.05E-04 ATM, MSH2, MSH6, POLB 
63 
Somatic Hypermutation of 
Immunoglobulin Genes 
GO:0016446 3 1.02E-04 MSH2, MSH6, POLB 
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ONTOLOGY 
# 
GENES P-VALUE REGULATED GENES 
64 
Mitotic Spindle Assembly 
Checkpoint 
GO:0007094 4 1.75E-04 ATM, BUB1B, BUB3, PLK1 
65 Mitotic Cell Cycle Checkpoint GO:0007093 8 1.91E-05 
ATM, BUB1B, BUB3, CCNA2, 
CDK1, MSH2, PLK1, PLK2 
66 
Negative Regulation of 
Proteolysis Involved in 
Cellular Protein Catabolic 
Process 
GO:1903051 5 1.70E-04 
ATM, BUB1B, BUB3, CDKN2A, 
PLK1 
67 
Negative Regulation of Cell 
Division 
GO:0051782 6 2.09E-05 
ATM, BUB1B, BUB3, MSH2, MYC, 
PLK1 
68 Meiosis I GO:0007127 4 2.63E-03 ATM, MSH2, MSH6, PLK1 
69 G2 DNA Damage Checkpoint GO:0031572 4 9.96E-05 ATM, CCNA2, CDK1, PLK1 
70 
Regulation of Execution 
Phase of Apoptosis 
GO:1900117 3 6.91E-04 AIFM1, CDKN2A, FAP 
71 
Cardiac Muscle Cell 
Development 
GO:0055013 3 5.41E-03 LMNA, MYH10, VEGFA 
72 
Regulation of Oxidative 
Stress-induced Intrinsic 
Apoptotic Signaling Pathway 
GO:1902175 3 1.03E-03 HIF1A, MCL1, NME5 
73 
TRIF-Dependent Toll-Like 
Receptor Signaling Pathway 
GO:0035666 4 1.65E-03 CDK1, FOS, MAP3K7, MAPK3 
74 
Positive Regulation of Viral 
Life Cycle 
GO:1903902 4 2.06E-03 CDK9, SSRP1, STAU1, SUPT16H 
75 
Regulation of Smooth Muscle 
Cell Proliferation 
GO:0048660 4 2.73E-03 CTNNB1, MYD88, PTGS2, SKP2 
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Supplementary Table 5: Differential regulation levels of genes identified in CUGBP1 regulated networks 
upon DEK downregulation by short hairpin RNA in SK-Mel-103 cells at day 4.5 (unpublished data). FC: Fold 
change. FDR<0.05. 
 
GENE FC LOG2FC 
UBE2C 0.13 -2.93 
DHFR 0.16 -2.60 
CDC20 0.20 -2.31 
PRKDC 0.21 -2.28 
CCNB1 0.29 -1.80 
RPA3 0.35 -1.51 
MCM4 0.37 -1.45 
MCM6 0.38 -1.38 
FANCA 0.40 -1.34 
FANCD2 0.45 -1.16 
RFC4 0.47 -1.08 
RFC5 0.52 -0.93 
RFC5 0.52 -0.93 
POLA1 0.57 -0.80 
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Supplementary Table 6: List of genes identified by RIP-Seq in melanoma cell lines SKMEL-103 and UACC. 
Sorted by identified region of binding. Gray highlights mark novel targets and blue genes indicate genes with 
CUG repeats in the indicated region. 
3' UNTRANSLATED REGION 
AAK1 CISD2 GNG12 MSN RAP2A SRSF7 
AASDHPPT CIT GNG2 MTAP RAP2B SRSF9 
ABCC9 CKAP4 GNPDA1 MTCH2 RAPH1 SS18 
ABHD2 CKS1B GNPNAT1 MTDH RASA2 SSB 
ABL2 CKS2 GOLIM4 MTHFD2 RASSF3 SSFA2 
AC006465.3 CLASP2 GOLT1B MTMR4 RBBP4 SSH2 
AC015987.2 CLIC1 GPCPD1 MTMR6 RBBP7 SSR1 
AC073346.2 CLIC4 GPD2 MTMR9 RBFOX2 SSR2 
AC104841.2 CLINT1 GPI MTPN RBM15 SSR3 
AC119673.1 CLIP4 GPR56 MTRNR2L1 RBM22 ST13 
AC120194.1 CLN6 GPS2 MTRNR2L10 RBM25 STAG2 
ACAT2 CLNS1A GPX1 MYL12A RBM27 STARD4 
ACBD3 CLPTM1L GRSF1 MYL12B RBM3 STARD7 
ACBD7 CLTA GRWD1 MYL6 RBM39 STAT3 
ACLY CLTC GSK3B MYLK RBM5 STAT5B 
ACOT13 CMAS GSTP1 MYO1B RBM8A STAU1 
ACSL3 CMIP GTF2A1 MZT2B RBMS1 STK17A 
ACSL4 CMPK1 GTF2E2 NAA20 RBMX STK4 
ACTB CMTM4 GTPBP3 NAA50 RBMXL1 STMN1 
ACTG1 CMTM6 GULP1 NAB1 RBPJ STRAP 
ACTR2 CMTM7 H2AFV NACA RBX1 STX3 
ACTR3 CNBP H2AFY NACA2 RC3H1 STX6 
ADAM10 CNIH H2AFZ NACC1 RC3H2 STYX 
ADAM9 CNN3 H3F3A NACC2 RCAN1 SUB1 
ADAR CNOT6 H3F3B NAMPT RCC2 SUCO 
ADH5 CNOT6L HAUS2 NAP1L1 RCCD1 SUDS3 
ADPGK CNPY2 HCFC1 NAPB RCN1 SUMO1 
ADSS COLGALT1 HDAC1 NAPG RCN2 SUMO2 
AFF1 COMMD10 HDAC2 NBN RCOR1 SUMO3 
AFF4 COPA HDDC2 NBPF16 RDX SUPT16H 
AGBL5 COPB1 HDGF NCAPD2 REEP3 SUSD5 
AGFG1 COPB2 HDLBP NCKAP1 REST SYAP1 
AGPAT5 COPRS HEATR3 NCL REXO1L1 SYNC 
AGPAT9 COPS7A HELLS NCOA3 REXO2 SYNCRIP 
AHCY COPS8 HERPUD1 NDNL2 RFK SYPL1 
AHNAK COPZ1 HIATL1 NDRG3 RFWD3 TACC1 
AK2 CORO1C HIF1A NDUFA1 RFX7 TAF1 
AK4 COTL1 HIF1AN NDUFA13 RHEB TAF13 
AKAP11 COX4I1 HIGD1A NDUFA4 RHOA TAF1L 
AKAP12 COX5B HIGD2A NDUFB2 RIF1 TAF5 
AKAP2 COX6A1 HINT1 NDUFB3 RLIM TAF7 
AKIRIN1 COX6B1 HINT3 NDUFB4 RMND5A TAGLN2 
AKR1B1 COX7A2 HIPK1 NDUFB9 RNASEH1 TANC2 
AKT2 COX7A2L HIPK2 NDUFC2 RND3 TAOK1 
ALDH9A1 COX7B HIST1H1B NDUFS2 RNF11 TARDBP 
ALDOA COX7C HIST1H1C NDUFS5 RNF114 TAX1BP1 
ALKBH5 COX8A HIST1H2AB NECAP1 RNF139 TBC1D13 
ALS2CR8 CPM HIST1H2AM NEDD8 RNF144A TBCA 
AMD1 CPNE3 HIST1H2BC NEK4 RNF219 TBL1XR1 
AMOTL1 CPNE8 HIST1H2BL NEK7 RNF38 TBPL1 
ANAPC13 CPOX HIST1H3B NF2 RNPS1 TCEA1 
ANKFY1 CPSF6 HIST1H3F NFAT5 ROMO1 TCEAL8 
ANKRD52 CREB3L2 HIST1H3J NFIB RP11-762I7.5 TCF7L2 
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ANLN CREB5 HIST1H4B NFYC RP5-1165K10.1 TCP1 
ANP32A CREBL2 HIST1H4D NGFRAP1 RPAIN TEAD1 
ANXA1 CRIM1 HIST1H4H NGRN RPL12 TERF2IP 
ANXA2 CRIP2 HIST1H4K NHP2L1 RPL13A TET3 
ANXA5 CRK HIST2H2AA3 NMD3 RPL14 TFCP2 
AP000350.10 CRKL HIST2H2AA4 NME1 RPL15 TFDP1 
AP000350.4 CRTAP HIST2H2AB NME1-NME2 RPL17 TFRC 
AP1G1 CSDE1 HIST2H3C NME2 RPL17-C18orf32 TGFBR1 
AP1M1 CSE1L HIST2H4B NME7 RPL18 TGFBR2 
AP1S1 CSNK1A1 HIST4H4 NOC2L RPL18A TGOLN2 
AP1S2 CSNK1E HK2 NOL9 RPL22 THBS1 
AP2M1 CSNK2A2 HLA-B NOLC1 RPL23 THOC3 
AP2S1 CTBP1 HLTF NONO RPL23A THRAP3 
AP3B1 CTBP2 HMG20A NOP56 RPL24 THUMPD1 
AP3M1 CTDSP2 HMGA1 NOP58 RPL26 TIMM17A 
AP3S1 CTDSPL2 HMGA2 NOTCH2 RPL27A TIMP2 
APH1A CTGF HMGB1 NOTCH2NL RPL29 TM4SF1 
API5 CTNNA1 HMGB2 NPAS2 RPL3 TM9SF3 
APLP2 CTNNB1 HMGCR NPC2 RPL30 TMA7 
APMAP CTSB HMGN1 NPM1 RPL31 TMBIM6 
APP CTSC HMGN2 NPTN RPL32 TMCO1 
APTX CUL4B HMGN3 NQO1 RPL35 TMED10 
ARCN1 CXorf57 HMGN4 NR3C1 RPL35A TMED2 
ARF1 CYCS HMOX1 NRAS RPL36 TMED7 
ARF3 DAD1 HN1 NREP RPL36AL TMED8 
ARF4 DAP3 HN1L NSF RPL37 TMEM107 
ARF6 DAZAP2 HNRNPA0 NT5DC3 RPL37A TMEM109 
ARFGEF2 DBI HNRNPA1 NUCKS1 RPL39 TMEM123 
ARHGAP12 DCAF12 HNRNPA1L2 NUDC RPL39L TMEM164 
ARID5B DCAF16 HNRNPA2B1 NUDCD3 RPL4 TMEM167A 
ARIH1 DCAF17 HNRNPA3 NUDT19 RPL41 TMEM19 
ARL1 DCAF7 HNRNPAB NUDT21 RPL7 TMEM2 
ARL2BP DCBLD2 HNRNPC NUDT3 RPL9 TMEM212 
ARL5A DCK HNRNPD NUFIP2 RPLP0 TMEM237 
ARL6IP1 DCP2 HNRNPF NUP153 RPN1 TMEM248 
ARL8B DCTN4 HNRNPH1 NUP62 RPN2 TMEM30A 
ARMCX6 DCUN1D4 HNRNPH2 NUP93 RPP14 TMEM33 
ARPC2 DDB1 HNRNPK NUPL1 RPRD1B TMEM47 
ARPC4 DDX1 HNRNPL NXPE3 RPS10 TMEM48 
ARPC5 DDX17 HNRNPM OAZ1 RPS11 TMEM59 
ARPP19 DDX21 HNRNPR OAZ2 RPS13 TMEM64 
ARRDC3 DDX24 HNRNPU ODC1 RPS14 TMEM66 
ASAP1 DDX3X HNRPDL ODF2L RPS15 TMEM9B 
ASH1L DDX3Y HOOK3 OPA1 RPS15A TMPO 
ASPH DDX5 HOXB7 OPHN1 RPS17 TMSB10 
ASTN2 DDX56 HP1BP3 OSBP RPS17L TMX1 
ATAD1 DEK HPCAL1 OSBPL10 RPS2 TMX2 
ATF1 DENND6A HPRT1 OSBPL3 RPS20 TMX3 
ATF2 DENR HSBP1 OSBPL8 RPS21 TNC 
ATF4 DEPDC1 HSD17B12 OST4 RPS23 TNFRSF21 
ATF7IP DESI2 HSP90AA1 OSTC RPS24 TNKS 
ATG7 DGCR2 HSP90AB1 OTUD4 RPS27 TNKS2 
ATL3 DGUOK HSP90B1 OTUD6B RPS27L TNPO1 
ATM DHX15 HSPA13 P2RY11 RPS28 TNPO2 
ATMIN DHX36 HSPA1A P4HB RPS29 TNRC6A 
ATOX1 DHX40 HSPA1B PABPC1 RPS3 TNRC6B 
ATP13A3 DHX9 HSPA8 PABPN1 RPS3A TOM1L2 
ATP1B1 DIABLO HSPA9 PACS2 RPS4X TOMM20 
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ATP1B3 DICER1 HSPD1 PAFAH1B1 RPS5 TOMM22 
ATP2A2 DIP2B HSPE1 PAFAH1B2 RPS6 TOMM34 
ATP5A1 DKC1 HSPH1 PAGR1 RPS6KA3 TOMM5 
ATP5B DLG1 IDS PAK2 RPS8 TOMM6 
ATP5C1 DLX1 IER2 PALM2-AKAP2 RPS9 TOMM7 
ATP5E DMXL1 IER3IP1 PANK3 RPSA TOMM70A 
ATP5EP2 DNAJA1 IER5 PAPD5 RQCD1 TOP1 
ATP5F1 DNAJA2 IFI16 PAPOLA RRAGA TOP2A 
ATP5G2 DNAJB1 IL1RAP PAPOLG RRM2 TOP2B 
ATP5G3 DNAJB11 IL6ST PARK7 RRP15 TOR1AIP2 
ATP5I DNAJC5 ILF2 PARN RSF1 TP53RK 
ATP6AP1 DNER ILF3 PARP1 RSL24D1 TPGS2 
ATP6AP2 DPY19L1 IMMT PCBP1 RTN4 TPI1 
ATP6V0B DPY19L3 IMP3 PCBP2 RUNX1 TPM1 
ATP6V0D1 DPY19L4 IMP4 PCGF3 RWDD1 TPM3 
ATP6V0E1 DPYSL2 IMPAD1 PCNA RYBP TPM4 
ATP6V1A DR1 INCENP PCNP RYK TPT1 
ATP6V1B2 DSTN INHBA PCYT1A S100A10 TRA2A 
ATP6V1C1 DTX3L INIP PDAP1 S100A13 TRA2B 
ATP6V1C2 DTYMK INO80D PDCD10 S100A6 TRAM1 
ATP6V1E1 DUSP11 INPP5A PDCD5 SAE1 TRAPPC10 
ATP6V1F DUSP5 IPO7 PDCD6 SAMD1 TRIB1 
ATP6V1G1 DUSP6 IQGAP1 PDE12 SAMD11 TRIM28 
ATP8B2 DUSP7 IRAK1 PDGFA SAMD4A TRIM4 
ATP9A DUT IRF2BP2 PDIA6 SAP18 TRIM58 
ATPIF1 DYNC1H1 IRF2BPL PDLIM5 SARNP TRIP12 
ATRX DYNC1I2 ISCA1 PDS5A SART3 TRIP6 
ATXN7 DYNC1LI2 IST1 PDZD8 SATB2 TRMT112 
ATXN7L3B DYNLL1 ITGA6 PEA15 SBNO1 TROVE2 
AUP1 DYNLL2 ITGAV PEBP1 SCD TRPS1 
AURKB DYRK2 ITGB1 PEG10 SCD5 TSC22D1 
AZIN1 E2F3 ITGB8 PERP SCOC TSN 
B2M EDARADD ITM2B PEX11B SDC4 TSPAN3 
B3GNT4 EEF1A1 JKAMP PEX26 SDCBP TSPAN31 
B4GALT1 EEF1E1 JUND PFDN2 SDE2 TSR1 
B4GALT5 EEF1G KBTBD2 PFDN5 SDHB TTC3 
B4GALT6 EEF2 KCMF1 PFKFB3 SEC23B TUBA1A 
BACH1 EEF2K KCNJ5 PFN1 SEC24A TUBA1B 
BAG4 EFCAB14 KCTD10 PFN2 SEC61A1 TUBA1C 
BAG5 EFHD2 KCTD20 PGAM1 SEC61B TUBB 
BAX EFNA5 KDELR2 PGAM4 SEC61G TUBB3 
BAZ2A EFR3A KDM5A PGK1 SEH1L TUBB4B 
BCAP31 EI24 KDM6B PGM2 SEL1L TUFM 
BCL2L2-PABPN1 EID1 KHDRBS1 PGRMC1 SELT TULP4 
BCLAF1 EIF1 KIAA0101 PHACTR4 SEPT11 TVP23B 
BEST1 EIF1AD KIAA0355 PHC1 SEPT15 TWF1 
BIRC2 EIF1AX KIAA1456 PHC3 SEPT2 TWISTNB 
BIRC5 EIF1B KIAA1715 PHF6 SEPT7 TWSG1 
BLCAP EIF2AK2 KIF13A PHF8 SEPT8 TXLNA 
BLMH EIF2S1 KIF18B PHLDA1 SEPT9 TXN 
BLOC1S5-
TXNDC5 
EIF2S2 KIF1C PHTF2 SEPW1 TXNDC17 
BLOC1S6 EIF2S3 KIF2C PIGS SERBP1 TXNDC5 
BMPR2 EIF3A KIF5B PIK3R1 SERF2 TXNRD1 
BNIP2 EIF3B KIFAP3 PIKFYVE SERINC1 TYMS 
BNIP3 EIF3D KLHDC10 PIP4K2B SERP1 U2AF2 
BRD4 EIF3E KLHDC7A PITHD1 SERPINE2 U2SURP 
BRI3 EIF3F KLHL8 PJA2 SERTAD2 UBA2 
BRI3BP EIF3G KLHL9 PKM SET UBA52 
X. Appendices/Apéndices 
160 
 
BRK1 EIF3I KPNA2 PLEKHA2 SETD7 UBAP2L 
BRWD1 EIF3L KPNB1 PLEKHA3 SF1 UBB 
BTBD1 EIF4A1 KTN1 PLEKHA5 SF3A3 UBC 
BTBD7 EIF4A2 LAMP2 PLEKHB2 SF3B1 UBE2A 
BTF3 EIF4A3 LAMTOR1 PLS3 SF3B14 UBE2C 
BTF3L4 EIF4B LAMTOR3 PMEPA1 SFPQ UBE2E1 
BTG1 EIF4E LAMTOR5 PMP22 SFT2D1 UBE2E3 
BUB3 EIF4E2 LAPTM4A PNN SFT2D2 UBE2G1 
BZW1 EIF4EBP2 LAPTM4B PNPO SGK1 UBE2K 
BZW2 EIF4G1 LARP1 POLDIP3 SGK196 UBE2M 
C11orf31 EIF4G2 LARP4 POLE3 SGPL1 UBE2N 
C11orf58 EIF4H LARS POLR2M SHISA5 UBE2W 
C12orf23 EIF5 LASP1 POLR3K SHISA9 UBE2Z 
C14orf166 EIF5A LBR POMP SHOC2 UBE3A 
C14orf2 EIF5AL1 LDHA POTEE SHQ1 UBL5 
C16orf52 EIF6 LDHB POU2F1 SIAE UBLCP1 
C17orf103 ELAVL1 LDLRAD3 PPAT SIAH1 UBN2 
C18orf25 ELK3 LDOC1L PPIA SIAH2 UBQLN1 
C1orf216 ELK4 LEF1 PPIB SKA2 UBXN7 
C1orf43 ELL2 LEPROT PPIC SKIL UGCG 
C1orf56 ELOF1 LETM1 PPIL4 SKP1 UGDH 
C1QBP ELOVL5 LGALS1 PPIP5K2 SLA2 UGGT1 
C20orf24 EMC1 LHFPL2 PPM1A SLC16A1 UGT8 
C21orf91 ENAH LIMA1 PPP1CB SLC1A5 UHMK1 
C2orf15 ENC1 LIMS1 PPP1CC SLC20A1 UPF3B 
C4orf46 ENO1 LIN52 PPP1R12A SLC25A1 UQCR10 
C5orf15 ENSA LIN7C PPP1R14B SLC25A12 UQCR11 
C5orf22 EOGT LMNB1 PPP1R15B SLC25A24 UQCRH 
C5orf24 EPB41L3 LMO4 PPP1R2 SLC25A3 UQCRQ 
C5orf45 EPDR1 LNPEP PPP2CA SLC25A39 USMG5 
C5orf51 EPPIN LONP2 PPP2CB SLC25A44 USP22 
C6orf62 EPT1 LPP PPP2R1A SLC25A46 USP34 
C7orf73 ERGIC3 LRPPRC PPP2R4 SLC25A5 USP37 
CADM1 ERH LRRC58 PPP3CB SLC26A2 UTP11L 
CALD1 ERLEC1 LRRC59 PPP3R1 SLC29A1 VAMP3 
CALM1 ERO1L LRRC8A PPP4R2 SLC30A5 VAPA 
CALM2 ETF1 LSM14A PPP6C SLC30A7 VAPB 
CALR ETFA LSM14B PPP6R3 SLC35B4 VAT1 
CALU ETNK1 LSM4 PRDX1 SLC35E1 VAV2 
CAMK2D ETS1 LSM5 PRDX3 SLC35F2 VDAC1 
CAMSAP2 ETV5 LYPLA1 PRDX4 SLC38A2 VDAC2 
CAND1 EVI5 LYPLA2 PRDX6 SLC39A10 VEZF1 
CANX EZR LZIC PREPL SLC39A14 VGLL4 
CAP1 FABP5 M6PR PRKAA1 SLC39A9 VHL 
CAPN2 FAM105B MAB21L3 PRKAR1A SLC44A1 VIM 
CAPRIN1 FAM120A MAFG PRKD3 SLC4A5 VMA21 
CAPZA1 FAM122B MAGEA12 PRKDC SLC4A7 VPS26A 
CAPZA2 FAM126A MAGEA3 PRMT1 SLC5A3 VPS29 
CARD8 FAM129B MAGEA4 PRMT5 SLC6A6 VPS35 
CASC3 FAM134A MAGEA6 PRNP SLC9A6 VPS36 
CASD1 FAM160B1 MAGEB10 PRPF4B SLIRP WBP5 
CASP2 FAM166A MAGT1 PRPF8 SLMO2 WDR1 
CAV1 FAM178A MANF PRPS1 SMAD2 WDR3 
CAV2 FAM199X MAP1LC3B PRR14L SMAD5 WDR36 
CBFB FAM219A MAP3K13 PRR3 SMAP2 WDR37 
CBL FAM3C MAP4 PRRC2B SMARCAD1 WDR77 
CBX1 FAM49B MAPK1 PRRG4 SMARCC1 WDR82 
CBX3 FAM60A MAPK14 PRSS23 SMARCE1 WEE1 
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CBX5 FAM83D MAPK6 PSAP SMC1A WIPF2 
CBX6 FAM91A1 MAPKAPK2 PSAT1 SMC5 WNK1 
CCDC50 FAM96A MAPRE1 PSD3 SMCR7L WSB2 
CCDC73 FAR1 MARCH5 PSMA2 SMG1 WTAP 
CCDC90B FAT1 MARCH6 PSMA3 SMG7 WWTR1 
CCNB1 FAU MARCH7 PSMA4 SMIM13 XIAP 
CCND1 FBXL17 MARCKS PSMA5 SMIM15 XPO1 
CCNI FBXO21 MARCKSL1 PSMA6 SMIM7 XPO4 
CCNT1 FBXO5 MAT2A PSMA7 SMNDC1 XPOT 
CCT2 FBXW11 MAT2B PSMB1 SMS XRCC2 
CCT3 FCF1 MATR3 PSMB4 SNAP23 XRCC5 
CCT4 FEM1C MAX PSMB5 SNRK XRCC6 
CCT5 FERMT2 MAZ PSMC1 SNRPB XRN1 
CCT6A FGF13 MBNL1 PSMD1 SNRPB2 YAP1 
CCT7 FHL2 MCAM PSMD10 SNRPD1 YBX1 
CCT8 FKBP1A MCL1 PSMD11 SNRPD2 YBX3 
CD151 FKBP4 MCM2 PSMD12 SNRPD3 YOD1 
CD164 FMNL2 MCM3 PSMD13 SNRPE YTHDF2 
CD2AP FNBP1L MCM7 PSMD2 SNRPG YWHAB 
CD44 FNBP4 MCMDC2 PSMD3 SNTB2 YWHAE 
CD46 FNDC3B MDH1 PSME3 SNX12 YWHAG 
CD47 FOXJ3 MDH2 PTAR1 SNX22 YWHAQ 
CD59 FOXK1 MDM2 PTBP1 SNX27 YWHAZ 
CD63 FOXK2 MEAF6 PTBP3 SNX3 YY1 
CD9 FRMD6 MECOM PTCH2 SNX30 ZBTB33 
CDC25B FRS2 MED28 PTGES3 SNX4 ZC3H11A 
CDC27 FTH1 MED29 PTMA SNX5 ZC3H13 
CDC34 FTL MELK PTP4A1 SOCS5 ZC3H15 
CDC42 FUBP1 MESDC2 PTP4A2 SOD1 ZCCHC3 
CDC42SE1 FUS METAP2 PTPN1 SOD2 ZFAND5 
CDC42SE2 FXR1 METTL21A PTPN11 SOX10 ZFAND6 
CDC73 FYTTD1 METTL5 PTPN12 SOX13 ZFHX3 
CDCA3 G2E3 METTL9 PUM1 SOX4 ZFP36L1 
CDCA4 G3BP1 MFSD1 PURA SP1 ZFP91 
CDK1 G3BP2 MGAT5 PURB SP3 ZFR 
CDK14 GABARAP MIA PXN SPARC ZFX 
CDK17 GABARAPL2 MIB1 PYGB SPATS2L ZMAT2 
CDK2 GAPDH MIDN PYGO2 SPCS1 ZMAT3 
CDK2AP1 GBE1 MIF PYURF SPCS3 ZMPSTE24 
CDK4 GCN1L1 MINOS1 QDPR SPECC1L ZNF146 
CDK5R1 GCOM1 MKRN1 QKI SPG21 ZNF346 
CDK6 GDI1 MLEC QSER1 SPIN1 ZNF37A 
CDKN1A GEMIN6 MLLT6 RAB10 SPIN4 ZNF451 
CDS2 GFM1 MMADHC RAB11A SPOPL ZNF460 
CDV3 GFPT1 MMGT1 RAB12 SPRED1 ZNF471 
CEACAM8 GGPS1 MMP14 RAB14 SPRYD7 ZNF532 
CEBPB GHITM MMS22L RAB18 SPTSSA ZNF611 
CEBPG GID8 MOB1A RAB1A SQSTM1 ZNF623 
CELF1 GINS1 MOB4 RAB23 SRD5A1 ZNF652 
CELF2 GIT2 MORF4L1 RAB2A SREK1 ZNF655 
CENPI GLO1 MORF4L2 RAB2B SRGAP1 ZNF664 
CERS2 GLRX3 MPRIP RAB5C SRI ZNF697 
CERS5 GLS MRFAP1 RAB7A SRP14 ZNF703 
CERS6 GLTP MRFAP1L1 RABL2B SRP72 ZNF706 
CFL1 GMFB MRPL19 RAC1 SRP9 ZNF770 
CGGBP1 GNA13 MRPL3 RACGAP1 SRPK1 ZNF772 
CHCHD2 GNAI3 MRPL30 RAD21 SRR ZNF793 
CHD9 GNAQ MRPL42 RAD23B SRRM2 ZNF805 
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CHORDC1 GNAS MRPL51 RAN SRSF1 ZRANB2 
CHP1 GNB1 MRPS24 RANBP1 SRSF2 ZWINT 
CHSY1 GNB2L1 MSI2 RANBP6 SRSF3  
CHTOP GNB4 MSL2 RAP1B SRSF6  
      
INTRON 
AAK1 CHD3 GNB2L1 MYEOV2 RACGAP1 SMIM7 
ABHD12 CLASP1 GNG2 MYL6 RAD23B SMS 
ABR CLIP4 GNPDA1 MYO1D RAPH1 SNAP23 
AC004076.9 CLTC GOSR2 NAP1L1 RBBP4 SNRPD3 
AC007401.2 CMTM4 GPATCH2L NAPEPLD RBBP7 SOD2 
AC024592.12 CNGA4 GPM6A NBL1 RBM15 SOX10 
AC073610.5 CNGB3 GPR75-ASB3 NCAPD2 RBMX SPAG17 
AC087645.1 CNPY2 GPS2 NCSTN RCC1 SPARC 
ACSM3 CNRIP1 GYG2 NDUFA11 RCCD1 SPECC1 
ACTN4 COL6A2 H2AFV NDUFA13 RDX SPRY1 
AGXT2L2 COPB2 HDDC2 NDUFB2 RFX7 SQRDL 
AHNAK CORO1C HDGF NDUFB9 RNF14 SRSF1 
AHRR COX7A2 HELLS NDUFC2-
KCTD14 
RNF144A SSR1 
AK2 COX7A2L HES6 NEDD8-MDP1 RP11-
1035H13.3 
SSR2 
AKIRIN1 CPM HFM1 NHSL2 RP 1-159D12.5 STMN1 
AL162431.1 CRTAP HHAT NKIRAS1 RP11-315D16.2 SUMF1 
ALDOA CSDE1 HIBADH NMD3 RP11-318A15.7 SUMO2 
AMY2B CSGALNACT1 HIST1H2BC NME2 RP11-343C2.3 SUPT20H 
ANXA2 CSNK2A2 HIST1H2BJ NONO RP11-618P17.4 TAF1 
ANXA5 CTBP2 HIST1H2BK NOTCH2 RP1-164F3.9 TARDBP 
AP1M1 CTC-203F4.1 HN1 NOTCH2NL RP11-664D7.4 TCEB1 
AP2S1 CTD-2510F5.6 HN1L NPC2 RP11-81K2.1 TCP1 
APH1A CTNNA1 HNRNPA1 NPM1 RP1-187N21.4 TEAD1 
ARF3 CTNNA3 HNRNPC NQO1 RP13-512J5.1 TERF2IP 
ARF4 CTNNB1 HNRNPH1 NR3C1 RPL10 TFRC 
ARHGDIA CTSB HOOK3 NREP RPL12 THOC3 
ARIH2 CTSC HOXA3 NUFIP2 RPL15 THUMPD1 
ARL10 CYB5D2 HSBP1 ODF2L RPL17-C18orf32 TICAM2 
ARL2BP DAGLB HSP90AA1 OR2W3 RPL18 TMED7-TICAM2 
ARL6IP1 DAZAP2 HSP90B1 ORAOV1 RPL18A TMEM19 
ARMC2 DCBLD2 HSPA8 OTUD7A RPL22 TMEM222 
ARPC4-TTLL3 DDX3X HSPD1 P4HB RPL23 TMEM33 
ARPC5 DHFR IGF2R PABPC1 RPL27A TMEM64 
ARSI DIDO1 IL1RAP PABPC1L RPL30 TMPO 
ASB3 DLG2 IL4I1 PAFAH1B2 RPL31 TMTC4 
ASPH DMD IMPAD1 PANK4 RPL37 TNC 
ASTN2 DNAJB11 IPO7 PCYT1A RPL37A TNPO1 
ATG16L1 DNMT1 IQCG PDCD6 RPL4 TNRC6A 
ATP1B3 DOLPP1 JUP PDE3A RPL6 TOP2A 
ATP2A2 DPP6 KAT8 PDS5A RPL7A TOR1AIP2 
ATP5A1 DPYSL2 KCNH8 PEX1 RPL8 TPGS2 
ATP5B DTWD2 KCNK15 PEX11B RPL9 TPM4 
ATP5E E2F3 KCNMA1 PFDN5 RPLP0 TRIM4 
ATP5L ECH1 KCTD2 PFN2 RPS11 TROVE2 
ATP6V0E1 EEF1E1 KIAA1456 PGK1 RPS2 TRRAP 
ATP7A EEF2 KPNA4 PHB RPS20 TSHZ1 
ATPIF1 EFCAB11 KTN1 PHB2 RPS23 TTC3 
AVL9 EFCAB14 LAMP2 PHC1 RPS24 TTC39C 
B4GALT1 EI24 LAMTOR1 PHC3 RPS29 TUBA1B 
BACH1 EIF1 LARP4 PHKB RPS3 TUBB 
BAG6 EIF2B5 LDHA PID1 RPS3A TUBB3 
BCL2L14 EIF2S2 LEPR PIP5K1C RPS5 UBA2 
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BMI1 EIF3E LMNA PKM RPS9 UBA52 
BOLA2B EIF4A1 LONP2 PLEKHA2 RUVBL1 UBAP2L 
BRI3 EIF4A2 LPIN2 PLEKHB2 SAMSN1 UBB 
BRWD1 EIF4G2 LRRC59 PLXDC1 SARNP UBC 
BTF3L4 ELAVL1 LRRTM3 PMEL SARS UBE2C 
BTRC ENO2 LRTOMT PMF1 SCD5 UBE2W 
BUB3 ENOSF1 LSM14A PMF1-BGLAP SDK2 UGT8 
BZW1 ENSA LYPLA2 POLDIP3 SEC14L1 UHMK1 
C11orf65 EPPIN LZIC POLR2F SEH1L UNC45B 
C16orf52 EPPIN-
WFDC6 
M6PR POLR2M SEPT11 UNC5D 
C16orf72 ERCC1 MAD1L1 POLR3G SEPT2 USP13 
C1orf228 ERO1LB MAP2K5 PPARG SEPT8 USP33 
CALR EYA4 MAP3K13 PPEF2 SEPT9 USP7 
CALU EYS MATR3 PPP1CC SERF2 UTP23 
CAND2 FAM122B MAX PPP1R8 SETD7 VSX2 
CANX FAM160B1 MAZ PPP2CB SEZ6 WDFY4 
CARD8 FAM189A1 MBNL1 PPP3CB SFRP4 WDR4 
CBFB FAM20B MDH1 PPP6R3 SGOL1 WEE1 
CBX3 FAM219A MDM2 PRDX1 SHANK3 XRCC6 
CCBL2 FASTKD2 MEAF6 PRKAR1A SHC4 YJEFN3 
CCNB1IP1 FBLN2 MED28 PRR14L SHOC2 YPEL1 
CCND1 FBRSL1 METTL21A PRRX2 SKP1 YWHAE 
CCT2 FBXO10 METTL5 PRSS23 SLC18A2 YWHAZ 
CCT3 FGF13 MIB2 PSMA1 SLC20A2 ZC3H11A 
CCT8 FICD MLEC PSMA4 SLC25A3 ZMIZ1 
CD164 FKBP4 MLPH PSMB5 SLC25A53 ZNF114 
CD44 FLJ27365 MME PSMD8 SLC26A2 ZNF280D 
CD46 FNDC3B MOB4 PSME3 SLC30A5 ZNF346 
CD59 FNTA MORF4L2 PTGR1 SLC39A14 ZNF417 
CDC42SE2 FRK MPRIP PTMA SLC39A9 ZNF451 
CDCA3 FTH1 MRPL19 PTP4A1 SLC3A1 ZNF483 
CDCA4 FUT5 MRPL3 PTPN6 SLC44A1 ZNF565 
CDH8 FXR1 MRPS6 PVRL3 SLC51A ZNF587B 
CDK1 GATC MSTO1 QDPR SLC9B1 ZNF706 
CDV3 GCOM1 MTAP QSER1 SLCO5A1 ZNF772 
CELF1 GLB1 MTHFD2 RAB1A SLIRP ZNF793 
CERS2 GLRX3 MTMR6 RAB5C SMCR7L  
CFTR GLS MUM1 RABEP2 SMEK2  
      
5' UNTRANSLATED REGION 
AC015987.2 FTL MTRNR2L8 RBBP4 RPS19 TUBA1A 
AC114546.1 G3BP1 MYL6 RND3 RPS20 TUBA1B 
AC119673.1 GAPDH NACA RP11-159D12.5 RPS3 TUBB 
AC120194.1 GPM6A NAP1L1 RPL10 RPS3A TXNRD1 
ANXA2 HES6 NELFB RPL23A RRAGC UGT8 
ARSI HN1 NKD2 RPL27 RYK USP33 
BEND3 HNRPLL NME2 RPL36A SLC25A1 WDR74 
CALR HSP90AA1 NPM1 RPL37A SNRPD2 XRCC6 
CANX HSPA8 NPTX1 RPL4 SPARC YWHAZ 
CRIPAK KPNB1 PAPOLA RPL5 SSH3 ZC3H11A 
CSDE1 MAPK6 PPARG RPL6 TARDBP ZNF146 
EIF3E MBNL1 PTP4A1 RPL7A TCP1  
EIF4A1 MORF4L2 PTP4A2 RPN1 TFDP1  
ERO1L MTHFD2 RABEP2 RPS11 TFRC  
FBLN2 MTRNR2L2 RAN RPS18 TPI1  
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CODING SEQUENCE 
AC015987.2 CNOT6 HIST1H3F NQO1 RPL22 SPRED1 
AC087645.1 COPRS HIST1H3H NR3C1 RPL23 SRP9 
AC119673.1 COPS7A HIST1H4C NUCKS1 RPL23A SRSF1 
AC120194.1 CORO1C HIST1H4D NUFIP2 RPL24 SRSF3 
ACLY COX4I1 HIST1H4E NUP62 RPL26 SRSF9 
ACSL3 COX6C HIST1H4H NUP93 RPL27 SSB 
ACSL4 COX7A2 HIST1H4I OAZ1 RPL27A SSR1 
ACTB COX7B HIST1H4J ODC1 RPL29 SSR2 
ACTG1 COX7C HIST1H4K ORAOV1 RPL3 SSR3 
ACTR2 CPM HIST2H2AA3 OSBPL8 RPL30 STARD7 
ACTR3 CREBL2 HIST2H2AA4 P4HB RPL31 STK4 
ADPRHL1 CRTAP HIST2H2AC PABPC1 RPL32 STRAP 
AHNAK CSDE1 HIST2H3A PABPC3 RPL34 STX16 
AKIRIN1 CSK HIST2H3C PABPN1 RPL35 SUB1 
ALDOA CSNK1A1 HIST2H3D PAFAH1B1 RPL35A SUMO2 
AMD1 CSNK2A2 HIST2H4A PAFAH1B2 RPL36 SUMO3 
ANLN CTNNA1 HIST2H4B PAPOLA RPL36A SYNCRIP 
ANXA1 CTNNB1 HMGA1 PARP1 RPL37 TARDBP 
ANXA2 CYCS HMGB1 PCBP1 RPL37A TBL1XR1 
ANXA5 DAZAP2 HNRNPA1 PCBP2 RPL38 TCEB1 
AP000350.10 DCBLD2 HNRNPA1L2 PCNA RPL4 TCP1 
AP000350.4 DDOST HNRNPA2B1 PDGFA RPL41 TEAD1 
AP1M1 DDX17 HNRNPC PDIA3 RPL5 TFDP1 
AP2S1 DDX3X HNRNPH1 PDIA6 RPL6 TFRC 
APH1A DDX5 HNRNPK PDZD8 RPL7 THOC3 
ARF4 DNAJA1 HNRNPU PEA15 RPL7A TM4SF1 
ARHGDIA DNAJB1 HNRPDL PFDN5 RPL8 TM9SF3 
ARL2BP DSTN HOXA4 PFN1 RPL9 TMBIM6 
ARL6IP1 DYNLL2 HSP90AA1 PFN2 RPLP0 TMCO1 
ARPC2 EEF1A1 HSP90AB1 PGAM1 RPLP1 TMED10 
ARPC5 EEF1B2 HSP90B1 PGK1 RPLP2 TMED2 
ARPP19 EEF1G HSPA4 PHB RPN1 TMEM123 
ATAD1 EEF2 HSPA5 PIGY RPS10 TMEM167A 
ATF4 EI24 HSPA8 PITHD1 RPS11 TMEM19 
ATP13A3 EIF1 HSPA9 PKM RPS12 TMEM30A 
ATP1B3 EIF1AD HSPD1 PLS3 RPS13 TMEM33 
ATP2A2 EIF2S2 HSPE1 POLR2M RPS14 TMEM48 
ATP5A1 EIF2S3 IFRG15 POTEE RPS15 TMEM64 
ATP5B EIF3E IMPAD1 PPIA RPS15A TMPO 
ATP5E EIF3G ITGA6 PPIAL4G RPS17 TMSB10 
ATP5F1 EIF3I ITGB1 PPIB RPS17L TMTC4 
ATP5G3 EIF3K ITGB8 PPP1CB RPS18 TMX1 
ATP5L EIF3L JUND PPP1CC RPS19 TNC 
ATP6V0B EIF3M KDELR2 PPP2R1A RPS2 TNPO1 
ATP6V1A EIF4A1 KIF5B PPP3CB RPS20 TOP2A 
ATP6V1G1 EIF4A2 KLF16 PPP4R2 RPS23 TPI1 
AUP1 EIF4B KPNA2 PRDX1 RPS24 TPT1 
AZIN1 EIF4E2 KPNB1 PRDX6 RPS25 TRA2B 
B2M EIF4G1 LAMP2 PRKAR1A RPS26 TRAM1 
B4GALT5 EIF4G2 LAPTM4B PRKDC RPS27 TRIM28 
BAG6 EIF4H LARP1 PRPF8 RPS27A TRIM58 
BCL2L2-PABPN1 EIF5A LDHA PRSS23 RPS27L TSN 
BIRC5 EIF5AL1 LDHB PSAP RPS28 TUBA1A 
BSG ELAVL1 LGALS1 PSMA4 RPS29 TUBA1B 
BTF3 ENO1 LIMS1 PSMA7 RPS3 TUBA1C 
BTF3L4 ENO2 LMNA PSMB1 RPS3A TUBB 
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BUB3 ERH LONP2 PSMB3 RPS4X TUBB4B 
BZW1 ERO1L LSM14A PSMB4 RPS5 TXN 
C16orf72 ETF1 LUZP6 PSMD2 RPS6 TXNRD1 
C1QBP FAM91A1 LYPLA2 PSMD8 RPS7 UBA1 
CALM2 FASN MAPK6 PSME3 RPS8 UBA2 
CALR FAU MAPKAPK2 PTAR1 RPS9 UBA52 
CANX FBXW11 MAPRE1 PTMA RPSA UBB 
CAPZA1 FERMT2 MARCH6 PTP4A1 RPSAP58 UBC 
CBFB FGF13 MAT2A PTP4A2 RRM2 UBE2C 
CBX3 FKBP1A MATR3 PTTG1 RTN4 UBE2E3 
CCDC50 FNDC3B MAZ RAB10 RYK UBL5 
CCNB1 FRMD6 MBNL1 RAB1A S100A6 UHMK1 
CCND1 FTH1 MDH1 RAC1 SAP18 UQCRFS1 
CCNI FTL MDM2 RAD21 SBNO1 UQCRH 
CCT2 FUS MEAF6 RAN SEC23B UQCRQ 
CCT3 G3BP1 METTL24 RANBP1 SEH1L USP22 
CCT4 GAPDH MFSD1 RAP2A SELT USP33 
CCT5 GBE1 MIF RAP2B SEPT2 USP34 
CCT6A GCOM1 MLEC RBBP4 SEPT7 UVSSA 
CCT7 GLS MMADHC RBBP7 SEPT9 VDAC1 
CCT8 GNA13 MOB1A RBX1 SERBP1 VDAC2 
CD44 GNAS MORF4L1 RCC2 SERF2 VHL 
CD59 GNB1 MORF4L2 RCN2 SERINC1 VIM 
CD63 GNB2L1 MRPL19 RFK SERPINE2 VMA21 
CDC42 GNPDA1 MRPL3 RHEB SET VPS35 
CDC42EP5 GPI MSN RNASEH1 SFPQ WDR82 
CDK1 GSTP1 MTCH2 RND3 SGK196 WTAP 
CDK2AP1 H2AFV MTHFD2 RNF139 SHISA5 XPO1 
CDK6 H2AFZ MTPN RP11-1035H13.3 SIAH1 XPO4 
CELF1 H3F3A MYL12B RP1-164F3.9 SLC16A1 XRCC5 
CFL1 HDDC2 MYL6 RP1-187N21.4 SLC1A5 XRCC6 
CGGBP1 HDGF MZT2B RPL10 SLC20A1 YBX1 
CHCHD2 HDLBP NACA RPL10A SLC25A1 YWHAB 
CHSY1 HEATR3 NAMPT RPL11 SLC25A3 YWHAE 
CISD2 HIF1A NAP1L1 RPL12 SLC25A5 YWHAQ 
CLASP2 HIF1AN NCL RPL13 SLC9B1 YWHAZ 
CLIC1 HINT1 NDUFC2 RPL13A SLIRP ZC3H11A 
CLIC4 HIST1H1B NEK7 RPL14 SMS ZFAND5 
CLTA HIST1H1C NGFRAP1 RPL15 SNRPB ZFAND6 
CLTC HIST1H2AG NHP2L1 RPL17 SNRPB2 ZFP91 
CMAS HIST1H2AH NME1 RPL17-C18orf32 SNRPD2 ZFR 
CMTM4 HIST1H2AI NME1-NME2 RPL18 SNX4 ZNF460 
CNBP HIST1H2BC NME2 RPL18A SNX5  
CNGA4 HIST1H2BO NONO RPL19 SOD1  
CNN3 HIST1H3B NPM1 RPL21 SPARC  
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